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ABSTRACT

INTERACTIONS OF THE SHIGA-LIKE TOXIN-2 (STX-2) FROM ESCHERICHIA
COLI 0157:H7 AND THE BCL-2 FAMILY OF PROTEINS
DURING HOST CELL APOPTOSIS

By
Lia K. Jeffrey
University of New Hampshire, May 2013

Stx-2 is a major contributor to the pathogenesis of Escherichia coli 0157:H7.
Prior reports suggest that Stx-2 increases necrosis and apoptosis of a variety of host cells
including those of endothelial origin as well as immune cells such as neutrophils (156).
However, the role Stx-2 plays in delayed apoptosis of neutrophils is not fully understood
given that previous studies have shown conflicting results (118, 51). The process of
apoptosis is mediated by the Bcl-2 protein family (2,46,226). The purpose of this
research was to define the molecular mechanisms of Stx-2 and Bcl-2 protein family
interactions. These studies examined the binding of Stx-2 to select Bcl-2 family proteins,
and outlined the effects that Stx-2 and a newly generated mutant of Stx-2 have on
neutrophil apoptosis and necrosis rates as well as on caspase-8 and caspase-9 activation.
Stx-2 did not bind to the select Bcl-2 family proteins examined nor did it consistently
show decreased apoptosis rates in neutrophils. The mechanisms behind Stx-2-induced

neutrophil apoptosis potentially involved the endoplasmic reticulum (ER) stress response
and/or interactions with other Bcl-2 family members such as Bak at the mitochondrial
membrane therefore inducing mitochondrial membrane permeabilization (MMP) and its
downstream effects.

xix

CHAPTER 1

INTRODUCTION TO ESCHERICHIA COLI 0 1 57:H7 INFECTION AND HOST CELL
RESPONSE

1.0

Microorganism Description

Escherichia coli is a major human disease agent on a world-wide basis. Despite
this, it was not until almost 100 years after the first description of the microbe that the
most serious form of the disease it causes became apparent.

The genus name Escherichia was derived from its discoverer, Theodor Escherich,
a German pediatrician. The genus currently consists of five species: E. hermannii, E.
fergusonii, E. vulneris, E. blattae, and the type species, E. coli. E. coli was first
discovered in 1885 from the feces of healthy humans and originally named Bacterium
coli commune (21, 48). In 1895 Migula renamed the bacterium to Bacillus coli and in
1919 the name Escherichia was chosen for the genus by Castellani and Chalmers (21).
The current taxonomic classification for this microorganism places it within the
Proteobacteria

phylum,

Gammaproteobacteria

class,

Enterobacteriales

order,

Enterobacteriaceae family, Escherichia genus, and coli species (21).

1

E. coli is a Gram-negative, cylindrical, straight rod typically 1 -1.5 pm wide by 2
- 6pm in length. The cells often have a single or paired arrangement, and varying degrees
of motility from non-motile to motile by way of peritrichous flagella (21). The general
biochemical profile for E. coli is to ferment various sugars, including D-glucose (which
results in the formation of gas and acid by-products), lactose, mannitol, sorbitol and
mucate (which result in the formation of acid by-products only). The organism also
breaks down indole and decarboxylate lysine, and can use sodium acetate as a sole
carbon source (21). E. coli is not able to use citrate as a sole carbon source nor can it
grow on potassium cyanide, use malonate, or form a yellow pigmentation like some other
members of the Escherichia genus (21).

E. coli is able to survive and proliferate within a temperature range of 15-45°C
(21-37°C for balanced growth) and is a neutrophilic organism that prefers to grow within
a pH range of 5.0 - 9.0 (21). Due to the structure of the outer membrane, E. coli is
intrinsically resistant to hydrophobic antibiotics such as actinomycin D, fusidic acid,
macrolides, novobiocins, and rifamycins (133). Acquired resistance to other antibiotics
including, but not limited to aminoglycosides, beta-lactams, chloramphenicol,
tetracycline, and trimethoprim has also been previously described (158). The mechanisms
for antibiotic resistance evolved through either genetic mutation or horizontal gene
transfer and were developed by alteration of the target site, enzymatic detoxification of
the antibiotic, decreased drug accumulation, and bypass of an antibiotic-sensitive step
(158).

2

As a result, many diverse strains comprise the species of E. coli and they run the
gamut from commensal to deadly pathogen. E. coli strains are differentiated by three
distinct antigenic structures; the O antigens, the H antigens, and the K antigens. The
resulting designation is referred to as the serotype of the microorganism. The O antigens
are designated based upon lipopolysaccharide (LPS), H antigens on the nature of the
flagella, and the K antigens on acidic capsular polysaccharide (CPS) composition (21).

In addition to these antigenic classifications, E. coli is also classified into groups
based upon the pathogenic mechanisms and include enteropathogenic E. coli (EPEC),
enterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli
(EAggEC), diffusely adherent E. coli, (DAEC), shiga toxin-producing E. coli (STEC),
enterohemorrhagic E. coli (EHEC), extraintestinal pathogenic E. coli (ExPEC),
uropathogenic E. coli (UPEC), and neonatal meningitis E. coli (NMEC) (21). These
pathogenic groups are described in Table 1.1.

E. coli 0157:H7 is the prototype organism of the STEC group, and has caused
numerous outbreaks in many countries including the United States. Outbreaks had been
associated with a wide variety of food types since first appearing in the early 1980’s. It is
hypothesized that the emergence of this microorganism as a food borne pathogen may be
related to feeding practices in cattle, the nonhuman reservoir (5). E. coli 0157:H7 is now
present on most farms and appears to coincide with feeding cattle grain rather than grass
(64,65). However, the ecology of this organism is complex and not fully

3

I a b l e 1.1: ( ) \ i T \ i e \ \ o f t h e p a t h o g e n i c g r o u p s o f E s c h e r ic h ia c o /i as o u t l i n e d in
Bc r gc y "s M a n u a l o f S y s t e m a t i c B a c t e r i o l o g y ( 2 1 )

Group Name

Acronym

Enteropathogenic
E. Coli

EPEC

Enterotoxigenic
E. Coli

ETEC

Enteroinvasive
E. coli

EIEC

Enteroaggregative
E. coli

EAggEC

Description
This was the first recognized category of diarrheagenic
E. coli. It has most recently been described to include
E. coli that have the ability to cause attaching and
effacing (A/E) lesions without producing Shiga toxins.
Many serotypes are included in this group, the most
recent of which are 088:H25, O127:H40,0157:H8,
0157:H16 and 0157:H45.
This type of E. coli is associated with diarrhea in both
humans and animals. They have the ability to produce
one or more enterotoxins that can be either heat-labile
or heat-stable. These toxins cause intestinal secretions
and are classified based on their biological activity,
receptors, and chemical and antigenic properties.
Strains commonly associated with humans include
011:H27, 025:K7:H42, 048:H26, 085:H7,0119:H6,
and O153:H10.
This type of E. coli is capable of invading and
propagating within intestinal epithelial cells of the
intestines. These strains obtain their virulence from
multiple genes located within the bacterial chromosome
and on plasmids. There are a very small number of
serotypes, most of which are non-motile. These
serotypes include 0 1 15:H', 0136:H\ 0159:H2,
0164:H', and 0173:H‘.
This type of E. coli is generally associated with
travelers’ diarrhea and other enteric symptoms such as
cramps. It is characterized by a plasmid-mediated
aggregative adherence pattern to HEp-2 cells.
Prominent autoagglutination of cells to each other and
host cell surfaces are observed. This type of cell
layering has been described as a “stacked brick”
configuration. Some of the most frequently reported
serotypes include 03:H2, 015:H18, 0111:H12, and
0125:H9.
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Group Name

Acronym

Diffusely adherent
E. coli

DAEC

Shiga toxinproducing E. coli
or Vero cytotoxinproducing E. coli

STEC or
VTEC

Enterohemorrhagic
E. coli

EHEC

Extraintestinal
pathogenic E. coli

ExPEC

Uropathogenic
E. coli

UPEC

Neonatal
meningitis E. coli

NMEC

Description
This type of E. coli is defined by a diffuse adherence
pattern to HEp-2 cells. This phenotype is a result of
surface fimbriae F I845 and adhesin AIDA-I in serotype
0126:H27. The role of DAEC in diarrhea is unclear.
This type of E. coli is characterized by its ability to
produce at least one of two distinct cytotoxins referred
to as Stx-1 or VT1 and Stx-2 or VT2. The most
influential serotype of this group is 0157:H7.
This group is a subgroup of STEC/VTEC and includes
all E. coli strains that commonly cause hemorrhagic
colitis and have the same clinical and pathogenic
features as E. coli 0157:H7.
This type of E. coli is commonly associated with
urinary tract infections, pyelonephritis, neonatal and
postneurosurgical meningitis, and septicemia. They are
distinctly different from commensal and intestinal
strains of E. coli. They typically are pathogenic clones
of a limited number of 0:K:H serotypes containing host
defense avoidance mechanisms including capsules,
serum resistance, and toxins such as a-hemolysin.
This type of E. coli is commonly associated with
urinary tract infections (UTIs) including pyelonephritis.
They are characterized by a number of virulence
factors. Predominantly this type is associated with a
limited number of 0 groups and K antigens. The most
common serotypes include 01 :K1 :H7, 02:K1 :H4,
04:K12:H1,04:K12:H5, 06:K2:H1, 06:K5:H1,
06:K13:H1, 016:K1:H6, and018AC:K5:H7.
This type of E. coli is frequently associated with
neonatal meningitis and usually includes the 0 groups
07, 018ac, 01, and 0 6 that have the K1 antigen
identical to the capsule of Neiserria meningitidis type
B.
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understood. Biochemically, E. coli 0157:H7 differs from that of other E. coli strains. It is
unable to ferment sorbitol, cannot produce P-glucuronidase which hydrolyzes a
compound known as MUG (4-methylumbelliferyl-|3-D-glucuronide) which will result in
cell fluorescence, and it grows poorly above 44°C (86,126). In the clinical laboratory,
MacConkey agar containing sorbitol and MUG are used to detect E. coli 0157:H7. Due
to the inability to utilize sorbitol or break-down MUG, colonies will appear colorless and
non-fluorescent (86). The most important differences between this strain and other nonpathogenic strains are those that aid in the pathogenicity of the microorganism and are
explained below.

2.0

Overview of E. coli Q157:H7 Infection

E. coli 0157:H7 is a major foodbome pathogen in North America and elsewhere
(125, 159, 220). This serotype (STEC) produces a potent Shiga-toxin that is associated
with large outbreaks (148). Although many toxic virulence factors are produced by E.
coli 0157:H7, the Shiga-like toxins are the most likely inducers of hemolytic uremic
syndrome (HUS) (131). HUS, with associated hemorrhagic colitis (HC), is a rare but
potentially fatal complication of infection often in children and is characterized by
hemolytic anemia (a low number of red blood cells due to premature destruction),
thrombocytopenia (low number of platelets), and renal injury (7).

Symptoms of disease usually present with severe abdominal cramping, nausea,
and diarrhea that may be watery or bloody (87). After 5-10 days, the gastrointestinal
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symptoms either resolve, or, in approximately 5% of cases, escalate to HUS (7, 87).
Typical features of HUS include: swollen and detached glomerular endothelial cells, the
deposition of fibrin and platelets in the renal microvasculature, and systemic thrombotic
lesions in the microvasculature of the bowel, brain, and pancreas (148,161). Disease
outcome depends on a number of host and organism factors including patient age, general
health, and the production of the Shiga-toxins, Stx-1 and/or Stx-2 (88).

Treatment of patients with STEC infection include limiting the severity and
duration of gastrointestinal symptoms, limiting life-threatening systemic complications
such as HUS, and preventing spread of infection to close contacts (148). As there is no
reliable treatment for patients with HUS, therapy usually involves fluid replacement,
treatment of hypertension, hemodialysis and peritoneal dialysis to maintain balance
(148). In general, the use of antibiotics is not recommended as they may increase toxin
production and precipitate HUS (99). Clinical studies showed that children treated with
antibiotics during the course of an STEC infection had a 17-fold higher chance of
developing HUS than those who did not receive antibiotic therapy (219).

3.0

Epidemiology of E, coli Q157:H7 Infection

This pathogen was not recognized as a threat until the first major outbreak
occurred in 1982. From 1982-2002, E. coli 0157:H7 became broadly recognized as an
important and life-threatening pathogen (162). In the US, it was the cause of 350
outbreaks in 49 states with 8,958 reported cases, 1,493 hospitalizations, 354 HUS cases,
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and 40 deaths (159). The number of reported outbreaks increased after 1993 and peaked
in 2000 (Figure 1.1); however, the overall size of the outbreaks decreased over time
(159). It is now estimated that E. coli 0157:H7 causes approximately 73,500 illnesses
and 61 deaths per year in the US (125).

There are many routes of transmission associated with E. coli 0157:H7 ranging
from the most common foodbome-related incidences (responsible for 61% of outbreakrelated cases) to the rare laboratory-related occurrences (2 cases) (159). Historically, E.
coli 0157:H7 outbreaks are most commonly associated with ground beef; however,
produce, other beef and dairy products, person-to-person contact, water, animal contact,
and laboratory accidents have been implicated in disease (Figure 1.2) (1, 11, 13, 30, 31,
53,159).

A unique and troubling issue is that E. coli 0157:H7 outbreaks remain common
even with improved US food supply safety regulations (200). For example, from 20062011 there were 12 foodbome outbreaks in the US. These outbreaks occurred in fresh
raw spinach, hazelnuts, prepackaged cookie dough, pizza, ground beef, Lebanon bologna
and cheeses (29). Recently 60 cases of 0157:H7 infection were associated with romaine
lettuce consumed at salad bars at grocery stores in the central US region in
October/November 2011 (29). Although this outbreak is considered ended the
investigation is still on-going (29).
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Figure 1.1: E. coli 0157:H7 outbreaks by year from 1982-2002. Diagram is courtesy
of Rangel et al. (159). A total of 350 outbreaks was recorded.
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Figure 1.2: E. coli 0157:H7 outbreak transmission routes by year from 19822002. Diagram is courtesy of Rangel et al. (159). The diversity of transmission
routes increased over time.
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About half the E. coli 0157:H7 produce-related outbreaks are linked to cross
contamination during food preparation and the remaining half are caused by
contamination during consumer preparation (159). Outbreaks related to food that is
intended for raw consumption pose the most serious problem, as once the food is
contaminated, prevention is difficult (14, 15). In fact, the last four E. coli outbreaks have
been associated with foods intended for raw consumption (cheese, hazelnuts, Lebanon
bologna, and romaine lettuce) (29). Key to outbreak termination is the timely recognition
of E. coli in the food supply and this together with prevention and treatment of HUS
remain top priorities.

4.0

Virulence Factors of is. coli Q157:H7

E. coli 0157:H7 harbors virulence factors that make it an important pathogen.
Such factors include shiga-like toxins, adhesins, LPS, enterohemolysin, extracellular
serine proteases, and enterotoxins. The genes for these virulence factors are located either
within the chromosome itself or on a distinct virulence plasmid (p0157) within the cell.

4.1

Shiga-like Toxins

Major virulence factors that increase the pathogenicity of E. coli 0157:H7 are the
shiga-like toxins. Initially designated as verotoxins due to their remarkable cytotoxic
effects on African green monkey kidney (Vero) cells, at least two of these toxins are
associated with human disease: Verotoxin 1 (VT1) and Verotoxin 2 (VT2) (87). VT1 was
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first identified by Konowalchuk et al. in 1977 (104). Both VT1 and VT2 were implicated
in infantile gastrointestinal disease and children with hemolytic uremic syndrome (HUS)
(89, 104, 148, 162). O’Brien et al (139, 140) reported that the structure and biological
activity of VT toxins were similar to those of the Shiga toxin produced by Shigella
dysenteriae type 1, and they could be neutralized by anti-Stx antibody. This led to the
current toxin nomenclature of shiga-like toxin 1 (SLT-1) or Stx-1 and shiga-like toxin 2
(SLT-2) or Stx-2 (139, 140). For simplicity and in keeping with international usage, the
toxins will be referred to as Stx-1 and Stx-2 throughout this thesis and their
corresponding genes designated as stx 1 and stx2 .

Both Stx-1 and Stx-2 are compound toxins that have a total molecular weight of
approximately 70,000 Daltons (70 kDa) (138). The nucleotide sequence of the genes that
encode for Stx-1 and Stx-2 was discovered in the late 1980s (25, 41, 81, 82, 106, 187).
The gene structure consists of an operon with a single translational unit that encodes both
the individual A subunit gene and the B subunit gene (148). The AB5 toxin structure (63)
comprises 2 main subunits: a single 32 kDa A subunit and five 7.7 kDa B subunits (138).
The B subunit gene has a stronger ribosomal binding site resulting in higher translation of
the B subunit. The A-subunit has 315 amino acids for Stx-1 and 318 amino acids for Stx2, and the B-subunit has 89 amino acids for both toxins (170).

The protein structure (Figure 1.3) follows an alpha-beta motif and each subunit
has a unique function. The A-subunit has two fragments; the Al and A2 fragments. The
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Figure 1.3: The structure of Stx. Diagram is courtesy of the European Bioinformatics
Institute PDBsum [www.ebi.ac.uk/pdbsum]. A) Stx holotoxin B) Stx A-subunit C) Stx Bsubunit single chain. Both Stx and Stx-1 have similar structures with only minor
differences in the amino acid sequence whereas Stx-2 has only 56% identity to both
toxins for the A and B subunits (81).
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Al fragment is the enzymatically active portion of the toxin, and the A2 fragment is the
portion that serves to bind the Al fragment to the pentameric B-subunit structure. The Bsubunit is involved in binding to specific glycolipid receptors on the surface of target
cells (148). Globotriaosylceramide (Gb3 ) is the eukaryotic glycolipid cell surface receptor
for Stx-1 and Stx-2 (115,206).

4.2

Adhesins

Adhesins are important as virulence factors in that they augment the pathogenicity
of E. coli 0157:H7. These adhesins allow for pathogen binding to intestinal epithelial
cells (156). E. coli 0157:H7 attaches in a localized manner and produces attaching and
effacing (A/E) lesions on host cells (156). As they bind, the bacteria trigger intercellular
signals through the Type III secretion system (148). The expression of the Type III
secretion system is regulated by quorum sensing (183). Proteins such as EspA, EspB,
EspD, Tir (translocated intimin receptor) and intimin are involved in the intracellular
signal triggering as well as the formation of the A/E lesion (148). EspA forms
filamentous structures on the bacterial cell surface that bridge to the host cell surface
(113). EspB is delivered into the host cell where in combination with EspD, it forms a
host cell membrane pore (113). This allows other effectors (e.g. Tir) access to the host
cell (113). Tir functions as the receptor for intimin which is located on the outer surface
of E. coli 0157:H7 cells. Tir-intimin binding subsequently attaches the bacterium to the
host cell and triggers localized actin cytoskeleton rearrangement and pedestal formation
(113).
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4.3

Lipopolvsaccharide (LPS)

LPS serves as a third virulence factor that aids in E. coli 0157:H7 pathogenicity.
LPS is an integral part of gram-negative bacterial cell walls and it stimulates a number of
immune responses including the production of tumor necrosis factor alpha (TNF-a) and
other inflammatory intermediates (130). It is noteworthy that high levels of circulating
antibodies to LPS were observed in 20 out of 22 patients with HUS (17). In addition,
increased levels of LPS binding protein were also present in patients with HC and HUS
which implied that these patients had an increased acute phase response to LPS (154,
156). However, this does not suggest that Lipid A (endotoxin) is expressed (156). Finally,
results from a number of studies indicated that a synergistic effect between Stx and LPS
may occur both in vivo and in vitro (8,90,120,156).

4.4

Enterohemolvsin

Bacterial enterohemolysins are well established virulence factors and this is also
the case for E. coli 0157:H7. Beutin et al. (16) reported that 89% of STEC strains tested
showed a hemolytic phenotype different from that of the E. coli alpha-hemolysin (Hly). It
was subsequently shown that this unique hemolysin was encoded by the 60-Mda
“virulence plasmid” p0157 identified from the 0157:H7 strain EDL933 (176). This
107 kDa enterohemolysin {EHEC-hlyA) produced by the gene hlyA is controlled by an
operon (EHEC-/i(yCABD) consisting of four open reading frames. This operon has 60%
homology to the E. coli alpha-hemolysin operon (/z/yCABD) (148). Production of this
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enterohemolysin has been associated with E. coli 0157:H7 infections that subsequently
developed into HUS. Of 18 isolates from patients with HUS, 16 were enterohemolytic
and positive for EHEC-hlyA (148). In addition, antibodies to EHEC-Hly were found in 19
of 20 patients that were recovering from 0157:H7 STEC-induced HUS. It is not fully
understood how EHEC-Hly contributes to the pathogenesis of STEC disease, but it is
thought that the hemoglobin released by the action of the hemolysin may provide a
source of iron, thereby stimulating growth of STEC in the gut (109). It was discovered
that alpha-hemolysin is cytotoxic to endothelial cells and increases superoxide production
by rat renal tubular cells (93, 189). The production of a combination of these
enterohemolysins may lead to increased toxin production and severe damage to the
tissues of the kidney and exacerbate HUS.

4.5

Extracellular Serine Protease

In addition to enterohemolysin, the pO 157 plasmid encodes the putative virulence
factor extracellular serine protease EspP (22). The espP gene encodes this 104 kDa
protein which is capable of cleaving pepsin and human coagulation factor V (148). By
these mechanisms it has been suggested that secretion of EspP could result in
exacerbation of hemorrhagic disease in the gut (22). Antibodies to this protein were
found in 5 of 6 children with STEC infection; however, it is not believed to be a universal
virulence factor of STEC as not all E. coli 0157:H7 strains produce EspP (22,148).
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4.6

Enterotoxin

To date, the most recently identified 0157:H7 virulence factor that contributes to
disease severity is enterotoxin EAST1 which is encoded by the astA gene (148). This
enterotoxin was detected in 100% of 75 different 0157:H7 strains tested, and may be
responsible for the watery diarrhea noted in early STEC infection (172).

5.0

Pathogenesis of E. coli Q157:H7 Infection

Induction of disease by E. coli 0157:H7 is a complex process in which the
preceding virulence factors play a major role. It should be noted that other host and
microbe components also play a crucial role in disease initiation as well as in disease
severity (148). Ingested organisms pass through the stomach to replicate in large numbers
in the intestines. E. coli 0157:H7 is acid-resistant, and withstands the harsh conditions in
the stomach (62). As a consequence, only a relatively low number (as few as 10
organisms) is needed to cause disease (157). The incubation period of STEC infection is
approximately 2-8 days with symptoms appearing, on average, after 3-4 days (157). The
organisms make their way through the small intestine and typically colonize the lower
portion of the small intestine and the colon (152). As indicated previously, E. coli
0157:H7 attaches to epithelial cells of the intestine by way of adhesins that cause A/E
lesions and induce structural changes in the host cell, including loss of microvilli and
rearrangement of the structural cytoskeleton components resulting in formation of a
pedestal (Figure 1.4) (148).
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When the organism has attached and is established in the gut, toxin production
increases and the toxin is translocated across the epithelial cells into the bloodstream
(113). Although Stx-1 and Stx-2 favor movement from the apical to the basolateral cell
surfaces (75), it appears that the mechanisms in which Stx-1 and Stx-2 cross epithelial
cells differ. Stx-1 makes its way across cells in a microtubule-dependent manner, whereas
Stx-2 is carried across cells independent of microtubules (75). In addition, translocation
of Stx-2 is much less efficient than that of Stx-1, and Stx-2 has the ability to translocate
across the cells in the opposite manner (e.g. from the basolaterial to the apical cell
surface) (75).

Once shiga-like toxins have reached the bloodstream, they target multiple cell
types that express Gbs receptors, including endothelial cells of the colon, kidney, and
central nervous system (CNS), as well as epithelial cells of the kidney (34). In addition,
shiga-like toxins may also bind to red blood cells (RBCs) through the human P blood
group antigens as well as the Gb3 -related moiety Pk (193). The binding affinity to RBCs
is dependent on the binding affinity to surrounding tissues in that when binding affinity to
RBCs is high, toxin binding to tissues is diminished, thus protecting Gb3 expressing
tissues (193).

The concentration and nature of the lipid moiety of the Gb3 receptor on the cell
surface influence whether or not the cell is susceptible to the effects of shiga-like toxins
(116). For instance, kidney cells express high levels of Gb3 , especially in the cortical
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Figure 1.4: The formation of attaching and effacing (A/E) lesions, caused by
Escherichia coli. This image is courtesy of Knutton et al. (103). The E. coli observed in
this electron micrograph is EPEC (strain E2348); however, the mechanism of attachment
for EPEC and STEC strains are similar. Bacteria are observed attached to intestinal
epithelial cells on cup-like pedestals (represented by the letter E). Microvilli present on
the intestinal surface have been disrupted and effaced as a result of the cytoskeletal
rearrangements (represented by the letters MV) (21).
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region, which is the principal region of lesions in patients with HUS (19). However, the
primary cell types that exhibit histopathological lesions in HUS and hemorrhagic colitis
as a consequence of exposure to the toxin are the endothelial cells (148). Endothelial cells
are 10-fold to 1,000-fold more sensitive to the effects of Stx-2 than Stx-1 (75,79,142).

After binding to the Gb3 receptor of the target cell, the shiga-like toxin triggers a
specific, cellular internalization response (Figure 1.5). The entire toxin-glycolipid
receptor complex is internalized from clathrin-coated pits, following the endocytotic
pathway and, it is presumed, circumvents late endosomes by way of TGN38 (a Golgiassociated protein) (59, 169). The complex is subsequently transported (possibly by way
of the endosomal perinuclear recycling compartment (ERC)) from sorting endosomes to
the trans-Golgi network (59). Cells that are not sensitive to Stx-1 or Stx-2 internalize the
toxin and confine it within lysosomes (169).

Once the toxin has entered the cell it is cleaved by fiirin (a membrane-bound
protease) within the endosome or within the trans-Golgi network (Figure 1.6) (56). Furin
recognizes the consensus sequence Arg-X-X-Arg, which is found within the loop region
of the toxin between the Al and A2 fragments of the A-subunit (56). It cleaves the Asubunit and generates a catalytically active 27 kDa N-terminal Al fragment and a 4 kDa
C-terminal A2 fragment (148). The disulfide bond between the fragments is reduced and
the enzymatically active portion of the A-subunit is transported in a retrograde fashion to
the endoplasmic reticulum (ER) and eventually to the cytosol (80, 191). It is possible that
the Al fragment plays a role in this transportation by directing insertion of a signal
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Figure 1.5: Pathogenesis of Shiga toxin binding to ceils with Gb3 receptors. Diagram
is courtesy of Sandvig et al. (169). The toxin is internalized by a clathrin coated pitdependent process, cleaved by furin, and transported to the trans Golgi network,
endoplasmic reticulum and eventually the cytosol.
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A

Figure 1.6: Furin cleavage site of Stx-1 and Stx-2. Drawing is adapted from Sandvig et
al. (170).
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sequence-like hydrophobic domain at the C-terminus into the endoplasmic reticulum
membrane (167). The Al fragment is responsible for death of the cell by way of RNA Nglycosidase activity (47,141). It inactivates the 60S ribosomal unit by cleaving the Nglycosidic bond at A-4324 in 28S ribosomal RNA (47). This inhibits elongation-factor 1
dependent binding of aminoacyl-tRNA to ribosomes and interferes with protein synthesis
within the cell, impeding peptide chain elongation, and results in necrosis of the cell (47).

6.0

Host Response to E. coli 0157:H7 Infection

It is possible that not all cells exposed to toxin die from RNA N-glycosidaserelated necrosis. Patients with hemorrhagic colitis and HUS have significant tissue
damage which generates an inflammatory response through leukocyte activation and
cytokine production and further exacerbates damage in the affected area (156).
Neutrophils, macrophages, cytokines, and chemokines play an important role in the
pathogenesis of disease and development of HUS (Figure 1.7) (156).

Neutrophils are the first line of cellular defense in the human’s host immune
system. As many as 5 x 1010 cells are released from the bone marrow each day (28). This
number is necessary in order to maintain a sufficient level to protect against infection
(28). The main reason why so many cells are required is due to their short half-life (28).
In the circulation, neutrophils are constitutively undergoing apoptosis with an estimated
half- life of 6 to 18 hours (3, 67, 173, 213). However, once neutrophils have crossed into
the tissues they can survive for longer periods depending upon the environmental factors
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Figure 1.7: Hypothetical sequence of events of E. coli 0157:H7 infection from
ingestion to the development of HUS. Diagram is courtesy of Proulx et al. (156). The
order of events is labeled numerically from 1-10. Events that may occur simultaneously
are sub-bulleted by letter (e.g. 4a, 4b, etc...). Hypothesis for which data are not known or
pending are shown in italics.
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surrounding them (28). For instance, neutrophils can be kept alive longer by exposure to
cytokines such as IL-lp, IL-2, IL-4, IL-15, INF-y, G-CSF, and GM-CSF as well as to
LPS. The effect of this is to decrease their normal rate of apoptosis (20, 38, 60, 61, 102,
128, 149). Apoptotic neutrophils are incapable of normal function and will not elicit
cellular responses such as chemotaxis, degranulation, adherence, phagocytosis, and the
respiratory burst (28,

6 6

, 186). In addition, cell surface receptor expression is decreased

by way of either receptor shedding or internalization.

TNF-a can have varying effects on neutrophils depending upon where in the host
the neutrophils reside. In the circulation neutrophils are more likely to undergo apoptosis
when exposed to TNF- a whereas apoptosis in neutrophils exposed to TNF- a in tissues
will be delayed. This may be due to the ability of TNF-a to activate a cell death caspaseactivating pathway or a cell survival nuclear factor kappa B (NF-icB)-activating pathway
(28).

The NF-kB pathway may be an important pathway for the control of neutrophil
apoptosis (28). NF-kB is a transcription factor that is a central regulator of the
inflammatory and immune process. It occurs as a dimer and the constituent proteins are
part of the NF-kB /Rel family. These proteins have the ability to bind DNA through the
conserved Rel homology domain, which is also required for homo- and heterodimerization. The role of the NF-kB pathway has been examined and results indicate that
there is evidence to suggest that the NF-kB pathway does play a protective role in both
spontaneous and modulated neutrophil apoptosis (45,134, 135,212,214).
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TNF-a induced NF-kB is more potent in the neutrophils from newborns relative
to neutrophils from adults and it correlates well with the elevated IL- 8 production
reported in neonatal neutrophils (148). This may be important to the pathology of E. coli
0157:H7 infection, as infants are more susceptible to the complications of HUS than are
adults.

Increased circulating numbers of both neutrophils and macrophages have been
associated with the severity of renal failure during HUS (156). In addition, increased
numbers of neutrophils and macrophages in the glomeruli of the kidneys have been
observed in children with HUS (77,203). Leukocytosis (increased number of white blood
cells) in the circulation is commonly associated with children that have HUS and is also
identified as an independent risk factor for developing HUS (12, 23, 37, 49, 50, 52, 74,
122, 127, 168, 208, 218). Circulating neutrophils activated in HUS patients can be
demonstrated by the increased elastase levels observed in the blood (49, 50, 52, 74). In
addition, levels of granulocyte colony-stimulating factor and IL- 8 have been reported in
children with HUS and IL- 8 levels correlated with white blood cell counts (50, 205).
These neutrophils also have a higher ability to adhere to cultured human endothelium and
induce injury by breaking down endothelial fibronectin (52). Stx-1 has the ability to bind
to a non-Gbs receptor on human neutrophils, and in the presence of endothelial cells will
relocate from the neutrophil to the endothelial cell (194). This suggests that neutrophils
may also serve as an additional transport mechanism for the toxin from the intestines to
the kidney (194). In addition to neutrophils, monocytes may play a role in pathogenesis
by binding Stx and subsequently secreting a number of other inflammatory mediators
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including TNF-a, IL-ip, IL-6 , and IL- 8 independent of the effects of LPS (204).

Not only do the cells of the immune system play a role in the pathogenesis of E.
coli 0157:H7, but other inflammatory mediators also have a significant effect.
Interleukins, chemokines, growth factors, acute phase response proteins, and soluble
adhesion molecules can all contribute to the host inflammatory response to infection
(156). Patients with HUS have presented with higher levels of pro- (IL- 8 and IL-6 ) and
anti- (IL-10 and IL-1 receptor antagonist) inflammatory chemokines than those without,
and these levels have been correlated to the severity of renal failure (117, 155). In
addition, shiga-like toxins may induce IL- 8 secretion from intestinal epithelial cells (197,
223). It appears that not all immune system cell types are involved in response to E. coli
0157:H7 infection. Lymphokines such as IL-2, IL-4, and IL-13 were not detected in
patients presenting with HC or HUS, and only low levels of interferon-y were detected.
This infers that T-cells are not part of the host immune response (156).

7.0

Mechanisms of Eukaryotic Cell Death

The two main pathways that cells follow to undergo cell death are necrosis and
apoptosis. There are distinct differences between these mechanisms of cell death. A
necrotic cell has undergone oncosis which is characterized by karyolysis (dissolution of
the nucleus) due to DNase activity and by expansion of the cell eventually leading to
leakage of the outer membrane (46). In general, necrosis is a “messy” process and will
invoke an inflammatory immune response due to the contents of the cell leaking into the
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extracellular matrix. In contrast, when a cell undergoes apoptosis it shrinks in size, the
cytoplasm becomes denser and the organelles tightly packed, the chromatin condenses
and marginalizes (pyknosis), the DNA-containing nucleus becomes fragmented
(karyorrhexis), and cell fragments are separated into apoptotic bodies (“budding”) (108,
226). The apoptotic bodies are then phagocytosed by macrophages or other similarly
functioning immune cells and degraded within the phagolysosome (46). Apoptosis does
not elicit an immune response. This is because cellular contents are not released into the
surrounding extracellular matrix, the apoptotic bodies are quickly phagocytosed after
being released from the cell and the macrophages do not produce cytokines (46). This
could be a beneficial way of increasing pathogenicity without the disadvantages
associated with a local immune-mediated response.

Apoptosis is commonly referred to as “programmed cell death” (46). There are a
number of possibilities as to why a cell may undergo apoptosis: it occurs normally during
development and aging; as a homeostatic mechanism to maintain cell populations; and as
a defense mechanism when cells are damaged by disease or noxious agents (136). As a
result there are many stimuli and conditions that may trigger apoptosis, but the cellular
response to these triggers will vary depending on the cell type (46). Apoptosis is a
complicated process, and the activity of many genes influence the likelihood of a cell
activating its self-destruction program (6 8 ).
The process of apoptosis is mediated by a family of proteins known as the Bcl-2
protein family. Approximately 15 proteins and 25 genes have been identified as members
of the Bcl-2 family in mammalian cells (32, 39, 40, 185, 224). These proteins are
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classified into two functional roles: pro-survival and pro-apoptosis; and are divided into
three subfamilies: the Bcl-2 subfamily, the Bax subfamily, and the BH3 subfamily (2).
The Bcl-2 subfamily promotes cell survival while the Bax and BH3 subfamilies promote
apoptosis (2). Examples of proteins that belong to each subfamily are listed in Table 1.2.

All of these proteins share at least one of four possible conserved motifs (BH1,
BH2, BH3 and BH4) known as Bcl-2 homology domains which are critical to the
function of the proteins, and most pro-survival proteins (those that inhibit apoptosis)
contain at least the BH1 and BH2 domains (2). The proteins closest in resemblance to
Bcl-2 contain all four homology domains (2). Alternatively, the Bax and BH3 subfamilies
(pro-apoptotic) differ in their homology domain content despite their shared cellular role
(95). The Bax subfamily contains BH1, BH2 and BH3 domains and more closely
resemble Bcl-2, whereas the BH3 subfamily contain only the BH3 domain (2). Both pro
survival and pro-apoptosis proteins have the ability to form homodimers and
heterodimers with each other, thereby keeping themselves in balance or check. This
suggests that the concentration of the proteins may be important in the outcome of the
cell’s fate (144). It is known that the BH1, BH2, and BH3 domains strongly influence the
formation of homodimers and heterodimers, and that these regions create an elongated
hydrophobic cleft to which a BH3 amphipathic alpha helix can bind (129,171).

Heterodimerization is not required for pro-survival function, but is required for the proapoptosis functions of the BH3 subfamily, and it may also play a role in apoptosis in the
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Table 1.2: The Bcl-2 Protein Family
Siibl'amih N a m e

Imution

Protein M e m b e r s

Bcl-2

Pro-survival

Bcl-2, Bc1-Xl, Bcl-w, Mcl-1, Al

Bax

Pro-death

Bax, Bak, Bok

BH3

Death domain

Bik, Blk, Hrk, BNIP3, Bim, Bad, Bid
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Bax subfamily (36,95). It is noted that there may be a preference in which proteins bind,
as not all pro-apoptosis and pro-survival proteins interact (2 ).

Apoptosis is regulated through three main pathways: the extrinsic or death
receptor pathway; the intrinsic or mitochondrial pathway; and the perforin/granzyme
pathway (either through granzyme A or granzyme B) (Figure 1.8 ) (46). The extrinsic,
intrinsic, and granzyme B pathways converge into a common downstream execution
pathway, which results in cellular changes commonly associated with apoptosis.
Research suggests that the apoptotic pathways are linked and molecules from one
pathway can interact and influence the other (76). In contrast, the Granzyme A pathway
results in direct DNA cleavage (46).

The extrinsic pathway is triggered by transmembrane receptor-mediated
interactions (46). When a trimeric ligand comes in contact with the surface of the cell,
death receptors trimerize and bind to the ligand (119). This activates adapter proteins
which in turn are recruited to the cellular membrane and bind to the death receptors (72,
207). The adapter proteins subsequently associate with procaspase- 8 (the inactive form of
caspase-8 ), form a death-inducing signaling complex (DISC), and activate procaspase- 8
to form caspase- 8 (101). Once caspase- 8 is activated, the execution pathway is set in
motion. The extrinsic pathway can be inhibited by alternative proteins which bind to
adapter proteins and caspase-8 , rendering them ineffective and therefore stopping the
execution pathway from being set in motion (92, 174).

31

Extrinsic Pathway

Intrinsic Pathway
f dUttow. twdn*. hypoKt*. Me.

♦

Perforin/Granzyme
Pathway
CytMoncTcMfc
♦

perforin
adaptors
disc formation
\

caspase 8 activation

mitochondrial changes (MPT)
♦

apoptosome forms
♦
caspase 8 activation
*
caspase 3 activation

(Execution Pathway)

\

granzyme B

granzyme A

caspase 10
activation

SET complex

I
I

DNA cleavage

endonudease activation -*■ degradation of chromosomal DNA
protease activation -* degradation of nudear and cytoskeletal proteins -* cytoskeietal reorganization
i
cytomorpholog icai changes:
chromatin and cytoplasmic condensation, nuclear fragmentation, etc.
4
formation of apoptotic bodes
Figure 1.8: The three main pathways of apoptosis: extrinsic, intrinsic and perforin/granzyme. Diagram is
courtesy of Elmore et al. (46). Each pathway activates an initiator caspase ( 8 , 9, and 10 respectively) which in turn
activates a common downstream executioner caspase-3. Note that Granzyme A has a unique pathway that is caspaseindependent.
U>

to

The perforin/granzyme pathway is triggered by T-cell mediated cytotoxicity.
Perforin (a transmembrane pore-forming molecule) is secreted and forms pores within the
target cell (198). Cytoplasmic granules are subsequently released from the T-cell into the
target cell through this newly formed pore (198). These granules contain either granzyme
A or granzyme B which are both known serine proteases (146).

Granzyme A activates a caspase-independent pathway (46). Once it is released
into the cell, the SET complex (responsible for suppressing DNase expression and
protecting DNA and chromatin structure) is cleaved (114). This results in active
expression of DNase which leads to DNA nicking and apoptotic DNA degradation and
thus blocks maintenance of DNA and chromatin structure integrity (46).

Granzyme B cleaves proteins at aspartate residues, and it is through this function
that procaspase-10 is activated to form caspase-10 (46). Once activated, caspase-10 sets
the execution pathway in motion. Granzyme B also has several other functions including
the cleavage of apoptotic inhibiting factors such as inhibitor of caspase activated DNase
(ICAD) (166). In addition, research has shown that Granzyme B can also use the intrinsic
pathway in two other ways; by cleaving Bid which causes cytochrome C release from the
mitochondria; and by directly activating caspase-3, thereby eliminating the upstream
signaling pathways and setting the execution pathway into motion (9,164).

The intrinsic pathway is triggered by a number of stimuli. These stimuli act
directly on targets within the cell and are always mitochondrial-initiated events (46).
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Intracellular signals are activated within the cell and cause changes within the inner
mitochondrial membrane (46). Mitochondrial permeability transition (MPT) pores are
opened and allow the release of two main groups of pro-apoptotic proteins into the
cytosol that function in both the intrinsic and the execution pathways (165). The first
group consists of cytochrome c, Smac/DIABLO, and a serine protease Htr2A/Omi, all of
which are responsible for activating a caspase-dependent mitochondrial pathway where
Cytochrome c binds with Apaf-1 and Procaspase-9 to form active Caspase-9 (24, 44, 57,
202). Caspase-9 or the other “initiator” caspases (caspase- 8 or caspase-10) will activate
caspase-3 and set the execution pathway into motion.

The execution pathway is the final pathway for apoptosis regardless of the
initiation pathway type (intrinsic, extrinsic or perforin/granzyme) (46). The “executioner”
caspases (caspase-3, caspase- 6 and caspase-7) activate cytoplasmic endonuclease and
proteases which degrade nuclear and cytoskeletal materials and proteins such as PARP,
cytokeratins, alpha fodrin (a plasma membrane cytoskeletal protein), and NuMA (nuclear
protein). This results in the classic morphological changes observed in apoptosis (182). In
particular, Smac/DIABLO and Htr2A/Omi are responsible for preventing the activity of
inhibitors of apoptosis proteins (IAP) thereby increasing the effectiveness of the proapoptotic response (175, 202). A second group of proteins consisting of apoptosis
inducing factor (AIF), endonuclease G, and caspase-activated DNase (CAD) is also
released from the mitochondria, but only in the late stages of apoptosis after cells are
committed to die, and act in a caspase-independent manner (with the exception of CAD)
(46). AIF translocates to the nucleus where it fragments DNA and condenses peripheral
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nuclear chromatin (85). Endonuclease G is also translocated to the nucleus, and it cleaves
nuclear chromatin to produce oligonucleosomal DNA fragments (112). CAD functions
similarly to AIF and endonuclease G after it is translocated to the nucleus; however, it
does not function until it is cleaved by caspase-3 (166). Once cleavage has occurred,
CAD causes DNA fragmentation, resulting in a more pronounced (Stage II) chromatin
condensation (188). In addition, Gelsolin (an actin binding protein) is cleaved by
activated caspase-3 and will subsequently cleave actin filaments in a calciumindependent manner leading to cytoskeletal, intracellular transport, cell division and
signal transport disruption (105).

The mechanisms of how Stx affects these cell death pathways are unclear. Toxins
typically trigger apoptosis through the intrinsic pathway (46), and previous studies have
shown that an interaction occurs between Stx-2 and Bcl-2 (190). The goal of this research
is to confirm Stx-2 and Bcl-2 protein interactions and further examine the interactions of
Stx-2 with other members of the Bcl-2 protein family in order to propose a mechanism of
action. The protein interactions will be observed in cell types that are associated with the
pathogenesis of HUS; human intestinal epithelial cells and neutrophils. Elucidating the
mechanisms of Stx-2 action in programmed cell death can lead to a better understanding
of E. coli 0157:H7 pathogenesis and open new avenues for treatment and potential
vaccines in humans.
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CHAPTER 2

PROTEIN-PROTEIN INTERACTIONS BETWEEN SHIGA-LIKE TOXINS AND THE
BCL-2 PROTEIN FAMILY

1.0

Abstract

Data from previous studies by Suzuki et al. (190) indicated that Stx-2 but not Stx1 interacts with the pentameric sequence, NWGRI within the BH1 domain (a highly
conserved region) on the anti-apoptotic protein, Bcl-2 (residues 143 to 147). This
interaction induces target cell death as a consequence of caspase-3 activation (190). Stx-2
contains this same sequence (residues 223-227) (190) as do other members of the Bcl-2
protein family. This may indicate that Stx-2 binds to other Bcl-2 family proteins. It is
hypothesized that Stx-2 interacts with the Bcl-2 family of proteins via this NWGRI
amino acid motif. If true, Stx-2 should interact with Bcl-2,

B c 1 -X l,

Mcl-1, A l, Bax, and

Bak. In order to test this hypothesis, Stx-2 was purified from E. coli 0157:H7 strain 902380 and the interaction of the toxin with the various members of the Bcl-2 family of
proteins isolated from Caco-2 cells was determined. The cytotoxicity of Stx-2 towards
Caco-2 cells was investigated. Next, proteins produced by Caco-2 cells were examined
by western blot analysis to identify the Bcl-2 family of proteins and interactions with Stx2 were assessed by far western blot analysis and co-immunoprecipitation. Data indicated
that the methods utilized did not show clear evidence that protein interactions occurred

36

using caco-2 cells as a model system.

2.0

Introduction

Suzuki et al. showed that Stx-2 but not Stx-1 interacts with Bcl-2, an antiapoptotic protein, via a pentameric amino acid sequence NWGRI located at residues 143
to 147, and this resulted in caspase-3 activated cell death (190). More precisely, this
interaction occurs within the BH1 domain (residues 136 to 155) of Bcl-2 (190) which is
highly conserved and critical for pro-survival protein function (180, 225). This same
sequence, NWGRI, is also found on Stx-2 at residues 223-227 (190). On Stx-1 the
sequence differs by one amino acid (NWGRL) and is found at residues 234-238 (190).

Evidence suggests that the ratio of anti- to pro-apoptotic proteins determines the
sensitivity of a target cell to an apoptotic stimulus by mediating mitochondrial
cytochrome c release (84). Therefore, it is postulated that Stx-1 and Stx-2 directly interact
with these proteins and act to disrupt the equilibrium between the anti-apoptotic and proapoptotic members of the Bcl-2 family, thereby enhancing caspase activation and
apoptosis within the cell. It is also hypothesized that since the NWGRI sequence is
present on more than one type of anti-apoptotic protein, it may offer explanation as to
why Stx-2 displays higher virulence during the course of disease than does Stx-1. It is
also possible that Stx-2 may mimic the acceptor surface of Bcl-2 and bind either Bcl-2 or
Bax depending upon its affinity for either protein. The interaction of these proteins was
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investigated at the molecular level in order to determine their role in Stx-triggered
apoptosis of host cells.

A study performed by Zhang et al. (227) reported that two distinct binding
surfaces play a role in homodimerization and heterodimerization of the Bcl-2 family of
host-cell proteins (227). The two surfaces, known as the “acceptor surface” and the
“donor surface”, are oriented at approximately 90° to each other on the Bcl-2 protein
(227). The acceptor surface has the ability to bind Bcl-2 molecules as well as Bax, while
the donor surface binds only Bcl-2 (227). In healthy cells, Bax primarily resides in the
cytosol of the cell and does not form dimers (227). When apoptotic stimuli occur, Bax is
switched to an active confirmation and is translocated to the mitochondria and
endoplasmic reticulum (227). At these locations, Bax forms homo-oligomers or
heterodimers with other Bcl-2 family members at the acceptor surface (227). It should be
noted that the glycine at position 145 in the middle of the acceptor surface is located
within the middle of the NWGRI pentameric sequence, which is the same sequence also
observed in Stx-2.

When this glycine in Bcl-2 was mutated to alanine,

heterodimerization but not homodimerization was abolished at the acceptor surface (227).
This may indicate that the NWGRI sequence was important in establishing the ratio of
dimerization between anti- and pro-apoptotic proteins, and thus determines the sensitivity
of a target cell to apoptotic stimuli (84). It is possible that Stx-2 may mimic this acceptor
surface and bind to either Bcl-2 or Bax depending upon its affinity for either protein.
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3.0

Hypothesis

Extrapolating from the studies by Suzuki et al. (190) and Zhang et al. (227), it is
hypothesized that Stx-1 and Stx-2 interact with the Bcl-2 family of proteins via the
NWGRL or NWGRI amino acid motifs. If true, then Stx-2 should interact with Bcl-2,
B c 1-X l ,

4.0

Mcl-1, A l, Bax, and Bak based upon its pentameric sequence (NWGRI).

Materials and Methods

The bacterial strains, toxins they produce and their origins together with all media
and reagent composition and preparation instructions are located in Appendix A.
Authorization to complete these experiments was obtained from the Institutional Review
Board for the Protection of Human Subjects In Research (IRB) under approval number
3679 (Appendix C).

4.1

Stx Protein Sequence Analysis

An analysis of Stx-1 and Stx-2 protein structures was made using ClustalX to
compare these with the members of the Bcl-2 family of proteins. The purpose of this
analysis was to determine if any sequence similarity was observed in other Bcl-2 family
members with the NWGRI sequence, located in a highly conserved region of Bcl-2.
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4.2

Purification of Stx-2 from Escherichia coli 0157:H7 strain 90-2380

E. coli 0157:H7 strain 90-2380 was inoculated into Luria Burtani (LB) Broth and
allowed to grow overnight at 37°C with shaking. The following day, the culture was
aliquoted into sterile 100x15mm Petri dishes (lOmL per dish). The lids were removed,
and the culture was exposed to ultraviolet (UV) light in a biosafety cabinet for 30
minutes. Subsequent to UV exposure, the dishes were transferred to a 37°C incubator and
allowed to incubate for an additional 48 hours. Following incubation, the culture was
pooled, centrifuged at 16,000 x g for 15 minutes at 4°C, and supernatant collected and
sterile filtered using Acrodisc 0.45pm low protein-binding membranes (Pall Corp, Port
Washington, NY). Ammonium sulfate precipitation was used to precipitate the toxin.
Initially, ammonium sulfate was slowly added to the supernatant until the concentration
reached 40% (w/v). The suspension was centrifuged and the supernatant was transferred
to a new beaker. The ammonium sulfate concentration was increased to 70%, and
centrifuged again. The pellet was resuspended in 15mL distilled water and dialyzed in
lOmM Tris pH 7.4 for 48 hours with a 30 kDa molecular weight cut-off dialysis
membrane (pre-soaked in 2% sodium bicarbonate, ImM EDTA dialysis membrane
preparation buffer at 60°C for 15 minutes).

Once dialysis was complete, the sample was concentrated using a Centricon 50
(Millipore Corp, Bedford, MA) with a 50 kDa molecular weight cut-off membrane. Then,
to obtain higher purification and eliminate large proteins, the toxin was processed
through a Centricon 100 (Millipore Corp) with a 100 kDa molecular weight cut-off
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membrane, the filtrate was collected, and a final concentration was performed using a
Centricon 50 filter unit.

4.3

Stx-2 Characterization

4.3.1

Native Analysis of Semi-Purified Stx-2

Sterile-filtered supernatants from E. coli 0157:H7 strain 90-2380 were analyzed
to assess overall protein content by native gel electrophoresis. Semi-purified Stx-2 was
analyzed to determine overall purity and the effectiveness of the purification method
outlined in section 4.2 (page 39-40). All samples were combined with 5x sample loading
buffer (5:1 ratio), loaded onto two identical 6% stacking /12% resolving gels, and placed
in a buffer tank containing native running buffer. A total of 4 gels was run at 120V for
approximately 1 h, 2 of these were used to assess the purity of the sterile-filtered
supernatants, and 2 to determine the purity of the semi-purified Stx-2.

Three gels were placed in Coomassie blue for at least 2 h to stain the proteins in
the gel. The gels were then placed in the destaining buffer described in Appendix A,
section 4.18 until the background was no longer blue, and visible protein bands were
observed.

One gel was aligned onto a polyvinylidene fluoride (PVDF) membrane (Millipore
Corp), and placed into a transfer sandwich consisting of fiber pads and filter paper

41

(Figure 2.1). The transfer sandwich was placed into a buffer tank containing Tris-Glycine
buffer (Appendix A, 4.19) and proteins were transferred at 60V for 4-5 h. After transfer,
the membrane was “blocked” overnight in Tris Buffered Saline containing 5%
dehydrated skim milk (Appendix A, 4.20) at 4°C. On the following day, the membrane
was incubated for 2 h at room temperature with lOpg/mL of primary antibody, STX211E10 (Toxin Technology, Sarasota, FL) raised in mice against Stx-2. Membranes were
then rinsed 3x in Tris Buffered Saline containing 0.05% Tween (TTBS) (Appendix A,
4.22) for 10 min at room temperature, and subsequently treated with anti-mouse alkaline
phosphatase-conjugated secondary antibody (Sigma-Aldrich, St. Louis, MO) for 2 h at
room temperature. After the secondary antibody incubation, the membrane was rinsed
twice in TTBS followed by one rinse in TBS for 10 min at room temperature. The blot
was developed with Nitro-Blue Tetrazolium Chloride /

5-Bromo-4-Chloro-3'-

Indolyphosphate p-Toluidine Salt (NBT/BCIP) tablets (Roche Diagnostics, Indianapolis,
IN).

4.3.2

SDS-PAGE Analysis of Semi-Purified Stx-2

Semi-purified Stx-2 was analyzed to detect the toxin in the sample by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Samples were diluted
1:2 in sample preparation buffer (Appendix A, 4.13), boiled at 95°C for 5 min, loaded
onto a 6% stacking / 12% resolving gel (Appendix A, 4.16), placed in a buffer tank
containing SDS-PAGE running buffer (Appendix A, 4.14), and run at 180V for 30-40
min. The gel was removed and stained in Coomassie blue (Appendix A, 4.17) for at
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Figure 2.1: Western Blot Transfer Sandwich Assembly. Diagram is courtesy of Bio-Rad
Trans-Blot Electrophoretic Transfer Cell Instruction Manual.
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least 2 h. After staining, the gel was added to a destain buffer (Appendix A, 4.18) until
the background was no longer blue, and protein bands were visible.

4.3.3

Western Blot Analysis of Semi-Purified Stx-2

Triplicate samples were diluted 1:2 in sample preparation buffer, boiled at 95°C
for 5 min, loaded onto a 6% stacking / 12% resolving gel, placed in a buffer tank
containing SDS-PAGE running buffer, and run at 180V for 30-40 min. One set of
samples was added to Coomassie blue for at least 2 h and then destained with destain
buffer. The remaining samples were each divided into two separate gels and aligned on
polyvinylidene fluoride (PVDF) membranes (Millipore Corp), and placed in a transfer
sandwich (Figure 2.1) consisting of fiber pads and filter paper. The transfer sandwich was
placed in a buffer tank containing Tris-glycine buffer (TGB) and the proteins transferred
at 60V for 4-5 h.

After transfer, the membranes were blocked overnight in TBS

containing 5% dehydrated skim milk at 4°C. On the following day, one membrane was
incubated for 2 h at room temperature with 10p,g/mL STX2-11E10 (Toxin Technology)
while the other remained in blocking buffer as a negative control. Both membranes were
rinsed 3x in TTBS for 10 min at room temperature, and subsequently treated with anti
mouse alkaline phosphatase-conjugated antibody (Sigma-Aldrich) for 2 h at room
temperature. The membranes were rinsed twice in TTBS followed by one rinse in TBS
for 10 min at room temperature. The blots were developed with nitro-blue tetrazolium
chloride / 5-bromo-4-chloro-3'-indolyphosphate p-toluidine Salt (NBT/BCIP) tablets
(Roche Diagnostics).
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4.3.4

Cleavage Analysis of Semi-Purified Stx-2 and A l Fragment Generation

Semi-purified Stx-2 was analyzed to ensure that cleavage at the Arg-X-X-Arg
consensus sequence would occur during subsequent experimentation in mammalian cells,
and to obtain a semi-pure suspension of toxin containing the Al fragment that is
generated after cleavage. This was performed by mimicking the natural cleavage of furin
with trypsin. Five pL of trypsin was added to 0.5mL of semi-pure Stx-2, vortexed briefly
and incubated at room temperature for 2 min. PMSF (2.5pL) and lpL of beta
mercaptoethanol was subsequently added to the solution to deactivate the enzyme and
ensure the disulfide bond was broken.

The preparation was analyzed by SDS-PAGE to determine if cleavage had been
successful. Samples were analyzed on a 6% stacking /12% resolving gel. Ten pL of each
sample were diluted 1:2 in sample preparation buffer. The samples were boiled at 95°C
for 5 min, loaded onto the gel, placed in a buffer tank containing SDS-PAGE running
buffer, and run at 180V for approximately 45 min. The gel was removed and placed in
Coomassie blue for at least 2 h. After staining was complete, the gel was placed in
destain buffer until the background was no longer blue, and protein bands were observed.

In addition a Western blot was performed to confirm that the Al fragment was
generated in the trypsin-treated toxin sample. A gel was prepared and run as described
above and the trypsin-treated toxin and untreated toxin samples were loaded onto the gel
in triplicate. Once the gel was electrophoresed, it was cut into thirds. One third was
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placed in Coomassie blue to stain while the remaining two samples of the gel were
prepared for a Western blot. The gels were aligned onto PVDF membranes (Millipore
Corp), and placed into a transfer sandwich consisting of fiber pads and filter paper. The
transfer sandwich was placed in a buffer tank containing TGB and proteins were
transferred at 60V for 4-5 h. After transfer, the membranes were blocked overnight at
4°C in TBS containing 5% dehydrated skim milk. On the following day, one membrane
was incubated for 2 h at room temperature with lOpg/mL STX2-11E10 (Toxin
Technology) and the other remained in blocking buffer as a negative control. The
membranes were rinsed 3x in TTBS for 10 min at room temperature, and subsequently
treated with anti-mouse alkaline phosphatase-conjugated antibody (Sigma-Aldrich) for 2
h at room temperature. The membranes were rinsed twice in TTBS followed by one rinse
in TBS for 10 min at room temperature. The blots were developed with NBT/BCIP
tablets (Roche Diagnostics).

4.3.5

Biological Activity Verification of Semi-Purified Stx-2

In order to verify that the toxin preparation was biologically active after the
purification procedure, African green monkey kidney (Vero) cells were exposed to the
semi-purified preparation. Vero cells were grown to confluency in two 25cm2 tissue
culture flasks (one to serve as a toxin assay and the second as a control). Semi-purified
Stx-2 (50pL) was added to the test flask. The test and control flasks were incubated at
37°C in 5% CO2 for 96 h. Each flask was observed at lOOx total magnification by
inverted phase-contrast microscopy to look for the presence of rounded, refractile or
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floating cells (indicating toxin activity). Following microscopic examination of the flasks,
the media was removed and lmL of crystal violet was added for 5 min. Monolayers in
the flasks were then gently rinsed with distilled water and allowed to air dry.

4.3.6

Quantitation of Semi-Purified Stx-2

The total protein concentration of the semi-purified Stx-2 preparation was
measured using the Bradford assay. A standard curve was set up in duplicate with bovine
serum albumin (BSA) (lmg/mL) and the following amounts were added per well: 0, 2,4,
8, 10, 15, and 20pL. The test samples were prepared by adding lpL of semi-purified
toxin sample to each of 6 wells. For all standards and test samples, 40pL of Bradford
reagent was added to each well and the final volume was brought to 200pL using distilled
water. Sample preparation was performed at the same time as the standard curve was
prepared. All standards and samples were placed in the plate reader immediately, shaken
for 10 sec and read at 595nm. The final protein concentration was calculated by
interpolation from the average standard curve regression equation.

4.4

Interactions of Stx-2 with Caco-2 Cells

Caco-2 cells are a transformed cell line derived from a colon carcinoma, and in
culture resemble enterocytes that line the small intestine and colon (69, 153). They
contain microvilli on their cell surfaces and connect by way of tight junctions. These cells
were examined to determine both the Bcl-2 family protein content within them, and to

47

assess the effects of Stx-2. They were cultured and maintained as described in Appendix
B.

4.4.1

Susceptibility of Caco-2 Cells to Stx-2

Two T25 flasks were seeded with O.lmL of a suspension of Caco-2 cells and
allowed to grow for 7 days by which time the monolayers were 60-70% confluent. The
media were exchanged for fresh Caco-2 media and 200pL of Stx-2 supernatant (sterilefiltered) was added to one flask while 200pL of PBS was added to the second flask. After
1 and 5 days of incubation, the cell monolayers in each flask were examined at lOOx total
magnification using an inverted phase-contrast microscope for rounded, retractile, and
floating cells (indicating toxin induced damage). At this point, the media were removed
from each flask and lmL of crystal violet added. After 5 min, the monolayers in the
flasks were gently rinsed with distilled water and allowed to air dry.

4.4.2

Protein Analysis of Caco-2 Cells

Caco-2 cells were allowed to grow to 100% confluency and harvested. Instead of
resuspending the cell pellet in cell culture media, it was resuspended in lmL of
autoclaved, distilled water. The suspension was vortexed briefly and divided into 2 x
500pL fractions (Sample A and Sample B). Fifty pL of protease inhibitor cocktail was
added to Sample B, and both samples were vortexed. Each sample was further divided in
two to give 4 tubes (Fractions 1 and 2 from Sample A, and fractions 3 and 4 from

48

Sample B) each containing 250pL. Fractions 3 and 4 were centrifuged at 1,000 x g for 10
min. The supernatants from these tubes were transferred to fresh tubes, and the pellets
were discarded.

All 4 fractions were analyzed on a 6% stacking / 12% resolving gel using SDSPAGE. Ten pL of each supernatant sample of Fraction 3 and 4 was diluted 1:2 in sample
preparation buffer and 5pL of each whole cell sample of Fraction 1 and 2 was diluted 1:4
in sample preparation buffer. All samples were boiled at 95°C for 5 min, loaded onto the
gel, placed in a buffer tank containing SDS-PAGE running buffer, and run at 180V for
approximately 45 min. The gel was removed and placed in Coomassie blue for at least 2
h. After staining, the gel was destained in buffer until the background was no longer blue,
and protein bands were visible.

The caco-2 whole cell suspension with added protease inhibitor (Sample B) was
chosen for more detailed analysis to determine if Bcl-2 family proteins were present in
the cells. Gels were prepared and run as described previously and the samples were
loaded onto the gel in triplicate. Once the gel was run, each triplicate sample was cut into
thirds. One third was placed in Coomassie blue to stain while the remaining two thirds of
the gel were prepared for Western blot. The gels were cut into 6 pieces and aligned onto
PVDF membranes (Millipore Corp), and placed in a transfer sandwich consisting of fiber
pads and filter paper. The transfer sandwich was placed into a buffer tank containing
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Table 2.1: Bcl-2 Protein Family Primary Detection Antibodies
AntilxHh N a im 1

( onc'cntialimi

Anti-Bcl-2 (Biolegend Clone Poly 6119)

2|iL/mL

Anti-Bcl-w (Biovision Cat #3034-100)

2.5(ig/mL

Anti-Bcl-XL (Biovision Cat #3312-100)

2.5ng/mL

Anti-Mcl-1 (R&D Systems Cat#AF828)

1.5ng/mL

Anti-Bax (Biolegend Clone Poly 6251)

2(o.L/mL
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TGB and proteins were transferred at 60V for 4-5 h. After transfer, the membranes were
blocked overnight in TBS containing 5% dehydrated skim milk at 4°C. On the following
day, a total of five membranes was incubated for 2 h at room temperature with one of the
primary antibodies outlined in Table 2.1 and the other remained in blocking buffer as a
negative control. A commercial antibody for Al was unavailable and as a result, Bcl-w
which contained the NWGRL pentameric sequence was chosen to be investigated in its
place. The membranes were rinsed 3 times in TTBS for 10 min at room temperature, and
subsequently treated with anti-rabbit alkaline phosphatase-conjugated secondary antibody
(1:10,000 dilution) for 2 h at room temperature. The membranes were rinsed twice in
TTBS followed by a rinse in TBS for 10 min at room temperature. The blots were
developed with NBT/BCIP tablets (Roche Diagnostics).

4.4.3

Interactions of Bcl-2 (from Caco-2 Cells) and Stx-2

To assess the interactions of Bcl-2 and Stx-2, a far western blot was performed.
For this, the Caco-2 whole cell lysate with added protease inhibitors was run in
quadruplicate on two 6% stacking /12% resolving SDS-PAGE gels. Seven pL of sample
was added to 13pL of sample preparation buffer for each replicate. The samples were
boiled at 95°C for 5 min, loaded onto the gels, placed in a buffer tank containing SDSPAGE running buffer, and run at 180V for approximately 45 min. Once the gels were
run, they were cut into four pieces. One fourth was placed in Coomassie blue to stain
while the other three quarters of the gels were prepared for far Western blot. The samples
were transferred to PVDF membranes and blocked overnight in TBS containing 5%
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dehydrated skim milk at 4°C as described above. The membranes were rinsed 3 times in
TTBS for 10 min each at room temperature, and then renatured with 3% Nonidet P-40
(NP-40) for 30 min. After renaturing, they were rinsed in TTBS 3x for 10 min each at
room temperature. One membrane (Far WB Test) was treated with the semi-purified,
trypsin-treated Stx-2 suspension containing the Al fragment, while the control
membranes (labeled as NCI and NC2) remained in blocking solution for 2 h at room
temperature. After treatment, all three membranes were rinsed as before with TTBS and
two membranes (NC2 and Far WB Test) were subsequently probed with STX2-11E10,
and the third (NCI) was put in blocking buffer at room temperature for an additional 2 h.
After incubation in the primary antibody was complete, the membranes were rinsed in
TTBS and all three membranes were treated with anti-mouse alkaline phosphataseconjugated antibody (diluted 1:10,000) (Sigma-Aldrich) for 2 h at room temperature.
Finally, the blots were rinsed twice in TTBS followed by a rinse in TBS for 10 min each
at room temperature and developed with NBT/BCIP tablets (Roche Diagnostics).

4.4.4

Caco-2 Cell Lysate Preparation for Co-Immunoprecipitation

Caco-2 cells were grown in 5 x T25 flasks to give 95-100% confluency. One mL
of sterile-filtered E. coli 0157:H7 supernatant was added to each flask and incubated for
an additional 24 h to collect the floating cells. The media was harvested from each flask
and these were pooled, centrifuged at 1000 x g for 10 min at 4°C, and the supernatant
fluid removed. The pellet was washed three times by centrifugation in 5mL PBS at 1000
x g for 10 minutes at 4°C.

52

To collect the attached cells from each flask, lmL of NP-40 lysis buffer was
added and the cells were removed from the flask surface using a rubber scraper. The
resultant cell suspension was added to the tube containing the washed floating cells prior
to the last centrifugation step and this was centrifuged at 1000 x g for 10 min at 4°C. The
pellet was resuspended in lOmL of NP-40 lysis buffer and lOOpL of each of the
following protease inhibitors was added to the lysate: aprotinin, leupeptin, and PMSF
(frozen in absolute ethanol). The cell lysate was sub-divided into 10 cryovials (lmL per
vial), flash-frozen in liquid nitrogen, and stored at -80°C.

4.4.5

Co-Immunoprecipitation of Stx-2 and Bcl-2 Family Proteins

Protein A/G resin (1.5mL) was prepared by adding lOmL NP-40 lysis buffer and
gently mixing. This slurry was then centrifuged at 3000 x g for 1 min. The supernatant
fluid was decanted and the pellet resuspended in lOmL NP-40 lysis buffer. This washing
step was repeated twice to give a total of 3 washes after which the resin was resuspended
in 1.5mL lysis buffer.

The Caco-2 cell lysate was prepared for co-immunoprecipitation by centrifuging
400pL of the washed resin slurry in a separate tube at 15,000 x g for 30 sec to remove the
liquid phase from the resin. One mL Caco-2 cell lysate was added to the tube and gently
rocked at 4°C for 20 min to bind any molecules having high affinity for the resin. After
incubation, the sample was centrifuged at 15,000 x g for 5 min at 4°C.
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The antibodies were prepared for the co-immunoprecipitation by transferring 1
aliquot of each test antibody (Table 2.2) in a 1.5mL screw cap centrifuge tube. The tubes
originally containing the antibody were rinsed with lOOpL NP-40 lysis buffer and this
rinse containing any residual antibodies was added to the 1.5mL screw cap centrifuge
tube. One hundred pL of resin-treated Caco-2 lysate was added to each antibody tube and
these were shaken gently, incubated on ice for 1 hour, and 75pL Protein A/G resin was
added. The samples were then incubated on ice for an additional 30 min and centrifuged
at 15,000 x g for 10 sec. Fifty pL of supernatant fluid was collected from each tube and
set aside. One mL of NP-40 lysis buffer was added to each tube to wash and resuspend
the gel, and the samples were centrifuged at 15,000 x g for 10 sec. This step was repeated
four times to give a total of 5 washes. The remaining supemate was removed to just
above the surface of the gel and frozen at -20°C until analyzed.

The samples were loaded onto four 6% stacking /12% resolving SDS-PAGE gels.
Ten pL of sample was added to lOpL of sample preparation buffer for each replicate. The
samples were boiled at 95 °C for 5 min, loaded onto the gels, placed in a buffer tank
containing SDS-PAGE running buffer, and run at 150V for 45-60 min.

After

electrophoresis, gels were cut into pieces and stained with Coomassie blue or transferred
to PVDF membranes for Western blotting as described previously. Once transfer was
complete, the membranes were blocked overnight in TBS containing 5% dehydrated skim
milk at 4°C. After blocking, the membranes were either left in blocking buffer (negative
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Table 2.2: Co-immunoprecipitation Pull-Down Antibodies
\ntibo(h Name

Amount

Anti-Bcl-2 (Biolegend Clone Poly 6119)

10fiL

Anti-Bcl-w (Biovision Cat #3034-100)

5>iL

Anti-Bcl-XL (Biovision Cat #3312-100)

5nL

Anti-Mcl-1 (R&D Systems Cat#AF828)

5(iL

Anti-Bax (Biolegend Clone Poly 6251)

10^L

STX2-11E10 (Toxin Technology)

5(j.L

NP-40 Lysis Buffer (Negative Control)

100^L
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controls) or were probed with the following primary antibodies for 2 h: STX2-11E10
(10pg/mL), Anti-Bcl-2 (2pL/mL), Anti-Bax (2pL/mL), Anti-Mcl-1 (1.5|ig/mL), AntiBcl- Xl (2.5pg/mL), and Anti-Bcl-w (2.5pg/mL). Following incubation, the membranes
were rinsed 3 times in TTBS for 10 min each at room temperature. The coimmunoprecipitation samples pulled-down with Bcl-2 family antibodies and probed with
STX2-11E10 were incubated with anti-mouse alkaline phosphatase-conjugated antibody,
diluted 1:10,000, (Sigma-Aldrich) for 2 h at room temperature. The samples pulled-down
with STX2-11E10 and probed with the Bcl-2 family antibodies were incubated with anti
rabbit phosphatase-conjugated antibody, diluted 1:10,000, (Sigma-Aldrich) for 2 h at
room temperature. Lastly, the blots were rinsed twice in TTBS followed by one rinse in
TBS for 10 min each at room temperature and developed with NBT/BCIP tablets (Roche
Diagnostics).

5.0

Results

5.1

Stx-2 Protein Sequence Analysis

Alignment of Stx-1 and Stx-2 with Bcl-2 family protein sequences were
performed to examine which proteins contained the pentameric sequences NWGRI,
NWGRL or NWGRV (Fig. 2.2). The NWGRI sequence was observed in Stx-2 as well as
in the BH1 domain of Bc1-Xl, Mcl-1, and Al. The NWGRL sequence was observed in
Stx-1 as well as in the BH1 domain of Bel-w. The proteins Bcl-XL, Bcl-w, Mcl-1, and Al
are anti-apoptotic proteins of the Bcl-2 family. The NWGRV sequence, identical except
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Figure 2.2: Alignment of Stx-1 and Stx-2 protein sequences. Exact matches between all sequences are depicted by the (*) at
the top of the outlined box. The bar graph below the aligned amino acid sequences shows relative sequence homology.

for the smaller valine [V] molecule as the final amino acid, was observed only in the BH1
domain of the Bax and Bak pro-apoptotic members of the Bcl-2 family.

5.2

Stx-2 Characterization

5.2.1

Native Analysis of Semi-Purified Stx-2

A native gel and western blot of UV-induced (to enhance toxin production) and
non UV-induced E. coli 0157:H7 strain 90-2380 sterile-filtered supernatant fluids
(Figure 2.3) was performed to determine protein content. Lane 2 and 4 show protein band
patterns of samples that had not been induced with UV light while lane 3 shows the
protein band pattern of the sample that was exposed to UV light. Differences in protein
content were observed between these sample types, the most important of which has been
highlighted by the box in Figure 2.3. This band corresponds with the band (also boxed)
observed in the Western blot that had been probed with anti-Stx-2 antibody, confirming
the protein as Stx-2. Native gels illustrating the effectiveness of Centricon 100 and 50
concentration units to purify and concentrate proteins between 50-100 kDa are shown in
Figure 2.4.

5.2.2

SDS-PAGE and Western Blot Analysis of Semi-Purified Stx-2

The SDS-PAGE gel of semi-purified Stx-2 from E. coli 0157:H7 strain 90-2380
is illustrated in Figure 2.5 and Figure 2.6 shows the Western blot of the semi-purified
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Figure 2.3: Native analysis of Stx-2 produced by E. coli 0157:H7 strain 90-2380. A)
Native gel of the molecular weight markers, bovine serum albumin and lysozyme (Lane 1
& 5), and non UV-induced (Lane 2 & 4) and UV-induced (Lane 3) sterile-filtered
supemate from E. coli 0157:H7 strain 90-2380. The box represents the area in which the
toxin is located. B) Western Blot of non UV-induced (Lane 2) and UV-induced (Lane 3)
sterile-filtered supemate from E. coli 0157:H7 strain 90-2380. The box represents the
area in which the toxin was detected.
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Figure 2.4: Purification
and concentration of Stx-2
produced
by E.
coli
0157:H7 strain 90-2380
using Centricon devices.
Native gel of the molecular
weight
markers,
bovine
serum albumin and lysozyme
(Lane 1 & 4), the semi
purified Stx-2 sample prior
to Centricon 100 processing
(Lane 2), the semi-purified
Stx-2 sample after Centricon
100 processing (filtrate)
(Lane 3 & 5), and the semi
purified Stx-2 sample after
Centricon 50 processing
(Lane 6).

6
ON

o

Figure 2.5: SDS-PAGE analysis of Stx-2 produced by E. coli 0157:H7 strain 902380. Pre-stained molecular weight markers are in Lane 1 and the semi-purified Stx-2
sample is in Lane 2. The box represents the area in which the toxin is located.
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Figure 2.6: Western blot confirmation of Stx-2 in the semi-purified toxin
preparation. Pre-stained molecular weight markers are in Lane 1 and the semi-purified
Stx-2 sample is in Lane 2. A) SDS-PAGE. B) Negative control Western blot probed with
anti-mouse IgG only, in the absence of Stx-2 specific antibody. No bands were detected.
C) Western Blot probed with STX2-11E10 mouse antibody and anti-mouse IgG. Stx-2
was seen in the boxed areas.
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Stx-2. Of interest are the bands between the 25 and 32.5 kDa markers indicating the
presence of the Stx-2 A-subunit (Fig. 2.5). Pre-stained molecular weight markers were
used for these procedures, and molecular weight estimates are not as accurate as
unstained markers. Panel A shows the SDS-PAGE gel in which multiple bands were
observed. However, the most important has been highlighted by the box and corresponds
to the molecular mass of Stx-2. Panel B shows a Western blot of the negative control
membrane that was treated only with secondary antibody and as expected, no bands were
detected. Panel C illustrates the Western blot treated with the anti-stx-2 antibody and the
secondary antibody. One band was clearly detected between the 25 and 32.5 kDa markers
and confirmed the presence of the A-subunit of Stx-2 in the purified sample.

5.2.3

Cleavage Analysis of Semi-Purified Stx-2 and A l Fragment Generation

Semi-purified Stx-2 was analyzed to ensure that cleavage at the Arg-X-X-Arg
consensus sequence would occur during subsequent experimentation in mammalian cells,
and results indicated that trypsin treatment effectively cleaved the toxin. The Stx-2 Asubunit comprises an Al and A2 fragment. The Al fragment has an approximate size of
28 kDa while the A2 fragment is 4 kDa. For these experiments the generation of the
larger Al fragment was determined. Figure 2.7 shows a gel containing molecular weight
markers, the trypsin treated Stx-2, and Stx-2 without trypsin treatment. Treatment of Stx2 resulted in the disappearance of a band located at approximately 32 kDa in lane 3 of
Figure 2.7. In addition, a new band was observed in the trypsin-treated sample in lane 2
of Figure 2.7 just under the 27 kDa marker. In order to ensure that this new band was not
from the added trypsin (molecular weight of approximately 24 kDa) a Western blot was
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Figure 2.7: SDS-PAGE analysis of trypsin-treated semi-purified Stx-2. Broad range
molecular weight markers are in Lane 1, trypsin-treated Stx-2 sample is in Lane 2, and
the Stx-2 sample without treatment is in Lane 3. The box represents the area in which the
32 kDa A subunit of Stx-2 is located. The arrows indicate the cleavage of the A-subunit
by trypsin in Lane 3, resulting in a new band (the Al fragment) in Lane 2 that is
approximately 4 kDa smaller.
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Figure 2.8: Western blot confirmation of Stx-2 cleavage and A l fragment generation
in the trypsin-treated Stx-2 preparation. A) SDS-PAGE of Stx-2. Pre-stained
molecular weight markers are in Lane 1, trypsin-treated Stx-2 is in Lane 2, and Stx-2
without treatment is in Lane 3. B) Negative control Western blot probed with anti-mouse
IgG in the absence of specific anti-Stx-2 antibody. Lanes are as outlined for A. C)
Western Blot probed with STX2-11E10 anti-Stx-2 antibody and anti-mouse IgG. Lanes
are as outlined for A. The band noted in the box in Lane 2, panel C, shows the Al
fragment in the sample while the box in Lane 3 shows the full (untreated) A-subunit of
Stx-2. The slightly smaller size of the band in Lane 2 (Al fragment) as compared to that
in Lane 3 (whole A-subunit) corresponds to the loss of the 4 kDa A2 fragment.
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performed. Results of the western blot are shown in Figure 2.8. These results confirmed
that the bands observed were the toxin, and not trypsin. Pre-stained molecular weight
markers were used for this procedure, and hence the molecular weight estimates were
slightly smaller than those shown in the SDS-PAGE gel. However, the molecular weight
of Stx-2 did correspond with the initial Western blot confirmation in Figure 2.6. Two
distinct bands were observed in the samples tested, with the trypsin-treated Stx-2 band
(Figure 2.8, panel C, lane 2) being approximately 4 kDa smaller than the untreated
sample in lane 3. This indicated that the A-subunit of Stx-2 was cleaved by trypsin
treatment (analogous to that of furin cleavage within host cells) and that the two
fragments (Al and A2) were separated and successfully detected in Western blots using
the specific antibody.

5.2.4

Biological Activity Verification of Semi-Purified Stx-2

After 96 h incubation, the T25 flasks containing monolayers of Vero cells that had
previously been inoculated with “semi-purified” Stx-2 preparation (as outlined in the
Materials and Methods section 4.3.5) were removed from the incubator and examined for
cytotoxic effects. The cells in the control flask were confluent and showed typical Vero
cell morphology (Figure 2.9 A & B). There were minimal cells floating in the medium.
However, the cells in the flask inoculated with 50pL of Stx-2 were approximately 50%
confluent and were lifting off the flask surface (Figure 2.9 C & D). There were many
rounded and refractile cells floating in the medium, indicating a large number of dead
cells typical of Stx-2 toxicity. Once the flasks were stained with crystal violet and dried,
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Figure 2.9: Biological activity of semi-purified Stx-2. A) Control flask containing no toxin and shown stained with
crystal violet. The density of the cell monolayer is evident in the intensity of the crystal violet staining. B) Image of Vero
cells viewed at lOOx magnification. Morphology typical of healthy Vero cells is seen. C) Test flask inoculated with Stx-2
and stained with crystal violet. Note the reduced staining indicating major loss of cells from the monolayer. D) Image of
Vero cells viewed at lOOx magnification. Note rounded, refractile cells and loss of monolayer integrity typical of Stx-2
action.

the difference in the density of the cell monolayers between the flasks was evident
(Figure 2.9).

5.2.5

Quantitation of Semi-Purified Stx-2

Duplicate bovine serum albumin (BSA) standards ranging from 0 to

8

mg/mL

were used to construct a standard curve to quantify the total protein concentration of the
Stx-2 preparation (Figure 2.10). The average background absorbance was calculated
between duplicate blanks and this value was subtracted from the total absorbance reading
in each well. The duplicate standard values were averaged and plotted to produce a
standard curve with a correlation coefficient (r2) of 0.9861. The total protein
concentration for the semi-pure Stx-2 was calculated by averaging the absorbance of the
six replicates assayed. This value was then entered into the standard curve regression
equation, and a final protein concentration of 3.07 mg/mL was obtained.

5.3

Interactions of Stx-2 with Caco-2 Cells

5.3.1

Susceptibility of Caco-2 Cells to Stx-2

Caco-2 cells required 9 days of culture to achieve 100% confluency (Figure 2.11,
A). These cells when subsequently exposed to Stx-2 for an additional 5 days and then
stained with crystal violet (Figure 2.11, B) showed monolayer destruction as compared to
the control. However, as expected this was much less pronounced than with the Vero cell

68

09

08
0 7
|

06

$

05

&

04

8

0. 3

1

02

2

0.1

<

0
0

1

2

3

4

5

6

7

8

9

P r o t e in C o n c e n tr a tio n (m g /m L )
a

A veStdC urve

■

Stx-2

Lin ear (AveStd Curve)

Figure 2.10: Total protein concentration of semi-purified Stx-2. The standard curve
shown by the ▲ symbol with correlation coefficient of r1- 0.9861 and regression
equation of y= 0.1023x + 0.0356. The total calculated protein concentration was
3.07mg/mL and is shown by the ■ symbol.

69

Figure 2.11: Cytotoxicity of Stx-2 on Caco-2 cells. Flasks were incubated for 9 days to
ensure confluency of monolayers at which point the test flask was inoculated with Stx-2.
Inoculated and control cells were examined daily for 5 days. After a total of 14 days of
incubation, flasks were stained with crystal violet. A) Control flask with no toxin present.
Note relative confluency of cell monolayer. B) Test flask inoculated with 200pL of
sterile-filtered Stx-2 supernatant fluid. Note destruction of monolayer integrity.
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monolayers which are highly susceptible to Stx, and this enhanced toxicity gave the toxin
its initial name of verotoxin.

5.3.2

Protein Analysis of Caco-2 Cells

SDS-PAGE of prepared Caco-2 cell lysates determined which preparation would
be best suited to detect Bcl-2 family proteins. Figure 2.12 shows the results of the SDSPAGE analysis. As can be seen, all samples resulted in preparations with multiple bands.
However, the Caco-2 whole cell lysate preparations resulted in more protein bands than
the supernatant fluid lysate preparations. The Caco-2 whole cell lysate preparation with
added protease cocktail inhibitors was selected for Western blot to determine the
presence of Bcl-2. These inhibitors would prevent proteases from degrading proteins in
the lysate. Figure 2.13 panel A illustrates the SDS-PAGE of Caco-2 cell lysate following
protease inhibitor treatment while panel B shows the Western blot of the negative control
membrane treated with anti-rabbit IgG and without prior treatment with rabbit anti-Bcl-2
antibody. No bands were detected on the control membrane. Panel C shows the Western
blot treated with rabbit anti-Bcl-2 antibody and then probed with alkaline phosphatase
conjugated anti-rabbit IgG. A band was detected at approximately 26 kDa which was
previously shown to correspond to the molecular weight of Bcl-2 (58). The second band
was detected just above the 175 kDa marker. It is thought that this band indicates Bcl-2
oligomers.

Using a range of specific antibodies (outlined in Table 2.1 in Materials and
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Figure 2.12: SDS-PAGE analysis of Caco-2 lysates. Broad range molecular weight
markers are in Lane 1, Caco-2 whole cell lysate preparation is in Lane 2, Caco-2
supernatant lysate preparation is in Lane 3, Caco-2 whole cell lysate preparation with
protease inhibitor cocktail is in Lane 4, and Caco-2 supernatant lysate preparation with
protease inhibitor cocktail is in Lane 5. Note the increased number of bands in the whole
cell lysate preparations.
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Figure 2.13: Western Blot confirmation of Bcl-2 in Caco-2 whole cell lysate
preparation with protease inhibitors. A) SDS-PAGE. Pre-stained molecular weight
markers are in Lane 1 and the Caco-2 whole cell lysate preparation with protease
inhibitor cocktail is in Lane 2. The bands noted in the boxes represent Bcl-2 in the
sample. B) Negative control Western blot probed with anti-rabbit IgG in the absence of
specific rabbit anti-Bcl-2 antibody showing no bands. Lanes are as outlined for A. C)
Western Blot probed with rabbit anti-Bcl-2 antibody and anti-rabbit IgG. Lanes are as
outlined for A. The bands noted in the boxes represent Bcl-2 in the sample. The larger
band is believed to be Bcl-2 oligomers.
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Figure 2.14: Analysis of Bcl-2 family proteins in Caco-2 whole cell lysate preparation with protease inhibitors. A) SDSPAGE. Pre-stained molecular weight markers are in Lane 1 and the Caco-2 whole cell lysate preparation with protease
inhibitor cocktail is in Lane 2. B) Negative control Western blot probed with anti-rabbit IgG in the absence of specific rabbit
antibodies showing no bands. Lanes are as outlined for A. C) Western Blot probed with rabbit anti-Bcl-w antibody and anti
rabbit IgG. Lanes are as outlined for A. No bands were detected. D) Western Blot probed with rabbit anti-BcI-XL antibody
and anti-rabbit IgG. Lanes are as outlined for A. The bands noted in the boxes represent detected proteins. The bands detected
at 28 kDa and 5 3 kDa are believed to be B c 1-X l and B c 1-X l dimers. The larger bands are believed to be cross-reactions of the
antibody to other unknown proteins present in the caco-2 lysate. E) Western Blot probed with rabbit anti Mcl-1 antibody and
anti-rabbit IgG. Lanes are as outlined for A. The bands noted in the boxes represent detected proteins. The smaller band is
believed to be a cross-reaction of the antibody to another unknown protein present in the caco- 2 lysate while the larger is
believed to be Mcl-1 dimers. F) Western Blot probed with rabbit anti-Bax antibody and anti-rabbit IgG. Lanes are as outlined
for A. The band noted in the box represents Bax in the sample.

Methods) the nature of the Bcl-2 family proteins was further investigated (Figure 2.14).
There were no bands detected with the Bcl-w antibody. Bcl-w has an expected molecular
weight of 22 kDa as previously reported by Wilson et al. (217). Since no bands were
detected, this indicates that the Caco-2 cell line does not produce Bcl-w.

There were five bands detected on the membrane probed with anti-Bcl-XL. These
bands were at approximately

53

kDa,

47

kDa,

45

kDa,

40

kDa, and

28

kDa. Since so

many bands were detected, the specificity of this antibody to

B c I-X l

The expected molecular weight of B c I-X l is 2 8 - 3 0 kDa

It is possible that the band

(5 8 ).

appears to be poor.

detected at 2 8 kDa corresponds with the presence of B c I-X l and that the band detected at
53

kDa corresponds with the detection of B c I-X l dimers since pre-stained markers were

used and molecular weight estimations are smaller than actual values. This would
indicate that the Caco- 2 cell line does in fact produce

B c I-X l ;

however it appears the

polyclonal nature of the antibody also results in cross-reactions with other unknown
proteins in the Caco-2 lysate.

There were two bands detected on the membrane probed with anti-Mcl-1. These
bands were at approximately 2 6 kDa and
1 is

37

kDa for the short form and

42

78

kDa. The expected molecular weight of Mcl-

kDa for the long form

(5 8 ,

detected bands matched the expected size for Mcl-1, however the
indicative of Mcl-1 dimers. The strong band detected at

26

111). Neither of the
78

kDa band may be

kDa may be indicative of an

antibody cross-reaction with other pro-apoptotic proteins such as Bak, which has an
expected molecular weight of 2 5 -2 8 kDa

(5 8 ).

Since the bands detected were not at the
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expected molecular weight for Mcl-1 it cannot be confirmed that Caco-2 cells produce
Mcl-1. Cross-reactions with other proteins in the Caco-2 lysate were due to the
polyclonal nature of the antibody.

There was one band detected on the membrane probed with anti-Bax. This band
was detected at approximately 20 kDa, which matches the expected molecular weight of
Bax. Therefore this indicates that the Caco-2 cell line produces Bax.

5.3.3

Interactions of Bcl-2 (from Caco-2 Cells) and Stx-2

Interaction of Stx-2 with the Bcl-2 family proteins was interrogated by far
Western blot (Fig. 2.15). Panel A illustrates the SDS-PAGE of Caco-2 cell lysate
following protease inhibitor treatment while panel B shows the far Western blot negative
control membrane treated with anti-mouse IgG in the absence of Stx-2 and specific
mouse anti-Stx-2 antibody. No bands were detected on this control membrane. Panel C
shows the far Western blot control membrane treated with mouse STX2-11E10 antibody
and then probed with alkaline phosphatase conjugated anti-mouse IgG. A band was
detected at approximately 55 kDa and it is believed that this is due to non-specific
binding of the primary antibody (STX2-11E10) to a highly concentrated protein band in
the caco-2 lysate. Panel D shows the far Western blot incubated with Stx-2 followed by
subsequent treatment with STX2-11E10 antibody and alkaline phosphatase conjugated
anti-mouse IgG. A band at 55 kDa was detected, identical to the one in panel C.
However, it is interesting to note that the exposure time of all membranes were the same,
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Figure 2.15: Far Western blot of Caco-2 whole cell lysate preparation with protease
inhibitors. A) SDS-PAGE. Pre-stained molecular weight markers are in Lane 1 and the
Caco-2 whole cell lysate preparation with protease inhibitor cocktail is in Lane 2. B)
Negative control far Western blot probed with anti-mouse IgG in the absence of Stx-2
and specific mouse anti-Stx-2 antibody showing no bands. Lanes are as outlined for A.
C) Negative control far Western blot probed with mouse STX2-11E10 antibody and anti
mouse IgG. Lanes are as outlined for A. The band noted in the box represents non
specific binding of the primary antibody (STX2-11E10) to a highly concentrated protein
band in the Caco-2 lysate. D) Far Western blot probed with Stx-2 followed by mouse
STX2-11E10 antibody and anti-mouse IgG. Lanes are as outlined for A. The band noted
in the box corresponds with the band observed in panel C, but is of increased intensity
which is believed to be a possible interaction of Stx-2 and this unidentified protein that
has a molecular mass of 55 kDa.
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but the intensity of the band in panel D is greater than that of the control in frame C,
indicating a possible interaction of Stx-2 with this unidentified protein.

5.3.4

Co-Immunoprecipitation of Stx-2 and Bcl-2 Family Proteins

A co-immunoprecipitation was performed using two different methods. In the
first method, potential immunocomplexes were isolated by binding them to the Bcl-2
family antibodies; anti-Bcl-2, anti-Bax, anti-Mcl-1, anti-Bcl-XL, and anti-Bcl-w. These
samples were then probed with the Stx-2 antibody, STX2-11E10 raised in mice followed
by alkaline phosphatase conjugated anti-mouse IgG antibody (Fig. 2.16 and 2.17). In all
samples except the negative control, the SDS-PAGE showed protein bands at
approximately 48 kDa, in particular with the Caco-2 pull-down processed with anti-Mcl1 and anti-Bcl-XL. This most likely corresponds to the molecular weight of the heavy
chain of the IgG antibodies. In addition, a second band was observed at 27 kDa in the
Caco-2 pull-down processed with anti-Mcl-1. This band most likely corresponds to the
light chain of the IgG antibodies. No other bands were detected. On the negative control
blot, there was one very faint band detected in the Caco-2 pull down processed with antiMcl-1 suggesting there may be a cross reaction between anti-Mcl-1 and anti-mouse IgG
antibodies. On the blot probed with STX2-11E10, there were bands detected in all lanes
at approximately 48 kDa and bands detected in lane 4, 5, and

8

at approximately 27 kDa.

Again it is thought that these bands correspond to the heavy and light chains of the Bcl-2
family antibodies used for the co-immunoprecipitation pull-down.
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Figure 2.16: SDS-PAGE of Caco-2 cell lysate and Stx-2 co-immunoprecipitation
interactions using Bcl-2 protein family antibodies. Pre-stained molecular weight
markers are in Lane 1, 4, and 8 , Caco-2 pull down with anti-Bcl-2 antibody is in Lane 2,
Caco-2 pull down with anti-Bax antibody is in Lane 3, Caco-2 pull down with anti-Mcl-1
antibody is in Lane 5, Caco-2 pull down with anti-Bcl-XL antibody is in Lane 6 , Caco-2
pull down with NP-40 lysis buffer (negative control) is in Lane 7, and Caco-2 pull down
with anti-Bcl-w antibody is in Lane 9.
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Figure 2.17: Western blot of Caco-2 cell lysate and Stx-2 co-immunoprecipitation interactions using Bcl-2 protein family
antibodies. A) Negative control Western blot probed with anti-mouse IgG in the absence o f specific mouse antibodies. Pre-stained
molecular weight markers are in Lane 1 and 1, Caco-2 pull down with anti-Bcl-2 antibody is in Lane 2, Caco-2 pull down with antiBax antibody is in Lane 3, Caco-2 pull down with anti-Mcl-1 antibody is in Lane 4, Caco-2 pull down with anti-Bcl-XL antibody is
in Lane 5, Caco-2 pull down with NP-40 lysis buffer negative control is in Lane 6 , and Caco-2 pull down with anti-Bcl-w antibody
is in Lane 8 . The band noted in the box represents a cross reaction between anti-Mcl-1 and anti-mouse IgG antibodies. B) Western
blot probed with mouse STX2-11E10 antibody and anti-mouse IgG. Lanes are as outlined in A. The bands noted in the boxes
represent detected proteins. The bands detected at 48 kDa and 27 kDa are believed to be the heavy and light chains of the Bcl-2
family antibodies used for the pull-down procedure. No other bands were detected.
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In the second method, potential immunocomplexes were isolated by binding them
to the STX2-11E10 antibody. These samples were then probed with anti-Bcl-2, anti-Bax,
anti-Mcl-1, anti-Bcl-XL, and anti-Bcl-w, and detected with the anti-rabbit IgG. The
results are summarized in Figure 2.18. Neither the SDS-PAGE nor the negative control
membrane showed any bands. In addition, the membrane probed with anti-Bcl-2 also did
not detect any bands. However, membranes probed with anti-Bax, anti-Mcl-1, anti-BclXL,

and anti-Bcl-w showed the same band pattern of

6

distinct bands with molecular

weights between approximately 50 kDa and 27 kDa. Since the band pattern was the same
for almost all the probing antibodies, it is hypothesized that these results are most likely
not true protein-protein interactions. The top and bottom bands (50 kDa and 27 kDa,
respectively) appear to correspond to the heavy and light chains of the pull-down
antibody (STX2-11E10) which was also observed in the previous pull-down method. The
remaining 4 bands present at approximately 48 kDa, 40 kDa, 32 kDa, and 28 kDa are
hypothesized to be complexes of Stx-2 and/or cross-reactions of the antibody with
unknown caco-2 proteins (48 kDa and 40 kDa), whole Stx-2 A-subunit remaining in the
caco-2 lysate (32 kDa), and Stx-2 that was processed by the caco-2 cells and reduced to
the A1 fragment (28 kDa). Further evidence to support this hypothesis was observed as
these protein-protein interactions were only detected when using the STX2-11E10 pull
down method. If a true protein-protein interaction was detected, then the interactions
would have been detected using both pull-down methods. Since there was no evidence
that these interactions were true, it was decided that an examination of the cross-reaction
of the Bcl-2 family antibodies with Stx-2 was not necessary.
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Figure 2.18: Western blot of Caco-2 and Stx-2 co-immunoprecipitation interactions using STX2-11E10 antibody. A)
SDS-PAGE. Pre-stained molecular weight markers are in Lane 1 and the caco-2 pull down with STX2-11E10 antibody is in
Lane 2. B) Negative control Western blot probed with anti-rabbit IgG in the absence of specific rabbit antibodies showing
no bands. Lanes are as outlined for A. C) Western blot probed with rabbit anti-Bcl-2 antibody and anti-rabbit IgG. Lanes
are as outlined for A. No bands were detected. D) Western blot probed with rabbit anti-Bax antibody and anti-rabbit IgG.
Lanes are as outlined for A. E) Western blot probed with rabbit anti-Mcl-1 antibody and anti-rabbit IgG. Lanes are as
outlined for A. F) Western blot probed with rabbit anti-Bcl-XL antibody and anti-rabbit IgG. Lanes are as outlined for A. G)
Western blot probed with rabbit anti-Bcl-w antibody and anti-rabbit IgG. Lanes are as outlined for A. All membranes
probed with anti-Bax, anti-Mcl-1, anti-Bcl-XL, and anti-Bcl-w showed 6 distinct bands with molecular weights between
50kDa and 27kDa indicating that these results are most likely not true protein-protein interactions. Instead, the top and
bottom bands (50kDa and 27kDa respectively) correspond to the heavy and light chains of the pull-down antibody (STX211E10). The remaining 4 bands present at approximately 48kDa, 40kDa, 32kDa, and 28kDa are hypothesized to be
complexes of Stx-2 and/or cross-reactions of the antibody with unknown caco-2 proteins (48kDa and 40kDa), whole Stx-2
A-subunit remaining in the caco-2 lysate (32kDa), and Stx-2 that was processed by the caco-2 cells and reduced to the A1
fragment (28kDa).

6.0

Discussion

Understanding what happens to Stx-2 once it has been endocytosed into the cell is
critical to finding treatments for patients infected with E. coli 0157:H7.

A study

published by Watanabe-Takahashi et al. (215) confirmed the importance of intracellular
Stx-2 transport to the endoplasmic reticulum in intestinal epithelial Caco-2 cells in order
for cytotoxicity to occur. Therefore, it is likely that the cytotoxic mechanisms of action
occur in the endoplasmic reticulum or cytosol, where Bcl-2 family proteins are known to
reside (4). The goal of these experiments was to assess the interactions of the Bcl-2
family of proteins with Stx-2 in vitro. Previous studies show there is an association
between Stx-2, Bcl-2, and the NWGRI peptide that suggested binding of these proteins
within a host cell by way of the BH1 domain (190). As a result, it was hypothesized that
Stx-1 and Stx-2 interact with the Bcl-2 family of proteins by way of the NWGRL or
NWGRI amino acid motifs, respectively. In particular, Stx-2 should interact with Bcl-2,
B c 1-X l ,

Bcl-2,

Mcl-1, A l, Bax, and Bak based upon the pentameric sequence of its NWGRI.

B c 1-X l ,

Bax, and Bak are known to be located in the endoplasmic reticulum and

cytosol of cells (73,107,137,178).

The data from the Stx protein sequence analysis suggested that Stx-1 shared the
NWGRL sequence only with Bcl-w, a pro-survival protein not originally within the scope
of these experiments. As such, it was decided that only the Stx-2 interactions would be
investigated since it is associated with the more serious form of HUS (18, 145, 179,196).
These data also indicated that Stx-2 shared the NWGRI sequence with Bcl-2, Bc1-Xl,
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Mcl-1, and A 1, all of which are pro-survival proteins containing BH1 and BH2 domains
(2). Finally, the sequence analysis suggested that the pro-apoptotic proteins Bax and Bak
did not share either of these sequences, but rather they shared with each other a sequence
of NWGRV. The last amino acid of each of these three pentameric sequences (NWGRI,
NWGRL, and NWGRV) is isoleucine, leucine, and valine. These amino acids are
nonpolar, aliphatic (do not contain nitrogen, oxygen, or sulfur in the side chain) and are
hydrophobic molecules (132). The structures between valine and leucine have a higher
similarity than isoleucine, and in terms of size, valine is the smallest of the three
molecules. This may provide a binding advantage to proteins containing valine such as
Bax and Bak by creating a binding site with the least amount of steric hindrance; thus
giving these pro-apoptotic proteins the ability to interact with more molecules than their
pro-survival counterparts and so encourage apoptosis. This is true especially if Stx-2 is
binding these pro-survival counterparts. Although not examined as part of this work, Stx1 may preferentially bind with Bax and Bak due to the amino acid structure similarity
between valine and leucine, leading to an increase in free intracellular pro-survival
proteins thus encouraging cell survival. It is possible that these interactions may explain
why Stx-2 induces higher virulence compared to Stx-1 in patients with EC or HUS (18,
145,179,196).

Previous studies by Suzuki et al. (190) used human hepatoma HepG2 cells that
overexpressed human Bcl-2 to study the interaction between Bcl-2 and Stx-2.
Hepatocytes are not typically associated with Stx-2 pathogenesis, therefore the
investigation of protein-protein interactions between Stx-2 and the Bcl-2 protein family
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in the studies described herein used Caco-2 cells as the model cell line. These cells are
epithelial cells of the human colon where colonization of E. coli 0157:H7 typically
occurs (152). The susceptibility of Vero and Caco-2 cells to a semi-pure preparation of
Stx-2 with a total protein concentration of 3.07 mg/mL was confirmed in these studies
and even though the cytotoxic effects were not as dramatic as that of Vero cells, distinct
effects were observed. Previous studies by Garred et al. (55) have noted that the disulfide
bond responsible for stabilizing the Stx-2 A-subunit also prevents dissociation of the A 1
fragment from the toxin-receptor complex during transport, therefore it is critical this
dissociation occurs properly to ensure toxin activity. The A-subunit of the semi-purified
toxin was cleaved when subjected to trypsin treatment to produce an Al and A2 fragment
that matched the expected molecular weights of 28 kDa and 4 kDa, respectively. This
cleavage mimicked the actual cleavage by Furin that occurs within cells and confirmed
that the toxin would indeed function as expected once taken into the cells.

Data indicated that Caco-2 cells expressed Bcl-2,

B c 1-X l ,

Bax, and an unknown

protein corresponding to the molecular weight of Bak, however an antibody specific for
Bak was not available to confirm its identity. Mcl-1 and Bcl-w were confirmed to be
absent. It is important to bear in mind that detection of these pro-survival and proapoptotic proteins was taken at a specific point in time while the expression of the Bcl-2
family proteins is known to vary during the lifespan of the cell (163). No true protein
interactions were observed between Stx-2 and Bcl-2,

B c 1-X l ,

or Bax, however one band

in the far western blot was detected in both the control and test membranes at
approximately 55 kDa and this indicated that there was a cross reaction between the

85

mouse anti-Stx2 antibody (STX2-11E10) and an unknown protein in the Caco-2 lysate.
There was an increase in the intensity of this band on the test membrane which could
indicate possible binding of Stx-2 to this unknown protein, but confirmation of this
interaction was not obtained using co-immunoprecipitation. There may be alterations to
the Bcl-2 family proteins, such as phosphorylation, that occur within the cell during a
potential interaction that can impact the binding of these proteins as has been observed in
other studies (42, 83). Clearly, these alterations do not occur when the proteins have been
immobilized on a PVDF membrane prior to their interaction.

The data gathered by Suzuki et al. (190) showed a direct correlation of Bcl-2 and
Stx-2 in HepG2 cells using far Western blot and co-immunoprecipitation, however the
molecular weight of these complexes and the methods used for co-immunoprecipitation
were not given, making it difficult to verify the validity of this data. In addition, the
effects of Bcl-2 overexpression on protein binding within the host cell are unknown. It is
possible that excess concentrations of Bcl-2 lead to an interaction with Stx-2 that would
not normally occur during E. coli 0157:H7 infection.

The data gathered in this study did not show clear evidence that protein
interactions occurred between Stx-2 and Bcl-2, Bcl-XL, or Bax, using either the far
Western blot or co-immunoprecipitation methods, despite the previous data obtained by
Suzuki et al.

(1 9 0 ).

This suggests that Stx-2 does not directly interact with Bcl-2, B c 1-X l ,

or Bax in colonic epithelial cells.
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CHAPTER 3

IMPACT OF STX-2 ON NEUTROPHIL APOPTOSIS AND NECROSIS

1.0

Abstract

Hemolytic Uremic Syndrome (HUS) is a severe complication in children and the
elderly that frequently follows infection with Escherichia coli 0157:H7. Stx-2 is a potent
toxin produced by this pathogen, and it has been identified as a key player in kidney
failure associated with HUS (131). Stx-2 may inhibit neutrophil apoptosis (118);
however, this has yet to be confirmed (51). If true, this would have the effect of Stx-2carrying neutrophils remaining in the bloodstream and tissues longer than normal, thus
exacerbating the potential for tissue damage. Apoptosis is under the control of the Bcl-2
family of proteins (2, 46, 226). These consist of both pro-death (Bax) and pro-survival
(Mcl-1) proteins. In the present study, it is hypothesized that Stx-2 decreases the
normally rapid rate of neutrophil apoptosis by binding to the pro-apoptotic protein Bax
resulting in a higher concentration of unbound pro-survival proteins such as Mcl-1, thus
leading to an extended neutrophil lifespan. Stx-2 interactions with the Bcl-2 family
proteins may occur through the amino acid motif, NWGRI, found in Stx-2 as well as in a
highly conserved region of the Bcl-2 family proteins. In order to test this hypothesis, Stx2 was harvested from E. coli 0157:H7 and applied to human neutrophils. At intervals of
0, 6 , 12, 18, 24, 48, and 72 h, samples were assayed using a cell death detection kit to
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determine the impact Stx-2 had on neutrophil apoptosis rates. Data indicated that there
was a significant difference in neutrophil apoptosis rates (p < 0.05, n=9) up to and
including 12 h after the neutrophils were exposed to Stx-2. These data suggest that Stx-2
delays neutrophil apoptosis by a mechanism other than binding to Bcl-2,

B c 1-X l ,

Bax,

Bcl-wor Mcl-1.

2.0

Introduction

According to the Centers for Disease Control (CDC), Escherichia coli 0157:H7
causes 73,000 illnesses per year (159). Primary symptoms include hemorrhagic colitis
(HC) but Hemolytic Uremic Syndrome (HUS), a potentially severe, often lifethreatening, complication of E. coli 0157:H7 infection, may also occur in the elderly and
children under 5 years of age. Typically, HUS presents as non-idiopathic, non-immune
hemolytic anemia, thrombocytopenia, acute renal failure, and occasionally central
nervous system (CNS) manifestations and may lead to death (148, 156). Stx-1 and Stx-2
are major toxins produced by E. coli 0157:H7 and they serve to increase the virulence of
this organism. Stx-2 is a 74 kDa, AB5 structured toxin consisting of alpha-beta motifs.
The A subunit has a molecular mass of 32 kDa and each B subunit chain is 7.7 kDa
(138). The role of the B subunit pentamer is to attach to the globotriaosylceramide (Gb3 )
receptor on host cells. After the toxin is endocytosed into the cell, it is transported to the
Golgi apparatus, endoplasmic reticulum, and cytosol (59, 80, 169, 191). The A subunit is
cleaved into

2

fragments within clathrin-coated pits by furin (a membrane bound

protease) (56). The A2 fragment remains attached to the B subunit and is degraded by the
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cell (170). The Al fragment is the enzymatically active portion of the toxin and has been
shown to elicit a necrotic response by preventing host-cell protein synthesis (47). In
addition, it is thought that this fragment may also play a role in the apoptotic pathway
once it is retrograde-transported into the cytoplasm of the host cell.

Apoptosis (programmed cell death) is a normal function of cells. The process is
mediated by the Bcl-2 protein family (2, 46). These proteins consist of anti-apoptotic
(pro-survival) and apoptotic (pro-death) proteins that possess conserved homology
domains. It is through these conserved homology domains that these proteins interact
with each other, and the ratio of protein type (pro-survival vs. pro-death) determines the
fate of the cell (46).

Human neutrophils routinely undergo relatively rapid apoptosis and have a typical
circulating lifespan of 6-18 hours (3, 67, 173, 213). Approximately 1010 neutrophils are
produced daily, and these account for 45-75% of the total white blood cell count (28).
During infection, neutrophils are the first responders capable of phagocytozing invading
pathogens, foreign cells, toxins, and viruses and, in an attempt to clear the infection,
release reactive oxidative intermediates (28).

Previous studies have shown conflicting results on whether neutrophil apoptosis is
delayed following exposure to Stx-2. Liu et al. (118) concluded that Stx-2 derived from
E. coli 0157:H7 exhibited both a dose- and time- dependent inhibition of spontaneous
neutrophil apoptosis, possibly involving the protein kinase C pathway. Flagler et a l (51)
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was unable to demonstrate a Stx-2 and neutrophil interaction nor did they observe an
altered apoptosis rate when these cells were exposed to 1pg/mL of Stx-1 or Stx-2. Suzuki
et a l (190) reported that Bcl-2 bound Stx-2. Further analysis of the Bcl-2 protein family
(Chapter 2, pg. 56-57) has also indicated that Stx-2 may bind with multiple Bcl-2 family
members through a conserved NWGRI amino acid motif, however no binding was
detected between Stx-2 and Bcl-2, Bcl-XL, or Bax using Caco-2 cells. The timing (delay
or otherwise) of human neutrophil apoptosis was examined in this study over the course
of 72 h following exposure to supernatant fluid from E. coli 0157:H7, strain 90-2380; a
strain that produces Stx-2.

3.0

Hypothesis

Stx-2 influences neutrophil apoptosis by a mechanism unrelated to Bcl-2, Bc1-Xl,
Bax, Bcl-w or Mcl-l binding, leading to a decrease in the baseline apoptosis rate and
thereby extending neutrophil lifespan.

4.0

Materials and Methods

4.1

Verification of Stx Genes

Four strains of E. coli 0157:H7 (Appendix A, 1.0) were analyzed for the presence
of either the stxl or stx2 gene by polymerase chain reaction (PCR) using primer
sequences published by Wang et al (210) and shown in Table 3.1. Strains 90-2380
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(stx2+), 95-2157 (stxl+), 43895 (stxl+, stx2+), and 43888 (stxl- , stx2~) were evaluated.
DNA from each strain was extracted from a loopful of bacterial cells which were
resuspended in 20pL of lysis buffer. The samples were heated in boiling water for 15 min
and 180pL of sterile, nuclease-free water was added to each sample and then centrifuged
at 13,000 rpm for 5 min. The supernatant fluid was used as the template DNA for the
PCR assay. For each sample, a 25 pL PCR reaction was prepared using 2pL of template
DNA, lpL of each primer (forward and reverse), lOpL PCR master mix (Promega,
Madison, WI) and l lp L nuclease-free water. The samples were held at 94°C for 5 min
and run for 30 cycles consisting of denaturation at 94°C for 30 sec, annealing at 54°C for
1 min, and extension at 72°C for 1 min. Upon conclusion of the cycling, the samples
were held at 72°C for 10 min for a final extension. Five pL of each PCR product was
loaded onto a 2.5% agarose gel along with 3.3pL of nuclease-free water and 1.7pL of 6x
gel loading dye (Promega). In addition, 1.6pL of a 100 base pair (bp) marker was loaded
into the first and last lane with 10.9pL nuclease-free water and 2.5pL 6x gel loading dye.
The gel was run at 100 volts for 30-45 min.

4.2

Isolation of Stx-2 Supernatant

E. coli 0157:H7 strain 90-2380 was grown overnight in 300mL Luria Burtani
(LB) broth (Appendix A, 2.2) at 37°C, and lOmL samples were placed in Petri dishes in a
BSL-2 biosafety cabinet. The lids were removed and the cultures were exposed to
ultraviolet (UV) light for 30 min. After UV exposure, the cultures were incubated for an
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Table 3.1: Primer Sequences for the Detection of stxl and stx2 Courtesy of Wans et
a l (210)

m

Stxl-a

TCTCAGTGGGCGTTCTTATG

777-796

Stxl-b

TACCCCCTCAACTGCTAATA

1114-1095

Stx2-a

GCGGTTTTATTTGCATTAGC

1228-1247

Stx2-b

TCCCGTCAACCTTCACTGTA

1342-1323

338

M17358

115

X07865
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additional 48 h and centrifuged at 16,000 x g for 15 min at 4°C. Each supernatant fluid
was collected and filtered through Pall Acrodisc® 0.2pm Supor® membranes.

4.3

Verification of Stx-2 Presence and Activity

Ten pL of sterile-filtered E. coli 0157:H7 strain 90-2380 supernatant was
analyzed to ensure that Stx-2 was present. This was achieved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and western blot using STX2-11E10
antibody raised in mice against Stx-2. Triplicate samples were diluted 1:2 in sample
preparation buffer (Appendix A, 4.13), boiled at 95°C for 5 min, loaded onto a 6%
stacking /12% resolving gel (Appendix A, 4.16), placed in a buffer tank containing SDSPAGE running buffer (Appendix A, 4.14), and run at 180V for 30-40 min. One set of
samples was placed in Coomassie Blue (Appendix A, 4.17) to stain for at least 2 h and
then destained with destain buffer (Appendix A, 4.18). The remaining samples were cut
to give two gels. These were aligned onto polyvinylidene fluoride (PVDF) membranes
(Millipore Corp, Bedford, MA), and placed into a transfer sandwich consisting of fiber
pads and filter paper. The transfer sandwich was placed into a buffer tank containing
Tris-glycine buffer (TGB) (Appendix A, 4.19) and proteins were transferred at 60V for 45 h. After transfer, the membranes were blocked overnight in Tris buffered saline (TBS)
containing 5% dehydrated skim milk (Appendix A, 4.20) at 4°C. On the following day,
one membrane was incubated for 2 h at room temperature with 10p,g/mL of the STX211E10 antibody (Toxin Technology, Sarasota, FL) and the other remained in blocking
buffer as a negative control. The membranes were rinsed 3 times in Tris buffered saline
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containing 0.05% Tween (TTBS) (Appendix A, 4.22) for 10 min each at room
temperature, and subsequently treated with anti-mouse alkaline phosphatase-conjugated
antibody (Sigma-Aldrich, St. Louis, MO) for 2 h at room temperature. The membranes
were rinsed twice in TTBS followed by a rinse in TBS for 10 minutes each at room
temperature. The blots were developed with nitro-blue tetrazolium chloride / 5-bromo-4chloro-3'-indolyphosphate p-toluidine salt (NBT/BCIP) tablets (Roche Diagnostics,
Indianapolis, IN).

The activity of the Stx-2 toxin was investigated using 50pL of sterile-filtered E.
coli 0157:H7 strain 90-2380 supernatant fluid. This was added to a 25cm2 tissue culture
flask with a confluent monolayer of African green monkey kidney (Vero) cells grown in
DMEM modified with 5% fetal bovine serum (FBS) (Appendix A, 5.5) and allowed to
incubate for 4 days. After incubation was complete, the flasks were observed at lOOx
magnification using an inverted phase-contrast microscope for rounded, retractile, or
floating cells (indicating dead cells).

4.4

Isolation and Cultivation of Neutrophils

Neutrophils were collected from human blood using a leukocyte separation
method (Sigma Aldrich) (Fig. 3.1). In a 15mL conical tube, 3mL of Histopaque™ 1119
was added followed by 3mL of Histopaque™ 1077, and 6mL of human blood. The tubes
were centrifuged at 700 x g for 30 min at room temperature. After centrifugation, layer
“B-Granulocytes” was aseptically transferred using a pipette to a 50mL conical tube and
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H|»TOM QUeM «77Htsra*aue«-ifitFigure 3.1: Sigma-Aldrich leukocyte separation method. This diagram is courtesy of
Sigma-Aldrich. Whole blood is separated into its cellular components by differential
centrifugation. Neutrophils are present in layer B - Granulocytes.
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an equal volume of Hank’s Balanced Salt Solution (HBSS) without magnesium or
calcium ions was added. The cells were washed by centrifugation at 250 x g for 10 min at
room temperature. Once centrifugation was complete, the supernatant fluid was removed
and the pellet resuspended in 12mL of 0.2% NaCl for 30 sec to lyse any remaining blood
cells. The fluid phase of the suspension was then returned to an isotonic state with the
addition of 12mL of 1.6% NaCl and centrifuged at 250 x g for 10 min. This was repeated
until all red blood cells were lysed. Neutrophils were subsequently stained with trypan
blue (Appendix A, 5.2) to assess viability and counted using a hemocytometer.
Neutrophils were seeded into a 96-well plate at a concentration of 10,000 cells in 200 pL
RPMI-1640 (Appendix A, 5.4) per well, and incubated at 37°C in a 5% CO2 atmosphere.

4.5

Assessment of Bcl-2 Family Proteins in Neutrophils

Isolated neutrophils were examined for Bcl-2 family protein content at three
different time points after isolation: 0 h chosen to represent healthy neutrophils, 6 h to
represent early apoptotic neutrophils, and 18 h corresponding to late apoptotic
neutrophils. At each time point the neutrophils were lysed with lmL Nonidet P-40 (NP40) lysis buffer, treated with leupeptin (10pM), and examined using SDS-PAGE and
western blot analysis for Mcl-1, Bax, Bcl-2, Bcl-w, and Bcl-XL. Negative controls using
secondary antibody only were also performed to ensure there was no cross-reaction of the
antibody to the lysate.

Triplicate or quadruplicate samples (as determined by the number of test
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antibodies) were diluted 1:2 in sample preparation buffer, boiled at 95°C for 5 min,
loaded onto a 6 % stacking / 12% resolving gel, placed in a buffer tank containing SDSPAGE running buffer, and run at 180V for 30-40 min. One set of samples was placed
into Coomassie Blue to stain for at least 2 h and then destained with destain buffer. The
remaining samples were cut, aligned onto PVDF membranes (Millipore Corp), and
placed into a transfer sandwich consisting of fiber pads and filter paper. The transfer
sandwich was placed into a buffer tank containing TGB and proteins were transferred at
60V for 4-5 h. After transfer, the membranes were blocked overnight in TBS containing
5% dehydrated skim milk at 4°C. On the following day, each test membrane was
incubated with the appropriate antibody (1.5pg/mL of Anti-Mcl-1 [R&D Systems
Cat#AF828]; 2|iL/mL of Anti-Bax [Biolegend Clone Poly 6251]; 2jiL/mL of Anti-Bcl-2
[Biolegend Clone Poly 6119]; 2.5pg/mL of Anti-Bcl-w [Biovision Cat #3034-100]; or
2.5|ig/mL of Anti-Bcl-XL [Biovision Cat #3312-100]) while the negative control
membrane remained in blocking buffer. The membranes were rinsed 3 times in TTBS for
1 0

min each at room temperature, and subsequently treated with anti-mouse alkaline

phosphatase-conjugated antibody (Sigma-Aldrich) for 2 h at room temperature. The
membranes were washed twice in TTBS followed by one rinse in TBS for 10 min each at
room temperature. The blots were developed with nitro-blue tetrazolium chloride / 5bromo-4-chloro-3'-indolyphosphate

p-toluidine

salt

(NBT/BCIP)

tablets

(Roche

Diagnostics).
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4.6

Analysis of Neutrophil Apoptosis & Necrosis Rates when Exposed to Stx-2

Neutrophil apoptosis and necrosis rates were measured over time at 0, 6 , 12, 18,
24, 48, and 72 hours using a cell death detection ELISA kit (Roche Diagnostics). This
ELISA system detects fragmented DNA and histone complexes, markers of cell death.
Neutrophils were isolated as described previously, a suspension was made containing
50,000 cells/mL and 200pL was dispensed into each well of a 96-well plate (Table 3.2).
All samples were tested at each of the time points indicated above. Three sample types
were tested in triplicate in 3 individual trials. The negative control consisted of
neutrophils only, the media control consisted of neutrophil suspension plus 10 pL of LB
broth, and the test sample consisted of the neutrophil suspension plus lOpL of Stx-2
supernatant from E. coli 0157:H7 strain 90-2380.

At each time point, the 96-well plate was centrifuged at 200 x g for 10 min and
the supernatant fluids were collected and held at 2-8°C to assay for necrosis. The cell
pellet was lysed for 30 min at room temperature with the lysis buffer provided in the kit
and the plate was centrifuged again at 200 x g for 10 min. The supernatant fluid was then
analyzed for apoptosis. Twenty uL of each supernatant (pre-lysis and post-lysis), positive
control (DNA-histone-complex), and background control (incubation buffer) was
transferred to a strepavadin coated plate and 80uL of immunoreagent (consisting of
incubation buffer, anti-histone biotin, and anti-DNA-POD) was added. The samples were
shaken at approximately 300rpm for 2 h at room temperature, rinsed three times with
300pL incubation buffer, and developed with lOOpL 2,2'-Azinobis [3-
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Table 3.2: Neutrophil Cell Death Detection Time Point Setup1
96-well Plate
Row/Column

1

2

3

A

C

C

C

B

M

M

M

C

T

T

T

4

5

6

7

8

9

10

11

12

D
E
F

-

G

-

H
cells were ac ded to each well suspencled in 200pL RPMI-164C1. A separate plate
was used for each time point.
1 1 0 ,0 0 0

Sample Kev:
‘C’
‘M’
‘T’

=
=
=

Negative Control (nothing added)
Media Control (10 pL LB broth added)
Test Sample (lOpL Stx-2 supernatant added)
Blank well
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ethylbenzothiazoline-6 -sulfonic acid]-diammonium salt (ABTS). Absorbance was
measured at 405nm using a Biorad 3550 microplate reader (Bio-Rad, Hercules, CA).

5.0

Results

5.1

Verification of Stx Genes

An agarose gel containing the PCR products from E. coli 0157:H7 strains was
prepared and it can be seen in Figure 3.2. Amplicons were not obtained for stxl or stx2 in
the negative control reactions (Lanes 2 & 3), indicating that the primers were specific to
the target genes. Amplicons were also not obtained for stxl or stx2 in E. coli 0157:H7
strain 43888 reactions (Lanes 4 & 5), indicating that neither toxin is produced in this
strain. An amplicon was not obtained for sfccl (Lane 6 ) but an amplicon of approximately
115 bp in size was obtained for stx2 (Lane 7) in the E. coli 0157:H7 strain 90-2380
reactions, indicating that only Stx-2 is produced in this strain. An amplicon of
approximately 340 bp in size was obtained for stxl (Lane 8 ), but no amplicon was
obtained for stx2 (Lane 9) in E. coli 0157:H7 strain 95-2157 reactions, indicating that
only Stx-1 is produced in this strain. Finally, amplicons of approximately 340 bp for .stxl
and 115 bp for stx2 (Lanes 10 & 11) were obtained for E. coli 0157:H7 strain 43895
reactions, indicating that both Stx-1 and Stx-2 are produced in this strain. These data
confirmed that the strains in question did indeed carry the genes for the toxins as outlined
in Appendix A.
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Figure 3.2: Agarose gel analysis of PCR products. DNA from four strains of
Escherichia coli 0157:H7 was amplified with primers specific to stxl and stx2. The 100
base pair ladder is in Lanes 1 and 12, negative controls for stxl and stx2 are in Lanes 2
and 3, strain 43888 for stxl and stx2 is in Lanes 4 and 5, strain 90-2380 for stxl and stx2
is in Lanes 6 and 7, strain 95-2157 for stxl and stx2 is in Lanes 8 and 9, and strain 43895
for stxl and stx2 is in Lanes 10 and 11. Amplicons were detected for stxl in strains 952157 and 43895 and stx2 in strains 90-2380 and 43895.
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5.2

Verification of Stx-2 Presence and Activity

SDS-PAGE and Western blot of Stx-2 containing supernatant fluid from E. coli
0157.H7 strain 90-2380 were prepared in Figure 3.3. Panel A shows the SDS-PAGE gel
in which multiple bands were observed. However, the most important one has been
highlighted by the box and corresponds to the molecular mass of Stx-2. Panel B shows a
Western blot of the negative control membrane that was treated only with secondary
antibody and as expected, no bands were detected. Panel C illustrates the Western blot
probed with the anti-stx-2 antibody, STX2-11E10, raised in mice and the anti-mouse
alkaline phosphatase conjugated secondary antibody. There was one band visible at
approximately 25 kDa confirming the presence of the A-subunit of Stx-2. A second band
was visible around the 47.5KD marker and this may be Stx-2 that was not completely
denatured during sample processing.

Stx-2 was confirmed in the sterile-filtered supernatant and was active and able to
elicit a cytotoxic response in Vero cells exposed to 50pL of supernatant fluid.
Examination of treated and untreated monolayers at lOOx final magnification showed
active Stx-2 (Figure 3.4). In the control without supernatant added, a confluent cell
monolayer with intact cells was observed (Fig. 3.4, A), while in the sample with 50pL of
Stx-2 supernatant fluid, many rounded, retractile (bright), and floating cells were seen as
well as a decrease in confluency of the monolayer (Fig. 3.4, B). These studies confirmed
the presence of the Stx-2 gene and the production of Stx-2 by E. coli 0157:H7 strain 902380.
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Figure 3.3: Western blot confirmation of Stx-2. Pre-stained molecular weight markers
are in Lane 1 and the supernatant fluid containing Stx-2 is in Lane 2. A) SDS-PAGE. The
band noted in the box represents Stx-2. B) Negative control Western blot probed with
anti-mouse IgG only, in the absence of Stx-2 specific antibody. No bands were detected.
C) Western Blot probed with STX2-11E10 mouse antibody and anti-mouse IgG. Stx-2
was seen in the boxed area just below the 25 kDa marker. The additional band is believed
to be Stx-2 that was not completely denatured during sample processing.
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Figure 3.4: Biological activity of semi-purified Stx-2. A) Vero cells without E. coli
0157:H7 strain 90-2380 supernatant fluid viewed at lOOx magnification. B) Vero cells
after 4 days incubation with 50pL E. coli 0157:H7 strain 90-2380 supernatant fluid
viewed at lOOx magnification. Cytotoxic effects typical of Stx-2 are shown by the large
number of rounded and refractile cells and loss of the cell monolayer confluency.
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5.3

Assessment of Bcl-2 Family Proteins in Neutrophils

SDS-PAGE and Western blot of the neutrophil lysates were prepared at times 0,
6

, and 18 h to determine the presence of Bcl-2 family proteins. Figure 3.5 shows the

results of these SDS-PAGE and Western blot analyses. In the figure, horizontal panel A
illustrates the SDS-PAGE and Western blot for the assessment of Mcl-1 while horizontal
panel B shows the assessment of Bax and Bcl-2, and finally, horizontal panel C presents
the results for Bcl-w and

B c 1-X l .

In panel A, four bands were observed, one in the

control blot and one at each time point on the blot probed with anti-Mcl-1. The first band
on both blots observed at time

0

h corresponding to freshly isolated neutrophils was

approximately 60 kDa in size; however, this was very faint and may have resulted from
non-specific antibody binding due to high protein concentration of this band. Two
identical bands at 26 kDa were seen in the 6 and 18 h preparations. Neither of these bands
corresponded to the expected size of Mcl-1 (37 kDa for the short form and 42 kDa for the
long form) ( 1 1 1 , 128); however, these bands did correspond with previously observed
similar bands from Caco-2 cells perhaps indicating an antibody cross-reaction with other
pro-apoptotic proteins such as Bak, which has an expected molecular weight of 25-28
kDa (58, 111). Thus, it cannot be definitively stated that the neutrophils expressed Mcl-1
at any of the three time points.

In panel B, a band was detected at approximately 62 kDa for both Bax (column 3)
and Bcl-2 (column 4) in freshly isolated neutrophils, however this band was also
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Figure 3.5: Assessment of Bcl-2 family proteins in neutrophils over 18 hours. A)
SDS-PAGE (column 1) and western blots probed with anti-rabbit IgG (negative control,
column 2) and anti Mcl-1 followed by anti-rabbit IgG (anti-Mcl-1, column 3). One non
specific interaction was noted on both blots at 60 kDa, and two bands were noted on the
anti-Mcl-1 blot which are indicative of a reaction with an unknown 26 kDa protein,
potentially Bak. B) SDS-PAGE (column 1) and western blots probed with anti-rabbit IgG
(negative control, column 2), anti-Bax followed by anti-rabbit IgG (anti-Bax, column 3),
and anti-Bcl-2 followed by anti-rabbit IgG (anti Bcl-2, column 4 ). One non-specific
interaction was noted on all blots at 60 kDa, and one band representative of Bcl-2 dimers
was observed on the blot probed with anti-Bcl-2. C) SDS-PAGE (column 1) and western
blots probed with anti-rabbit IgG (negative control, column 2), anti-Bcl-w followed by
anti-rabbit IgG (anti-Bcl-w, column 3), and anti-Bcl-XL followed by anti-rabbit IgG (antiB c 1-X l , column 4 ). Two similar bands were observed on the blots probed with anti-Bcl-w
and anti-Bcl-XL at 60 kDa but this was thought to be a non-specific interaction related to
high sample protein load.
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observed very faintly in the negative control (column 2). It is believed that neither result
was specific for the antibody tested, and probably was the consequence of non-specific
secondary antibody binding due to the high protein concentration of this band. In
addition, there was a second pronounced band detected on the membrane probed with
anti Bcl-2 at approximately 52 kDa. This band does not correspond to the expected size
of 26 kDa for Bcl-2, although it is possible that it may represent a dimer of Bcl-2.

In panel C, a faint band was detected for both Bcl-w (column 3) and

B c 1-X l

(column 4) in freshly isolated neutrophils at approximately 60 kDa, however much like
that of Mcl-1, it is believed that this may be a result of non-specific antibody binding due
to high protein concentrations of this band as seen in the SDS-PAGE (column 1). A
similar phenomenon was found in the 18 h sample and the same band was again observed
for both samples due to the higher protein load as seen in the SDS-PAGE. Neither result
was specific for the antibody tested, nor were Bcl-w and

B c 1-X l

detected in any

neutrophil samples.

In summary Bcl-2 was the only protein detected in this study. These studies were
not repeated since the only bands observed were associated with non-specific binding due
to high protein load. Loading less protein would not increase the chances of protein
detection. A study by Moulding et a l indicated that freshly isolated neutrophils produced
Bax, Mcl-1, and very low levels of Bcl-2 (128). Even though the results in the present
study do not match, it is believed that these proteins may be present at some point during
the cell’s lifespan and potential interactions could still occur.
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5.4

Analysis of Neutrophil Apoptosis & Necrosis Rates when Exposed to Stx-2

The cell death detection ELISA was used to determine, over time, the apoptosis
and necrosis rates induced by Stx-2 in neutrophils. For this assay, absorbance readings
were adjusted for background interference by subtracting the average background control
value from the results on each respective plate and these results were then standardized
by expressing the final result as a percent of the positive control provided in the kit for
each assay. This was done in order to assess the rates of apoptosis/necrosis over time
since the assay development time was not standardized between plates. Necrosis rates
have been summarized in Figure 3.6 and apoptosis rates in Figure 3.7. Once the data had
been standardized across all tests, a t-test was performed to assess the effects of the
culture medium (LB broth) and the Stx-2-containing supernatant fluid on neutrophil
apoptosis and necrosis rates. The negative control (without medium or toxin) was
compared to the LB medium control (medium only), and the medium control was
compared to the Stx-2 containing supernatant fluid to determine if significant differences
between neutrophil apoptosis and necrosis rates were observed.

There was a significant decrease (p < 0.05) between the negative control and
medium control necrosis rates up to and including 18 h suggesting that the medium may
have provided some protective effect to the neutrophils against necrosis. There was also a
significant decrease (p < 0.05) in neutrophil necrosis rates between the medium control
and the neutrophils exposed to Stx-2 up to and including 18 h. At 24 h, the necrosis rates
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Neutrophil Necrosis Rates Over Time

120

100

Ohr

6hr

12hr

18hr

24hr

48hr

72hr

Time
■ N egative Control

■ Media Control

Stx-2 Su p ern atan t

Figure 3.6: Necrosis rates of neutrophils exposed to Stx-2 supernate for 72 h. Data
are presented as the average percent necrosis when compared to the positive assay
control. Error bars represent the standard deviation calculated between the averaged
triplicates. Necrosis rates of neutrophils exposed to Stx-2 were significantly reduced
(p<0.05) at all time points except 24 h.
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Neutrophil Apoptosis Rates Over Time

120

100

•5

80

Ohr

6hr

12hr

18hr

24hr

48hr

72hr

Time
■ N egative Control

■ M edia Control

Stx-2 S u p ern atan t

Figure 3.7: Apoptosis rates of neutrophils exposed to Stx-2 supernate for 72 h. Data
are presented as the average percent apoptosis when compared to the positive assay
control. Error bars represent the standard deviation calculated between triplicates.
Apoptosis rates of neutrophils exposed to Stx-2 were significantly reduced (p<0.05) at
the 6 h and 1 2 h time points.
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were similar, but decreased at 48 and 72 h, most likely due to the simultaneous increase
in apoptosis.

There were no significant differences observed between the negative control and
medium control apoptosis rates; however, there was a significant decrease (p < 0.05) in
neutrophil apoptosis rates between the medium control and the neutrophils exposed to
Stx-2 up to and including 12 h. After that point, the apoptosis rates were similar to the
controls.

In summary, the data obtained during this study show that neutrophils exposed to
Stx-2 have less necrosis than the untreated controls at all time points except 24 h, where
the rates are similar. In addition, the data show that these neutrophils exhibit a delay in
apoptosis for the first

12

h of exposure, followed by an increase in apoptosis that matched

the controls for the remaining time points tested. This shows that Stx-2 did play a role in
increasing neutrophil lifespan. The exact mechanism of how this occurs is still to be
elucidated but it may potentially be due to the interaction of Stx-2 and pro-apoptotic
proteins other than those tested in this study.

6.0

Discussion

It is thought that neutrophils may provide a way for Stx-2 to be distributed
throughout the body during infection (195). Therefore, during pathogenesis, it is critical
that neutrophils remain within the circulation and tissues to provide maximum
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distribution of the toxin, and indeed this is observed (37, 208). Previous studies on the
impact of Stx-2-induced neutrophil apoptosis have shown conflicting results. Liu et al.
(118) observed a time- and dose-dependent delay in spontaneous neutrophil apoptosis
when exposed to Stx-2 whereas Flagler et al. (51) did not. The goal of the present
experiments was to assess the effects that Stx-2-containing E. coli 0157:H7 supernatant
fluid had on neutrophil apoptosis and necrosis rates. A cell death detection ELISA was
used to obtain simultaneous neutrophil apoptosis and necrosis rates following exposure to
Stx-2. It was hypothesized that Stx-2 influences neutrophil apoptosis by a mechanism not
related to Bcl-2, Bcl-XL, Bax, Bcl-w or Mcl-1 binding (as determined in Chapter 2) and
this leads to a decrease in the baseline apoptosis rate, thereby extending neutrophil
lifespan. A study by Moulding et al. (128) indicated that freshly isolated neutrophils
produced Bax, Mcl-1, and very low levels of Bcl-2. The data obtained in this study
showed that neutrophils did not contain

B c 1-X l ,

Bax, Mcl-1 or Bcl-w at 0, 6 , and 18h

after isolation, but did contain Bcl-2 dimers in freshly isolated neutrophils. In addition, an
unknown protein was detected in an antibody cross-reaction that corresponded to the
molecular weight of Bak as seen previously with Caco-2 cells (Chapter 2), however an
antibody specific for Bak was not available to confirm this. This data and data generated
previously by Moulding et al. (128) and Ruemmele et al. (163) support the notion that
Bcl-2 family protein expression does vary during the lifespan of the cell. This may
influence the interactions of Stx-2 within the cell depending upon at what point the toxin
is endocytosed.
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Data produced in this study also showed that medium used to grow E. coli
0157:H7 was protective against Stx-2 induced necrosis but had no effect on Stx-2
induced neutrophil apoptosis. The reasons for this are unknown, but it is suspected that
the extra nutrients in the medium allowed the cells to live longer or prevented oxidative
burst from occurring. Bax was not detected in neutrophils in this study, yet a delay in
Stx-2 induced apoptosis up to and including 12 h was observed (p<0.05). It is possible
that Stx-2 bound with the unknown protein suspected to be Bak, in turn reducing
neutrophil apoptosis. A similar study performed with Helicobacter pylori water extracts
showed that the expression of Bax and Bak was upregulated in HL-60 cells, human
promyeolocytic leukemia cells which can differentiate into neutrophil-like cells, during
neutrophilic differentiation (98). If Bak was upregulated in the experiments performed
here, it may provide high concentrations of protein for Stx-2 to bind to in the
endoplasmic reticulum or cytosol, thus leaving the anti-apoptotic proteins free to promote
cell survival. Stx-2 induced neutrophil necrosis was significantly decreased (p<0.05) at
all time points except 24 h, showing an overall trend of reduced cellular necrosis. No
difference in the oxidative burst of neutrophils was found between patients with and
without HUS (74), therefore it seems that inhibition of oxidative burst could not be the
cause of reduced necrosis. It is possible, that if Stx-2 bound Bax within the endoplasmic
reticulum, there would be less Stx-2 available to elicit N-glycosidase activity on the
ribosomes of the cell, which is the primary cause of Stx-2 induced cellular necrosis (47).

Overall, the data from these assays confirm that a delay in neutrophil apoptosis
occurs up to and including 12 h after exposure to Stx-2 and a significant decrease in
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necrosis at all time points except 24 h after exposure. It is theorized that this may be a
result of Stx-2 triggering apoptosis within the endoplasmic reticulum of the cell.
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CHAPTER 4

GENERATION OF MUTANT STX-2 G225A

1.0

Abstract

A mutation was generated in the gene encoding Stx-2 in E. coli 0157:H7 at
amino acid position 225 using splicing by overlap extension PCR (PCR SOE). The
objective of this mutation was to change this sequence from NWGRI to NWARI, thereby
abolishing the ability of the mutated Stx-2 to trigger apoptosis and so demonstrating a
decreased pathogenicity for the toxin. The mutated gene was ligated to pBR322 and
transformed into E. coli 0157:H7 strain 43888 (a strain that produced neither Stx-1 nor
Stx-2) in order to express and purify the toxin and determine its pathogenicity compared
to native Stx-2.

2.0

Introduction

Apoptosis (programmed cell death) is a normal function of cells. It is mediated by
the Bcl-2 protein family (46). These proteins are classified into two groups based on
functional activity; they are either pro-survival or pro-apoptosis proteins, and they are
divided into three subfamilies: the Bcl-2 subfamily, the Bax subfamily, and the BH3
subfamily (2). The Bcl-2 subfamily promotes cell survival while the Bax and BH3
subfamilies promote apoptosis (2). All of these proteins share at least one of four possible
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conserved motifs (BH1, BH2, BH3 or BH4) known as Bcl-2 homology domains which
play a role in the function of the proteins (2). The proteins with the closest resemblance
to Bcl-2 contain all four homology domains (2). On the other hand, the Bax and BH3
subfamilies differ in their homology domain content despite their shared pro-apoptosis
cellular role and contain only the BH3 domain (95).

The process by which Bcl-2 family proteins regulate apoptosis has been
documented (4, 151, 177, 181). In essence, BH3-only proteins are activated by signaling
pathways, and then these activate either proapoptotic proteins or inhibit antiapoptotic
proteins (or both). Activated proteins form oligomers in the mitochondrial outer
membrane leading to the release of cytochrome c and other proapoptotic proteins, unless
they are inhibited by Bcl-2 proteins. These proteins then activate caspases which
eventually cause the cell to undergo apoptosis (4, 151,177,181).

Both pro-survival and pro-apoptosis proteins have the ability to form homo- and
heterodimers with each other, suggesting that the relative concentration of the proteins
may play a role in the outcome of the cell’s fate (144). It is known that the BH1, BH2,
and BH3 domains strongly influence the formation of homodimers and heterodimers, and
that these regions create an elongated hydrophobic cleft into which a BH3 amphipathic
alpha helix can bind (129, 171). Heterodimerization is not required for pro-survival
function, but it is required for the pro-apoptosis function of proteins in the BH3
subfamily and possibly also those of the Bax subfamily (2, 36, 95). It is noted that these
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proteins may bind in a preferential fashion, as it has been shown that not all pro-apoptosis
and pro-survival proteins interact (2 ).

Zhang et al. (227) investigated the mechanisms of Bcl-2 protein family
interactions under normal and apoptotic conditions in an effort to understand homo- and
heterodimerization regulation. Their work was accomplished by performing mutations to
different areas of the Bcl-2 protein and measuring the resultant ability to form homo- and
heterodimers. Results of the study determined that Bcl-2 dimerization involved the use of
an acceptor and donor surface shown in Figure 4.1. The acceptor surface was able to bind
both Bcl-2 and Bax; however, the donor surface was only able to bind Bcl-2 (227).

Suzuki et al (190) investigated the binding capabilities of Bcl-2 and Stx-2 and
determined that these proteins were able to bind. It is suspected that this interaction
occurs by mimicking the Bcl-2 protein family. The pentameric amino acid sequence,
NWGRI that is common to both Bcl-2 and Stx-2 occurs within the center of the acceptor
surface described by Zhang et al. (227). In order to determine if Stx-2 has the ability to
heterodimerize with the Bcl-2 family of proteins within neutrophils in the manner
described by Zhang et al. (227), the present study was designed to examine the rate at
which neutrophil apoptosis occurs when a point mutation at the center of the aligning
NWGRI sequence (G225A) is introduced by PCR SOE, a method first described by
Higuchi et al. (70).
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Figure 4.1: The Bcl-2 dimerization interface. This diagram, adapted from Zhang et al.
(227), was modeled based upon previously determined Bcl-2 core structure (150). Two
distinct surfaces were discovered: A) the acceptor surface and B) the donor surface. The
middle of the binding surface is located at the G145 position (see arrows). This portion of
the molecule is the same portion that contains the pentameric sequence found in Stx-2
(NWGRI).

3.0

Hypothesis

An introduced mutation of glycine to alanine at amino acid position 225 in Stx-2
will result in reduced virulence of Stx-2 due to the inability of the toxin to trigger the
apoptotic pathways, thereby interrupting the normal apoptotic process in these cells.

4.0

Materials and Methods

Authorization to complete this recombinant DNA project was obtained from the
UNH Institutional Biosafety Committee (IBC) under approval number R:2-2007
(Appendix D).

4.1

Determination of E. coli Q157:H7 strain 43888 Susceptibility Profile to
Ampicillin

A minimum inhibitory concentration (MIC) assay was performed to determine the
antibiotic susceptibility pattern of E. coli to ampicillin. A solution of ampicillin (Sigma
Aldrich, St. Louis, MO) was prepared at a concentration of 25mg/mL in sterile PBS and
filter sterilized. Thirty two pL of this solution was added to 1968pL of LB broth to give a
final concentration of 400pg/mL ampicillin. A 1:2 dilution series was prepared in
duplicate by transferring lmL of this broth to a new tube containing lmL fresh LB broth.
Six tubes were prepared with ampicillin concentrations ranging from 400pg/mL to
25pg/mL. A positive control was also prepared without ampicillin. Each tube was
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inoculated with 50pL of an overnight culture of E. coli 0157:H7 strain 43888 and
incubated at 37°C for 24 h. Two hundred pL of each suspension from the

6

tubes

containing ampicillin and bacteria were added in duplicate to the wells of a 96 well plate,
and the opacity was read at 600nm on a Biorad 3550 microplate reader (Biorad, Hercules,
CA).

4.2

Creation of a Recombinant Plasmid: Mutant stx2 with Vector p BR322

4.2.1

Primer Design and PCR

The sequence of Stx-2 producing E. coli 0157:H7 VT2-Sakai (NCBI Reference
Sequence NC 002695.1) was used for primer design. The stx2 gene comprises two parts;
the Stx-2 subunit A gene and the Stx-2 subunit B gene with a promoter region. The
genome encompassing these genes is depicted in Figure 4.2. Primers were created that
cloned the sequence from base pair 1266525 to 1268219, and these are shown in Table
4.1. Primers were designed using the GeneFisher2 Interactive PCR Primer Design
program on the Bielefeld University Bioinformatics Server (BiBiServ) and checked with
NetPrimer software (Premier Biosoft, Palo Alto, CA). Primers were synthesized
(Integrated DNA Technologies, Coralville, IA) and purified using standard desalting
processes. The complete sequence that was cloned is listed in Figure 4.3. NEBcutter
(New England Biolabs, Ipswich, MA) was used to determine the appropriate enzyme
restriction sites to add to the end of the primer sequences to allow for insertion into
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pBR322 (Figure 4.4), thereby eliminating the risk of cutting the cloned sequence during
insertion.

4.2.2

Mutation of stx2 using PCR SOE

E. coli 0157:H7 strain 90-2380 was grown overnight at 37°C, and genomic DNA
was isolated using the UltraClean™ Microbial DNA Isolation Kit (MoBio Laboratories
Inc., Carlsbad, CA) following the manufacturer’s instructions. An alternative lysis
method was used in order to reduce the amount of DNA shearing and lessen the chance
of unwanted damage to large DNA. PCR was performed using genomic DNA and the
primers listed in Table 4.1. The mutagenesis primers were designed using Stratagene’s
Quick Change Primer Design Program (http://www.stratagene.com/qcprimerdesign.com)
and the suggested guidelines for mutagenesis primer design in the QuickChange® SiteDirected Mutagenesis kit instruction manual. Primers were synthesized by Integrated
DNA Technologies and purified using polyacrylamide gel electrophoresis (PAGE).

An stx2 mutant construct was generated by PCR SOE following published
protocols by Horton et al. (71) using the Expand Long Template PCR system and
supplied Buffer 3 (Roche Applied Science, Indianapolois, IN). The outer forward and
reverse primers contained engineered restriction enzyme sites (SphI and EcoRI
respectively) to aid in directional cloning of the cloned stx2 gene. Internal,
complementary forward and reverse SOE primers containing a single base pair mutation
(G to C, resulting in a change in protein coding from glycine to alanine) were also
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designed (Table 4.1). The first two PCR amplicons were generated with 1) Stx2-Sphl-F
with G225A_reverse mutagenic primer and 2) G225A forward mutagenic primer with
Stx2-EcoRI-R, using the stx2 gene (amplified with Expand HiFi plus enzyme) as a
template. Following amplification, the PCR products were gel purified (Epock Biolabs,
Missouri City, TX), combined at equal molarity, and a second round of SOE was
performed using the purified PCR products as a template and outer primers only (Stx2Sphl-F and Stx2-EcoRI-R). A second PCR amplification was conducted with the purified
SOE product to increase the yield, and the amplicon was gel purified prior to cloning.
The expected size of the mutant stx2 gene was 1743bp.

4.2.3

Insertion of Mutant stx2 into pBR322

In order to insert the mutant stx2 gene into pBR322 (see Fig. 4.5), both the SOE
product and pBR322 were double digested with SphI and EcoRI (New England Biolabs)
at 37°C for 2 h in the manufacturer’s suggested buffer and this was then heat inactivated
at 65°C for 20 min. This was performed to remove the tetR gene, allowing screening for
inserts by sensitivity to tetracycline. Once digestion was complete, the mutant stx2 gene
was ligated into pBR322 using a 3:1 insert:vector ratio with T4 ligase (New England
Biolabs). The ligation was performed overnight with thermal cycling alternating between
10°C for 30 sec and 30°C for 30 sec. This temperature-cycle ligation method was
demonstrated to have higher cloning efficiency than the typical method ( 1 2 1 ).
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Figure 4.2: Genome map of the stx2 gene. This genome map (base pair 1266525 - 1268219) is courtesy of the
Comprehensive Microbial Resource (http://cmr.icvi.org/tigr-scripts/CMR/CmrHomePage.cgi). This map is derived from the
Escherichia coli 0157:H7 VT2-Sakai strain (NCBI Accession # NC 002695) and includes the stx2 subunit A (base pair
1266965 - 1267924) and stx2 subunit B (base pair 1267936 - 1268205) genes as well as the upstream sequence containing the
gene promoters (base pair 1266525 - 1266924).

Table 4.1: Primer Sequences
Name

Sequence

5’- TAT TAA GCA TGC CGG GCG
TTTTGAGCA -3’
5’- TAA TGA ATT CGT TAC CCA
Stx2-EcoRI-R
CAT ACC ACG A -3’
5’- CTC ACT CTG AAC TGG GCG
G225A1
CGA ATC AGC AAT GTG -3’
5’- CAC ATT GCT GAT TCG CGC
G225A_antisense1
CCA GTT CAG AGT GAG -3’
Stx2-Sphl-F

pBR322-653-R

5’- TCT CAA GGG CAT CGG TC -3’

pBR322-4327-R

5’- GCC TCG TGA TAC GCC TA -3’

Stx2-A2
Stx2-B2

5’- GCG GTT TTA TTT GCA TTA
GC-3’
5’- TCC CGT CAA CCT TCA CTG
TA -3’

Description
Forward stx2 primer
with SphI cutting site
Reverse stx2 primer
with EcoRI cutting site
Forward stx2
mutagenesis primer
Reverse stx2
mutagenesis primer
Reverse pBR322-s/x2
vector-insert junction
primer
Reverse pBR322-,s*c2
vector-insert junction
primer
Forward stx2 primer
Reverse stx2 primer

1 These mutagenesis primers were designed using Stratagene’s quick change primer
design program.
2 These primers were previously designed by Wang et al. (210).
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GTGCAATTGGCGTTGAGCTGGAGAGfGGGCGTTTTGAGCAfiACGGTCAGGGAAGT
TCAGAATGTAGTCAGTCAGAACGGATGATATTGCAGGATTAGTTACGTACCGTTATT
ATCCTGCGCCCGGCCCTTTAGCTCAGTGGTGAGAGCGAGCGACTCATAATCGCCAGG
TCGCTGGTTCAAATCCAGCAAGGGCCACCATATCACATACCGCCATTAGCTCATCGG
GACAGAGCGCCAGCCTTCGAAGCTGGCTGCGCGGGGTTCGAGTCCTCGATGGCGGTC
CATTATCTGCATTATGCGTTGTTAGCTCAGCCGGACAGAGCAATTGCCTTCTGAGCAA
TCGGTCACTGGTTCGAATCCAGTACAACGCGCCATATTTATTTACCAGGCTCGCTTTT
GCGGGCCTTTTTTATATCTGCGCCGGGTCTGGTGCTGATTACTTCAGCCAAAAGGAAC
ACCTGTATATGAAGTGTATATTATTTAAATGGGTACTGTGCCTGTTACTGGGTTTTTC
TTCGGTATCCTATTCCCGGGAGTTTACGATAGACTTTTCGACCCAACAAAGTTATGTC
TCTTCGTTAAATAGTATACGGACAGAGATATCGACCCCTCTTGAACATATATCTCAG
GGGACCACATCGGTGTCTGTTATTAACCACACCCCACCGGGCAGTTATTTTGCTGTGG
ATATACGAGGGCTTGATGTCTATCAGGCGCGTTTTGACCATCTTCGTCTGATTATTGA
GCAAAATAATTTATATGTGGCCGGGTTCGTTAATACGGCAACAAATACTTTCTACCG
TTTTTCAGATTTTACACATATATCAGTGCCCGGTGTGACAACGGTTTCCATGACAACG
GACAGCAGTTATACCACTCTGCAACGTGTCGCAGCGCTGGAACGTTCCGGAATGCAA
ATCAGTCGTCACTCACTGGTTTCATCATATCTGGCGTTAATGGAGTTCAGTGGTAATA
CAATGACCAGAGATGCATCCAGAGCAGTTCTGCGTTTTGTCACTGTCACAGCAGAAG
CCTTACGCTTCAGGCAGATACAGAGAGAATTTCGTCAGGCACTGTCTGAAACTGCTC
CTGTGTATACGATGACGCCGGGAGACGTGGACCr€^GTeT6MGI«»i©G^i&|!f
CA©CdiA.T©Ti5CTTCCGGAGTATCGGGGAGAGGATGGTGTCAGAGTGGGGAGAATAT
CCTTTAATAATATATCAGCGATACTGGGGACTGTGGCCGTTATACTGAATTGCCATCA
TCAGGGGGCGCGTTCTGTTCGCGCCGTGAATGAAGAGAGTCAACCAGAATGTCAGAT
AACTGGCGACAGGCCTGTTATAAAAATAAACAATACATTATGGGAAAGTAATACAG
CTGCAGCGTTTCTGAACAGAAAGTCACAGTTTTTATATACAACGGGTAAATAAAGGA
GTTAAGCATGAAGAAGATGTTTATGGCGGTTTTATTTGCATTAGCTTCTGTTAATGCA
ATGGCGGCGGATTGTGCTAAAGGTAAAATTGAGTTTTCCAAGTATAATGAGGATGAC
ACATTTACAGTGAAGGTTGACGGGAAAGAATACTGGACCAGTCGCTGGAATCTGCA
ACCGTTACTGCAAAGTGCTCAGTTGACAGGAATGACTGTCACAATCAAATCCAGTAC
CTGTGAATCAGGCTCCGGATTTGCTGAAGTGCAGTTTAATAATGACTGAGGCATAAC
CTGATfCGTGGTATGTGGGTAACAAGTGTAATCTGTGTCACAATTCAGTCAGTTGA
CAGTTGCCTGTCAGACTGAGCATTTGTTAAA
Figure 4.3: Genomic sequence of stx2 from Escherichia coli 0157:117 VT2-Sakai.
Nucleotides 1266500- 1268300 (forward strand). The forward and reverse primers used
to clone the gene are bolded and boxed respectively near the beginning and end of the
sequence. The genomic sequence representing the NWGRI protein region has been
bolded and shaded.
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Figure 4.4: Restriction enzyme map of the cloned stx2 gene. This restriction enzyme map (base pair 1266525 - 1268219)
is courtesy of NEBcutter (http://tools.neb.com/NEBcutter2/index.php) and derived from Escherichia coli 0157:H7 VT2Sakai (NCBI Accession # NC 002695). Available enzyme cutting sites are indicated by cleavage type.
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Figure 4.5: Vector map of pBR322. This map is courtesy of New England Biolabs. The
vector will confer ampicillin and tetracycline resistance to the transformed bacteria
without inserts. The mutated stx2 segment was inserted at the EcoRI and SphI restriction
sites, highlighted by the boxes above.
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4.3

Transformation of the Recombinant Plasmid into E. coli Q157:H7 Strain
43888

4.3.1

Preparation of Electrocompetent E. coli Q157:H7 Strain 43888

E. coli 0157:H7 strain 43888 cells were made competent and prepared for
electroporation through a series of ice-cold centrifugation and washing steps. Fifty mL of
LB broth was inoculated with E. coli and allowed to incubate overnight at 37°C with
vigorous shaking. On the following day, lmL of overnight culture was transferred to
200mL of fresh LB broth and the optical density was measured at 600nm. The new
culture was placed into the 37°C incubator and monitored hourly until the optical density
reached approximately 0.400. At that point, the culture was placed on ice and swirled
gently until well chilled. The culture was split in half, placed into 2 x 250mL pre-chilled
sterilized centrifuge bottles, and centrifuged at 4,000 x g for 10 min at 4°C. The
supernatant was discarded, each cell pellet was washed by resuspending in 200mL
sterilized ice-cold water, and the samples were centrifuged again under the same
parameters. The cells were washed once more with lOOmL sterilized ice-cold water, and
centrifugation was repeated a third time. The supernatant was discarded and the pellets
were resuspended in lOOmL sterilized ice-cold 10% glycerol and combined into one
centrifuge tube. A final centrifugation at 4,000 x g for 10 min at 4°C was done and the
electrocompetent cells were resuspended in 2mL sterilized ice-cold 10% glycerol. The
culture was dispensed into individual microcentrifuge tubes (40pL/tube) and frozen
immediately at -80°C.

128

4.3.2

Electroporation of Electrocompetent E. coli 0157:H7 Strain 43888 cells
with stx2 and pBR322

Clean, sterile electroporation cuvettes with a 1mm gap between side walls were
placed into an ice bucket and allowed to chill. Each sample was processed separately to
ensure DNA degradation did not occur prior to exposure to electrical current. Just before
electroporation, four tubes of electrocompetent E. coli were removed from the -80°C
freezer and allowed to thaw on ice. Two pL of DNA was added to one tube containing
thawed electrocompetent E. coli cells for each of the sample types listed in Table 4.2. The
contents of each tube were subsequently transferred to pre-chilled electroporation
cuvettes and immediately placed into the electroporator where 1800 volts were applied
for 4 milliseconds. At this time 400pL of SOC medium (Appendix A, 2.7) was added.
The suspension was immediately transferred to a sterilized 1.5mL microcentrifuge tube
and the cells were allowed to recover at 37°C for 1 h with gentle shaking. Upon
completion of the recovery step, each sample was spun at 10,000 x g for 30 sec,
resuspended in lOOmL fresh SOC medium, and plated as follows: lOpL was spread onto
a LB plate as a control to ensure viability of the cells, 90pL was spread onto LB plates
containing lOOpg/mL ampicillin in triplicate, and 90pL was spread onto a LB plate
containing 20pg/mL tetracycline.
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Table 4.2: Samples Electroporated Into E. coli 0157:H7 strain 43888
Number

Sample Name

1

Nuclease-free water (negative control)

2

Supercoiled pBR322 plasmid (positive control)

3

stx2 vector only ligation

4

stx2 vector and pBR322 insert ligation
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4.4

Verification of Recombinant Plasmid Transformation into E. coli Q157:H7
Strain 43888

A selection of ampicillin-resistant colonies was patched onto LB agar plates with
tetracycline (20pg/mL). The colonies that showed sensitivity to tetracycline were
screened with PCR using Stx2-Sphl-F and Stx2-EcoRI-R to determine if the mutant stx2
insert was detected. A plasmid prep and additional PCR reaction using the same primers
were also performed to confirm that the cells had the mutant 5 /x2 -containing plasmid. An
additional PCR reaction used cross-junction primers (pBR322-653-R and pBR322-4327R) to ensure that the mutant stx2 gene was inserted into the plasmid at the correct
location.

Plasmids were purified using the PureYield Plasmid Miniprep System (Promega,
Madison, WI) according to the manufacturer’s instructions. Plasmid DNA was probed
with two sets of primers. Set 1 consisted of Stx2-A and Stx2-B primers, which amplify a
115bp product located within stx2. Set 2 consisted of Stx2-B and pBR322-653R primers,
which amplify a 1649bp segment that spans the stx2 insert and pBR322 vector junction.

Sequencing was performed on four clones (L4, L14, L42, and L94) using
pBR322-653R and pBR322-4327-R primers. The sequences were blasted using NCBI
Blast: Nucleotide Sequence and aligned to E. coli 0157:H7 strain Sakai, complete
genome (Accession # NC_002695.1) to determine homology to stx2.
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4.5

Creation of Mutant Clone Stocks

Overnight cultures of E. coli 0157:H7 mutant clones were frozen at -80°C in LB
broth containing 15% glycerol and lOOpg/mL ampicillin.

5.0

Results

5.1

Determination of E. coli Q157:H7 strain 43888 Susceptibility Profile to
Ampicillin

The assay was performed with duplicate samples and results are summarized in
Table 4.3. No growth was detected in any of the wells containing antibiotic indicating
that E. coli 0157:H7 strain 43888 was inhibited by ampicillin at concentrations greater
than or equal to 25pg/mL.

5.2

Creation of a Recombinant Plasmid: Mutant stx2 with Vector pBR322

Primer design, PCR SOE, enzyme digestion, and insert-vector ligation were
performed and a recombinant plasmid was created as outlined in Figure 4.6. Gel
electrophoresis indicated a successful PCR SOE product was obtained with a length of
approximately 1734bp, and analysis of the stx2-pBR322 recombinant plasmid indicated
successful ligation with the expected overall size of approximately 5,500bp.
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Table 4.3: MIC Assay for E. coli 0157:H7 Strain 43888 and Ampicillin

Ampicillin
(Sigma)

1

0.485

0.017

0 .0 0 0

0.005

0.007

-0 . 0 0 1

2

0.493

0.027

0.008

0.013

0 .0 1 0

0.004

3

0.521

0.023

0.029

0.013

0.004

0 .0 0 1

4

0.530

0.019

0.026

0 .0 1 1

0 .0 0 1

0 .0 0 2
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Figure 4.6: Vector map of recombinant plasmid stx2-pBR322. This map is adapted
from New England Biolabs. The mutated stx2 gene is shown inserted at the EcoRI and
SphI restriction sites. This vector conferred only ampicillin resistance to the transformed
bacteria.
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5.3

Verification of Recombinant Plasmid Transformation into E. coli Q157:H7
Strain 43888

The stx2-pBR322 recombinant plasmid was successfully transformed into E. coli
0157:H7 strain 43888. Nine colonies were identified to be ampicillin resistant and
tetracycline sensitive. PCR results indicated that the following clones contained the
mutant stx2 inserted at the correct location within the plasmid: L4, LI4, L25, L31, L42,
L43, L87, L93, and L94 and these are shown in Figure 4.7. The secondary PCR showed
positive results for the stx2 specific gene primers that produced a 118bp amplicon for all
samples (Figure 4.8). Results of the plasmid preparation show plasmid bands aligned
approximately with the 6 ,0 0 0 bp marker; however, the resolution of this marker was not
very high so it was difficult to detect the precise molecular weight (Figure 4.9). It is
suggested that this is the stx2-pBR322 plasmid. The remaining bands in the preparation
were thought to be supercoiled and knicked plasmid DNA.

Results of the sequencing indicated that three (L14, L42, and L94) of the four
clones contained the point mutation at G225 (Figure 4.10, 4.11, 4.12, and 4.13). The
identity match of these clones to E. coli 0157:H7 strain Sakai, complete genome
(Accession # NC_002695) was 94% (L14), 99% (L42), and 92% (L94). The clone that
did not contain the mutation (L4) had poor sequence quality with an identity match of
78%.
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KI;| j

Figure 4.7: Verification of recombinant stx2-pBR322 plasmids. A) Lane 2-9 contains
ampicillin resistant and tetracycline sensitive clones showing the correct insert size of
1743bp. B) Lane 2 shows ampicillin resistant and tetracycline sensitive clone L94
showing the correct insert size of 1743bp, Lane 3-5 shows clones having incorrect insert
sizes, Lane 6 shows PCR SOE control (product prior to ligation with pBR3222), and
Lane 7-8 show genomic DNA controls for E. coli 0157:H7 strain 90-2380 and 43888
respectively.
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Lane
1
2

3
4
5
6

7
8

Description
500 bp - 10 kbp Ladder
L4
L14
L25
L31
L31
L42
L43

Lane
9
10
11
12

13
14
15

Description
L87
L87
L93
L94
LI (control)
L7
L13

Figure 4.8: Verification of the stx2 insert within the recombinant stx2-pBR322
plasmid. The boxed area shows all clones contained the stx2 insert as illustrated by a
band at approximately 1 2 0 bp.
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Lane
1
2

3
4
5
6

7
8

Description
500 bp - 10 kbp Ladder
stx2 SOE Product
90-2380 (positive control)
43888 (negative control)
water only control
Plasmid prep L4
Plasmid prep LI4
Plasmid prep L25

Lane
9
10
11
12

13
14
15

Description
Plasmid prep L31
Plasmid prep L43
Plasmid prep L87
Plasmid prep L42
Plasmid prep L93
Plasmid prep L94
50 bp-2 kbp Ladder

Figure 4.9: Verification of recombinant plasmid size. Lane 6-14 shows ampicillin
resistant and tetracycline sensitive E. coli 0157:H7 strain 43888 clones indicating the
presence of the recombinant stx2-pBR322 plasmid (expected size ~5.5Kbp).
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Figure 4.10: E. coli clone L14 sequence alignment. Alignment of E. coli clone L14 to
Accession NC 002695.1 (E. coli 0157:H7 strain Sakai, complete genome). Identity
match was 94% and the mutation was observed (C->G) at nucleotide 409 of the query
strand (see boxed area).
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Figure 4.11: E. coli clone L42 sequence alignment. Alignment of E. coli clone L42 to
Accession NC 002695.1 (E. coli 0157:H7 strain Sakai, complete genome). Identity
match was 99% and the mutation was observed (C->G) at nucleotide 400 of the query
strand (see boxed area).
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Figure 4.12: E. coli clone L94 sequence alignment. Alignment of E. coli clone L94 to
Accession NC 002695.1 {E. coli 0157:H7 strain Sakai, complete genome). Identity
match was 92% and the mutation was observed (C->G) at nucleotide 395 of the query
strand (see boxed area).
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Figure 4.13: E, coli clone L4 sequence alignment. Alignment of E. coli clone L4 to
Accession NC 002695.1 (E. coli 0157:H7 strain Sakai, complete genome). Identity
match was 78% and the mutation was not observed (sequence quality was poor).
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6.0

Discussion

Whether or not Stx-2 binds to Bcl-2 family proteins seems to be a controversial
topic. Previous research has indicated that Stx-2 binds Bcl-2 (190) however this could
not be repeated in the studies performed in Chapter 2. The effects that Stx-2 has on the
apoptosis of neutrophils has also been debated in the past (51,118) and studies performed
in Chapter 3 showed that a Stx-2-induced delay in neutrophil apoptosis was observed for
up to 12 h, and could be due to the binding of Stx-2 with Bak in the endoplasmic
reticulum. An additional method to determine if binding between Stx-2 and apoptosis
related proteins occurs is through the use of a Stx-2 mutant. Annis et al. (4) has used
mutants to determine the contribution of Bcl-2 family proteins in the endoplasmic
reticulum or mitochondria numerous times. One study performed by Yin et al. (225)
indicated that a mutation to a portion of the NWGRI sequence of Bcl-2 resulted in failure
of heterodimerization with Bax. It was believed that if Stx-2 bound with Bcl-2 family
proteins through this same binding site, mutation of Stx-2 at the NWGRI sequence should
also result in the failure of dimerization between Stx-2 and other proteins. The goal of
these experiments was to perform a point mutation in the stx2 gene, specifically to the
region encoding the glycine residue within the pentameric sequence NWGRI at amino
acid position 225, and change it to alanine in a manner similar to that performed by Yin
et al. (225) with Bcl-2. This gene would then be ligated into pBR322, and finally
transformed into E. coli 0157:H7 strain 43888 (a Stx-2 negative strain) for purification.
It was hypothesized that this mutation would result in a mutant protein that was less
pathogenic than the wild-type due to its inability to trigger the apoptotic pathways. Data
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obtained indicated successful mutation of glycine to alanine at position 225 within stx2.
This mutant gene was also successfully inserted into pBR322 and transformed into E. coli
0157:H7 strain 43888 which does not produce either Stx-1 or Stx-2.

In these experiments, a mutant Stx-2 protein was created containing an alanine at
amino acid position 225 such that the pentameric sequence reads NWARI. Having a
mutant toxin will help elucidate the mechanisms of Stx-2 action within host cells,
especially when determining the role of Stx-2 in the apoptotic pathway. Further
experiments with this mutant toxin will be done to determine the effects it has on Vero
cell cytotoxicity, neutrophil apoptosis and necrosis rates, as well as activation of caspase8

and caspase-9 within neutrophils.
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CHAPTER 5

THE EFFECTS OF MUTANT STX-2 AND NATIVE STX-2 WITH AN
INTERLEUKIN- 8 INHIBITOR ON NEUTROPHIL APOPTOSIS, NECROSIS, AND
CASPASE- 8 AND CASPASE-9 ACTIVATION

1.0

Abstract

Apoptosis is mediated by the Bcl-2 protein family (4, 151, 177, 181) and these
may bind with Stx-2 through a conserved NWGRI amino acid motif. A mutation was
introduced into Stx-2 to change the NWGRI sequence to NWARI, influencing apoptotic
outcomes. Other factors that may influence human neutrophil apoptosis include the
presence of Interleukin- 8 (IL-8 ), which results in a delay of spontaneous and TNF-amediated apoptosis in both a dose- and time-dependent manner (96). This process is not
reliant on inducing expression of Bcl-2 especially within the first 30 h (96). In this study,
apoptosis and necrosis rates of isolated human neutrophils were examined at intervals of
0, 6 , 12, 18, 24 and 48 h following exposure to Stx-2 from E. coli 0157:H7 or to mutant
Stx-2 (G225A cloned from E. coli 0157:H7 strain 90-2380). An IL- 8 inhibitor together
with Stx-2 was studied to determine if IL- 8 contributed to the delay in apoptosis.
Caspase- 8 and 9 levels were examined to determine which apoptotic pathway was
involved. Data indicated that although there was no clear correlation between delayed
apoptosis due to Stx-2, it was clear that cells exposed to mutant Stx-2 had apoptosis rates
similar to those of the untreated cells.
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2.0

Introduction

Human neutrophils routinely are subjected to relatively rapid apoptosis
(programmed cell death) and typically have a short circulating lifespan of approximately
is 6-18 h (113). Approximately 101 0 neutrophils are produced daily, and these account for
45-75% of the total white blood cell count (113). Neutrophils are the first responders
during infection, and these cells are capable of phagocytozing foreign material and in an
attempt to clear the infection, they release reactive oxidative intermediates (113).

Apoptosis is a normal function of cells mediated by the Bcl-2 protein family (46).
These proteins consist of anti-apoptotic (pro-survival) and apoptotic (pro-death) proteins
that possess conserved homology domains. It is through these conserved homology
domains that these proteins interact with each other, and the relative ratio of unbound
protein type (i.e. pro-survival or pro-death) available in the cell determines the ultimate
fate of the cell (46).

Exposure of neutrophils to Interleukin- 8 (IL-8 ) results in a delay of spontaneous
apoptosis as well as of TNF-a-mediated apoptosis in both a dose- and time-dependent
fashion (96). During the early phases of apoptosis (within the first 30 h) this process is
not determined by the expression of Bcl-2 (96). Phenomena that can be induced in human
neutrophils following exposure to IL- 8

included: changing shape (221); actin

polymerization (216); degranulation (123); and up-regulation of adhesion molecules (43).
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Stimulated neutrophils can release a variety of cytokines including IL- 8 and TNF-a (6 ,
27). TNF-a can rapidly increase neutrophil apoptosis 2 h after exposure (97,143,192).

Data from previous studies have shown conflicting results as to whether
neutrophil apoptosis is delayed following exposure to Stx-2. Liu et al. (118) concluded
that Stx-2 derived from E. coli 0157:H7 exhibited both a dose- and time- dependent
inhibition of spontaneous neutrophil apoptosis, possibly involving the protein kinase C
pathway. Flagler et al. (51) were unable to demonstrate a Stx-2 and neutrophil interaction
nor did they observe an altered apoptosis rate when cells were exposed to lpg/mL of Stx1 or Stx-2. In agreement with Liu et al. (118), Suzuki et al. (190) reported that Bcl-2 did
bind Stx-2. Further analysis of the Bcl-2 protein family (Chapter 2, pg. 56-57) indicated
that Stx-2 has the potential to bind with all Bcl-2 family members through a conserved
NWGRI amino acid motif, but binding was not detected to Bcl-2,

B c 1-X l

or Bax isolated

from Caco-2 cells.

The timing (increase or delay in the rate) of human neutrophil apoptosis was
examined over the course of 48 h following exposure of cells to 5 ng semi-purified Stx-2
from E. coli 0157:H7 strain 90-2380 and also to 5 ng mutant Stx-2 (G225A cloned from
E. coli 0157:H7 strain 90-2380). The impact of IL- 8 inhibitor at concentrations of
0.0 ImM was also examined at the same time as treatment with Stx-2 to determine if the
presence of IL- 8 contributed to a delay in apoptosis previously seen in past
experimentation (Chapter 3, pg. 109-112). Caspase- 8 and caspase-9, cellular components
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critical to apoptosis induction, were evaluated to better understand which apoptotic
pathways were involved.

3.0

Hypothesis

Neutrophils treated with mutant Stx-2 will show apoptosis rates that align with the
baseline (untreated) apoptosis rate, resulting from an inability to trigger the apoptosis
pathway. Alternatively, neutrophils treated with Stx-2 in combination with an IL- 8
inhibitor will also show apoptosis rates that align with the baseline (untreated) apoptosis
rate. The presence of IL- 8 will contribute to a delay in apoptosis as opposed to Stx-2
alone.

4.0

4.1

Materials and Methods

Purification of Stx-2

E. coli 0157:H7 strain 90-2380 was inoculated into LB broth and allowed to grow
overnight at 37°C with shaking. The following day, the culture was aliquoted into sterile
100x15mm Petri dishes (lOmL per dish). The lids were removed, and the culture was
exposed to ultraviolet (UV) light in a biosafety cabinet for 30 minutes. Subsequent to UV
exposure, the dishes were transferred to a 37°C incubator and allowed to incubate for an
additional 48 h.
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Following incubation, the culture samples were pooled and centrifuged at 16,000
x g for 15 min at 4°C. The supernatant fluid was collected and sterile filtered using
Millex 0.45pm low protein-binding membranes (Millipore Corp, Bedford, MA). The
toxin was precipitated using ammonium sulfate precipitation. First, ammonium sulfate
was slowly added to the supemate until the concentration was 40%. The mixture was
centrifuged and the supernatant fluid was transferred to a new beaker. The ammonium
sulfate concentration was increased to 70%, and the mixture was again centrifuged. The
pellet was resuspended in 25mL PBS and placed into a Slide-a-lyzer® 20 kDa molecular
weight cut off dialysis cassette (Thermo Scientific, Rockford, IL). The cassette was
inserted into a tank containing 4L PBS and incubated overnight at 4°C. On the following
day, the buffer was exchanged and the cassette was incubated at room temperature for an
additional 5 h with two buffer exchanges during the incubation period. The cassette was
unloaded and the semi-purified Stx-2 was loaded into a 100 kDa Centricon device and
spun at 3220 x g for 15 min. The filtrate was collected and processed through an Amicon
50 kDa device for 15 minutes. The retentate was collected and measured for total protein
concentration using the A2 8 0 method on the Nanodrop spectrophotometer. An A2 8 0 / A2 6 0
reading was also performed to determine protein purity. Approximate protein
concentrations were calculated from this data using the Warburg-Christian Method (211).

4.2

Purification of Mutant Stx-2

Escherichia coli 0157:H7, strain 43888 (the otherwise toxin negative strain), L42
mutant with the Stx-2 insert was inoculated into LB broth containing 50pg/mL ampicillin
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and allowed to grow for 72 h at 37°C with shaking. Following incubation, the culture was
placed in a -20°C freezer for 48 h to aid in cellular disruption. The culture was then
thawed and processed using a B-PER® Bacterial Protein Extraction Reagent (Thermo
Scientific). The bacterial cells were centrifuged at 5,000 x g for 10 min and 4mL of BPER® reagent was added per gram of cell pellet. The suspension was mixed by pipette to
homogeneity and allowed to incubate for 15 min at room temperature. The lysate was
centrifuged at 15,000 x g for 5 min to separate the soluble and insoluble proteins. The
fluid phase was collected and processed through Pierce Detergent Removal Spin
Columns (Thermo Scientific) according to the manufacturer’s instructions. The sample
was then loaded into a Slide-a-lyzer® 20 kDa molecular weight cut off dialysis cassette
(Thermo Scientific), placed into a tank containing approximately 4L PBS and incubated
for 48 h at 4°C. The buffer was exchanged and the cassette was incubated for 24 h at 4°C
and the resultant semi-purified mutant Stx-2 was loaded into a 100 kDa Centricon device
and centrifuged at 3220 x g for 15 min. The filtrate was collected and 20mL of PBS was
added. The sample was then processed through an Amicon 50 kDa device for 15 min.
The retentate was collected and measured for total protein concentration using the A2 8 0
method on the Nanodrop spectrophotometer. An A2 8 0 / A2 6 0 reading was also performed
to determine protein purity. Approximate protein concentrations were calculated from
this data using the Warburg-Christian Method (211).
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4.3

Conjugation of STX2-11E10 Antibody

Horseradish peroxidase (HRP) was conjugated to the mouse STX2-11E10
antibody (Toxin Technology) using the EZ-Link™ Plus Activated Peroxidase Kit
(Thermo Scientific). One mg of lyophilized EZ-Link™ Plus activated peroxidase was
resuspended with lOOpL of MilliQ water and added to lmL PBS containing lmg/mL of
STX2-11E10. Ten pL of cyanoborohydride was added to this reaction mixture in the
fume hood and allowed to incubate for 1 h at room temperature. Twenty pL of quenching
buffer (3M ethanolamine, pH 9) was added and allowed to react at room temperature for
15 min.

The conjugated antibody was then purified using the Pierce Conjugate
Purification Kit (Thermo Scientific). An immobilized Iminodiacetic acid column was
activated by adding 10-20mL of TBS and allowing the fluid to drain through the column.
When the flow of TBS had stopped, 2mL of Pierce column activator buffer was added
and once the flow had stopped a second time, it was incubated for an additional 5 min. A
column wash was then performed with 10-20mL of TBS to remove non-bound nickel.
The conjugated antibody was added to the activated column followed by 5-10mL of TBS.
This was then allowed to drain through. Elution buffer (1.7mL) was applied to the
column forming a blue band indicating the elution front and an additional 0.8mL of
elution buffer was added and the blue liquid was collected.
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Buffer exchange was subsequently performed on the conjugate by loading it on a
polyacrylamide desalting column that was previously equilibrated with 50mL of PBS.
Half mL aliquots of PBS were added to the column for each fraction collected and 16
fractions were collected in total. Fractions were tested for enzyme activity by adding 2pL
of each fraction to separate tubes containing lmL TBS with 0.05% Tween-20. Five pL
from each prepared tube was then added to a 96-well microtiter plate and lOOpL of 1-step
ABTS (Thermo Scientific) was added to each well. The first three fractions with the
highest enzyme activity were pooled and stored at 2-8°C.

4.4

Verification of Stx-2 and Mutant Stx-2 Presence and Activity

SDS-PAGE and Western blot were performed to verify the presence of Stx-2 and
mutant Stx-2 in the semi-purified preparations. SDS-PAGE was performed under both
reducing and non-reducing conditions. Samples were diluted 1:2 in sample preparation
buffer (Appendix A, 4.13), and treated in each of three ways; 1) samples were heated at
95°C for 5 min with P-mercaptoethanol added (reducing), 2) samples were heated at
95°C for 5 min 3) samples were not heated and P-mercaptoethanol was not added (non
reducing). Protein from the semi-pure Stx-2 samples was added at 2.4pg/well and from
the mutant Stx-2 samples at 1.4pg/well. All samples were loaded onto a 4-20% Tris-HCl
gel cassette (Bio-Rad, Hercules, CA), and run at 300V for 20 min. The gel was then
stained with GelCode Blue Safe Protein Stain (Thermo Scientific) for 2 h, and destained
with water overnight until the background was no longer blue, and visible protein bands
were observed.
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A Western blot was performed under reducing conditions with the Stx-2 and
mutant Stx-2 samples which were diluted 1:2 in sample preparation buffer. These were
heated at 95 °C for 5 min with P-mercaptoethanol added. Samples were loaded onto a 420% Tris-HCl gel cassette (Bio-Rad) in duplicate and run at 300V for 20 min. The gel
was aligned onto a polyvinylidene fluoride (PVDF) membrane (Millipore Corp), and
placed into a transfer sandwich consisting of fiber pads and filter paper (Figure 2.1, pg.
49). The transfer sandwich was placed in a buffer tank containing Tris-glycine buffer
(TGB) (Appendix A, 4.19) and proteins were transferred at 60V for 4-5 h. After transfer,
the membrane was processed for Western blotting using the Snap ID Protein Detection
System (Millipore Corp). The blot holder was opened and thoroughly soaked with MilliQ
water. The pre-wet blot was placed into the blot holder protein side down and gently
rolled to remove all air bubbles. A spacer was placed on top of the blot membrane and
rolled again to ensure contact of the spacer with the blot membrane. The blot holder lid
was closed and placed into the chamber of the Snap ID system ensuring that the blot
holder tabs were aligned with the notches of the chamber. To block the membrane, 30mL
of TBS containing 0.1% Tween 20 and 0.5% dry non-fat milk was added and the vacuum
was turned on until all the fluid passed through the blot. Next, 3mL of HRP-conjugated
mouse anti-Stx-2 antibody, STX2-11E10, (lOpg/mL) (Toxin Technology, Sarasota, FL)
containing lpL of StrepTactin-HRP conjugate (to detect the bands of the Precision Plus
Protein™ WestemC™ standards) (Bio-Rad) was added to the blot and incubated for 10
min at room temperature. Once the incubation was complete, the vacuum was turned on
and the blot was washed three times with 30mL of TBS with 0.1% Tween 20. The blot
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was removed from the Snap ID system and incubated with the Immun-Star WestemC™
kit (Bio-Rad) for CCD imaging.

In order to determine if the Stx-2 preparation was biologically active after the
purification procedure and what type of biological activity the mutant Stx-2 preparation
had, African green monkey kidney cells (Vero cells) were exposed to the semi-pure
preparations for 96 h. Vero cells were grown in three 25cm tissue culture flasks. Once
confluent, the first flask remained untreated, to the second flask 50pL of mutant Stx-2
was added, and to the third 50pL of Stx-2 was added. The control and test flasks were
incubated at 37°C in 5% CO2 for 96 h. Each flask was observed at 200x total
magnification using an inverted phase-contrast microscope for the presence of cytotoxic
effects.

4.5

Quantitation

of

Stx-2

and

Mutant

Stx-2

Using

Enzvme-Linked

Immunosorbent Assay (ELISA)

The concentration of Stx-2 and mutant Stx-2 was determined using a sandwich
“capture” ELISA (Figure 5.1). Two hundred pL of the primary antibody STX2-BB12
specific to the B-subunit of Stx-2 (20pg/mL) was added to the wells of a 96-well plate
and allowed to incubate at room temperature for 2 h while shaking. Unbound antibody
was removed from the wells and 300pL of PBS was added to each well and the plate was
rinsed with shaking for 5 min to remove excess antibody. This wash was repeated three
times and then 300pL of blocking buffer was added to the wells and incubated at room
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temperature for an additional 2 h while shaking. Once again, the liquid was removed
from the wells and they were washed three times using the same procedure described
above. Once the plate had been copiously rinsed, 200pL of 1:2 dilutions containing
2 pg/mL to 31.25 ng/mL of a commercial Stx-2 preparation (Toxin Technology) were
added to the plate in triplicate to generate a standard curve (Figure 5.2). Next the Stx-2
and mutant Stx-2 were added to the wells of the plate in triplicate and the plate was
incubated at room temperature for 2 h with shaking. After the wells of the plate were
emptied and rinsed three times, 200pL of the secondary antibody STX2-11E10 HRPconjugate (5pg/mL) was added to each well and incubated again for 2 h at room
temperature with shaking. A final series of rinses was performed five times with 300pL
of PBS incubated at room temperature for 5 min with shaking and 150pL of 1-Step
ABTS (Thermo Scientific) was added to each well and developed for 10 min at room
temperature. The reaction was stopped by the addition of lOOpL of 1% SDS and
measured for absorbance at 405nm.
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Ag- Antigen
Substrat
E- Enzyme

Capture
antibody
Capture Assay
"Sandwich”
Figure 5.1: Setup of a sandwich ELISA. A primary or capture antibody is affixed to a
microtiter plate and the antigen of interest is bound. A secondary antibody conjugated
with an enzyme is bound to the antigen and developed with a substrate to produce a color
change. Diagram courtesy of Amrita Vishwa Vidyapeetham University, Coimbatore,
Tamil Nadu, India.
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standard curve

= PBS Blank with entire process

= mutant Stx-2 sample

= ABTS Solution only!! (no antibody)

= Stx-2 sample

= empty w d l

Figure 5.2: Setup of the ELISA plate. The standard curve was diluted 1:2 and tested in triplicate. Values listed represent the total
number of nanograms of commercially prepared Stx-2 per well. Stx-2 and mutant Stx-2 samples were also diluted 1:2 and tested in
triplicate along with PBS blank and ABTS controls (n=5).

4.6

Isolation of Human Neutrophils

Neutrophils were collected from human blood using the Sigma Aldrich leukocyte
separation method shown in Figure 3.1 on pg. 96. Three mL of Histopaque™ 1119 was
added to a 15mL conical tube and 3mL of Histopaque™ 1077 was carefully layered on
top followed by 6mL of human blood. The tubes were centrifuged at 700 x g for 30 min
at room temperature. After centrifugation, layer B containing the granulocytes was
aseptically transferred using a pipette to a 50mL conical tube and an equal volume of
modified Hank’s balanced salt solution (HBSS) was added. The cells were washed by
centrifugation at 250 x g for 10 min at room temperature and the supernatant fluid was
removed. The cell pellet was resuspended in 12mL of 0.2% NaCl for 30 sec to lyse any
remaining red blood cells. The suspension was then returned to an isotonic state with the
addition of 12mL of 1.6% NaCl and centrifuged at 250 x g for 10 min. This was repeated
three times until all red blood cells were lysed. The neutrophils were resuspended in 2mL
RPMI-1640 (Appendix A, 5.4), assessed for viability with trypan blue, and counted using
a hemocytometer.

4.7

Analysis of Neutrophil Apoptosis and Necrosis Rates Following Exposure to
Native and Mutant Stx-2

Neutrophil apoptosis and necrosis rates were measured over time at 0, 6, 12, 18,
24 and 48 h using the Cell Death Detection ELISA kit (Roche Diagnostics). This ELISA
detects fragmented DNA and histone complexes. Neutrophils were isolated as described
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previously, a suspension was made in RPMI-1640 containing 50,000 cells/mL and 200pL
was dispensed into each well of a 96-well plate (see Table 5.1 for time points). A separate
plate was used for each time point. Three blood samples from different donors were
tested in triplicate (n=9 total). The negative control consisted of neutrophils only (C), the
IL-8 inhibitor control consisted of neutrophil suspension plus 0.01 mM IL-8 inhibitor (I),
while the test samples consisted of the neutrophil suspension plus the semi-pure protein
preparations containing either 5 ng mutant Stx-2 (M) or 5 ng of Stx-2 (T), or the
neutrophil suspension plus 5 ng Stx-2 and 0.0 ImM IL-8 inhibitor (TI).

For each time point, the 96-well plate was centrifuged at 200 x g for 10 min and
the supernatants were collected and held at 2-8°C to assay for necrosis. The cell pellet
was lysed for 30 min at room temperature with the lysis buffer provided in the kit, the
plate was centrifuged again at 200 x g for 10 min, and the supernatant fluid was analyzed
for apoptosis. Twenty uL of each supernatant sample (pre-lysis and post-lysis), positive
control (DNA-histone-complex), and background control (incubation buffer) were
transferred to a streptavidin coated plate and 80uL of immunoreagent containing
incubation buffer, anti-histone biotin, and anti-DNA-POD were added. The samples were
shaken at 300 rpm for 2 h at room temperature, rinsed three times with 300pL incubation
buffer each wash, and developed with lOOpL ABTS. Absorbance was measured at
405nm using a SpectraMax M5 plate reader with SoftMax Pro v5.4.2 (Molecular
Devices, Sunnyvale, CA).
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Table 5.1: Neutrophil Cell Death Detection Time Point Setup1
96-well plate
Row/Column

F
G
H
1 10,000 cells were added to each well suspended in 200pL RPMI-1640. A separate plate
was used for each time point.
Sample Kev:
‘C’
‘I’
‘M’
‘TP

Negative control (neutrophils only)
IL-8 inhibitor added at final concentration 0.0ImM (IL-8 inhibitor control)
5 ng mutant Stx-2 added
5 ng Stx-2 added
5 ng Stx-2 and IL-8 inhibitor added at final concentration 0.0ImM
Blood Donor A
Blood Donor B
Blood Donor C
Blank well
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4.8

Analysis of Neutrophil Casoase-8 and Capase-9 Activation Following
Exposure to Native and Mutant Stx-2

Caspase-8 and Caspase-9 activation were monitored at times 0, 6, 12, 18, 24, and
48 h after exposure to Stx-2 and mutant Stx-2. In addition, the effect of an IL-8 inhibitor
was analyzed to better understand the type of apoptotic trigger(s) involved. Enzyme
activation was detected using the Caspase-Glo® 8 and Caspase-Glo® 9 Assays
(Promega). All reagents were prepared according to the manufacturer’s instructions with
the addition of the MG-132 inhibitor. Neutrophils were isolated from whole blood and
diluted in RPMI-1640 to give a concentration of 50,000 cells/mL. One mL was placed in
glass test tubes and treated as follows: sample 1, negative control, untreated (C); sample
2, IL-8 inhibitor added at O.lmM (I); sample 3 mutant Stx-2 added at 0.25 ng/pL (M);
sample 4, Stx-2 added at 0.25 ng/pL (T); and sample 5, Stx-2 added together with IL-8
inhibitor at 0.25 ng/pL and O.lmM, respectively (TI). All tubes were allowed to incubate
at 37°C in 5% CO2 until the elapsed time point. At each time point, the tubes were gently
mixed and 20pL of neutrophil cell suspension was added in triplicate to wells of a 384well plate for each caspase test. Twenty pL of caspase-8 or caspase-9 reagent was added
to each well, gently mixed for 30 sec and allowed to incubate at room temperature for 45
min. After incubation was complete, the plate was assayed for luminescence using a
SpectraMax M5 plate reader with SoftMax Pro v5.4.2 (Molecular Devices).
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5.0

Results

5.1

Verification of Stx-2 and Mutant Stx-2 Presence and Activity

The purification of Stx-2 from E. coli 0157:H7 strain 90-2380 (native Stx-2) and
mutant Stx-2 from the L42 mutant of E. coli 0157:H7 strain 43888 (mutant Stx-2) was
achieved as demonstrated by total protein concentration and purity, SDS-PAGE, and
Western blot.

To determine total protein concentration and purity of the native and mutant Stx-2
preparations, optical densities were taken at A2 8 0 nm and A2 6 0 nm. The total protein
concentrations were determined to be 0.300 mg/mL for native Stx-2 and 0.110 mg/mL
for mutant Stx-2 while the purity (as determined by the A2 8 0 / A2 6 0 ratio) was 1.05 for
native Stx-2 and 0.810 for mutant Stx-2. These values indicate the presence of nucleic
acid which can influence the total protein concentration accuracy. Correction factors of
0.81 and 0.63 were applied to the native and mutant Stx-2 values respectively in
accordance with the Warburg-Christian Method (211). The final protein concentrations
were determined to be 0.243 mg/mL protein with 3.5% nucleic acid (native Stx-2) and
0.069 mg/mL protein with 6.0% nucleic acid (mutant Stx-2).

SDS-PAGE of semi-purified native Stx-2 (panel A) and mutant Stx-2 (panel B)
are shown in Figure 5.3. Target protein load was 2.4 pg for native Stx-2 and 1.4 pg for
mutant Stx-2. As can be seen by comparing lanes 2, 3, and 4 with each other in panel A,
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Figure 5.3: SDS-PAGE analysis of semi-purified native and mutant Stx-2. A) Broad-range Precision Plus Protein WestemC
standards (Bio-Rad) are in Lane 1, semi-pure Stx-2 under non-reducing conditions is in Lane 2, semi-pure Stx-2 under heat only
conditions is in Lane 3, and semi-pure Stx-2 under reducing conditions is in Lane 4. B) Broad-range Precision Plus Protein
WestemC standards (Bio-Rad) are in Lane 1, semi-pure mutant Stx-2 under non-reducing conditions is in Lane 2, semi-pure Stx-2
under heat only conditions is in Lane 3, and semi-pure Stx-2 under reducing conditions is in Lane 4. No differences in band pattern
were observed.

it was evident that there was no difference in the protein profile for the semi-purified
toxin whether untreated, heated, or subjected to reducing conditions. Similarly, no
differences were noted in the protein profiles of the mutant Stx-2 under reducing, non
reducing, or heated conditions despite the faintness of the band patterns. In addition there
appears to be fewer bands in the mutant Stx-2 preparation than in the native Stx-2
preparation. It seems likely that this is due to the differences in loading concentration and
in the purification procedure.

Figure 5.4 illustrates the Western blot of semi-purified native and mutant Stx-2
treated with the HRP-conjugated STX2-11E10 antibody. There was a band visible in
each sample at approximately 32 kDa as highlighted by the boxed areas. These bands
show the A-subunit of native and mutant Stx-2 and confirm the presence of the toxin in
both samples.

The biological activity of Stx-2 and mutant Stx-2 on Vero cells was observed at
200x magnification and is illustrated in Figure 5.5. Panel A shows untreated Vero cells
while panel B corresponds to Vero cells treated with 50pL of semi-purified mutant Stx-2
and panel C shows Vero cells treated with 50pL of semi-purified native Stx-2. Cytotoxic
effects typical of Stx-2 were observed in the cell monolayers (rounded, refractile and
dead cells with monolayer thinning) as evident in panel C of Figure 5.5. Minimal
cytotoxic changes were observed in the cells from the mutant Stx-2 indicating that the
point mutation within the NWGRI motif had a profound impact on the ability of Stx-2 to
cause cellular damage in these otherwise highly sensitive cells.
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5.

Figure 5.4: Western blot analysis of toxin preparations. Broad-range Precision Plus
Protein WestemC standards are in Lane 1, semi-pure native Stx-2 preparation probed
with HRP-conjugated STX2-11E10 is in Lane 2, and semi-pure mutant Stx-2 preparation
probed with HRP-conjugated STX2-11E10 is in Lane 3. The A-subunit of Stx-2 and
mutant Stx-2 was detected in the boxed areas of Lane 2 and 3, respectively.
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Figure 5.5: Biological Activity of semi-purified Stx-2 and mutant Stx-2 viewed at
200x magnification. A) Image of untreated Vero cells after 96 h. B) Image of Vero cells
after 96 h incubation with 50jj.L semi-purified mutant Stx-2. C) Image of Vero cells after
96 h incubation with 50pL semi-purified native Stx-2. Cytotoxic effects are evident by
the large number of rounded and reffactile cells in panel C. Note that the cells treated
with mutant Stx-2 were similar to controls and showed minimal cytopathic changes.
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5.2

Quantitation of Stx-2 and Mutant Stx-2 Using ELISA

Standard curves were assayed in triplicate and the results are shown in Figure 5.6.
The average background absorbance was calculated between the quintuplet blanks, and
this value was subtracted from the total absorbance reading in each well. Three points
were used to generate a standard curve between 25 and lOOng of Stx-2. The triplicate
standard curve values were averaged and plotted to produce an average standard curve
with a correlation coefficient (r2) of 0.9673.

The total Stx-2 protein concentration for the semi-pure preparation was calculated
by averaging the absorbance of the undiluted triplicate samples assayed as these values
were within the center of the standard curve. This average value was then entered into the
standard curve regression equation, and a final protein concentration of 6.42pg/mL was
obtained.

The total mutant Stx-2 protein concentration for the semi-pure preparation was
calculated by averaging the absorbance of the 1:2 diluted triplicate samples assayed as
these values were within the center of the standard curve. The average value was entered
into the standard curve regression equation, and a final protein concentration of
9.46pg/mL was obtained after adjusting for a 1:2 sample dilution.
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Figure 5.6: Total protein concentration of toxin preparations. Total protein
concentration of Stx-2 and mutant Stx-2 in the semi-purified preparations. The average
standard curve shown by the ♦ symbol with correlation coefficient of t*= 0.9673 and
regression equation of y= 0.0042x - 0.0563. The total calculated Stx-2 concentration was
6.42pg/mL shown by the ■ symbol and the total calculated mutant Stx-2 concentration
after 1:2 dilution adjustment was 9.46jig/mL shown by the ▲symbol.
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5.3

Isolation of Human Neutrophils

Neutrophils from three blood donors were isolated and counted using a
hemocytometer and the total cell concentration and viability of each sample were
obtained (Table 5.2). The viability of neutrophils from Donor B was much higher
(97.3%) when compared to Donor A (85%) and Donor C (86.2%). This was most likely
due to the effect of multiple red blood cell lysis steps on the suspension. In order to lyse
contaminating red blood cells, neutrophil suspensions were osmotically shocked. This
method lysed the red blood cells and undoubtedly some neutrophils accounting for the
differences in viability noted. The overall health of isolated neutrophils also influences
how susceptible they are to osmotic damage. Indeed, the maximum number of times the
suspension can be shocked should be limited to three times. During this experiment, a
high number of red blood cells were present after granulocyte collection and the full three
rounds of osmotic shocking were needed to lyse and remove them. This accounted for the
lower viability seen in the neutrophil suspensions from Donors A and C and this may
have either increased the initial necrosis and/or apoptosis results or may have made the
cells more susceptible to the effects of the toxin. Regardless, the results obtained for all
three donor cell preparations have been presented. Based on the higher viability and the
overall higher neutrophil cell count from Blood Donor B as compared with those from
either Blood Donors A or C, all subsequent investigations on the action of native Stx-2,
mutant Stx-2 or IL-8 inhibitor on necrosis or apoptosis was conducted on neutrophils
collected from Blood Donor B. Similarly, the caspase-8 and caspase-9 levels were
assayed in Blood Donor B neutrophils.

169

Table 5.2: Viability of Neutrophils Collected from 3 Donors

Blood Donor A

608

107

85.0

Blood Donor B

1128

31

97.3

1.1 xlO 7

Blood Donor C

638

1 0 2

8 6 .2

6.38 x 106

6.08 x

106
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5.4

Analysis of Neutrophil Necrosis and Apoptosis Rates After Exposure to
Native Stx-2. Mutant Stx-2. and IL-8 Inhibitor

Necrosis and apoptosis rates were examined for the neutrophil preparation
isolated from Donor B after 0, 6 , 12, 18, 24, and 48 h of treatment with native Stx-2,
mutant Stx-2 or IL- 8 inhibitor. Assays were performed in triplicate and the results were
standardized by expressing the final result as a percent of the positive control provided in
the kit for each assay. The mean and standard deviation of each test article was
calculated, and a t-test was performed on seven sample comparisons (neg. control vs.
native Stx-2, neg. control vs. mutant Stx-2, mutant Stx-2 vs. native Stx-2, neg. control vs.
IL- 8 inhibitor, neg. control vs. IL- 8 inhibitor & native Stx-2, and IL- 8 inhibitor vs. IL- 8
inhibitor & native Stx-2) to assess the effects of native Stx-2, mutant Stx-2, and IL- 8
inhibitor on neutrophil apoptosis and necrosis.

5.4.1

Necrosis Rates

Significant differences were observed between sample comparisons with a 95%
confidence interval (p < 0.05). Necrosis rates are shown in Figure 5.7 and a summary of
the statistical comparison is shown in Table 5.3. In comparison with untreated
neutrophils, the cells showed significantly more necrosis at

6

and

12

h when exposed to

native Stx-2 and at 12, 24, and 48 h when exposed to mutant Stx-2. There were no
significant differences in necrosis noted between cells exposed to native Stx-2 and mutant
Stx-2 except at 48 h, where mutant Stx-2 exhibited significantly more necrosis. These

171

Neutrophil Necrosis Rates Over Time
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Figure 5.7: Necrosis rates for blood donor B. Data is presented as the average percent
necrosis when compared to the positive assay control. Error bars represent the standard
deviation calculated between triplicates. Significant differences were observed between
treatments with peak necrosis rates for the IL- 8 inhibition control at 48 h, mutant Stx-2 at
48 h, native Stx-2 between 6-12 h, and Stx-2 with IL- 8 inhibitor peaking at 12 h.
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Table 5.3: Summary of Statistical Analysis for Blood Donor B: Necrosis
* indicates a significant difference (p < 0.05)_________________________
Sample
Time Point (h)
Unpaired t-test P-value
0
0.0932
6
0.0036*
Negative Control
12
0.0354*
vs.
18
0.8046
Stx-2
24
0.1091
48
0.5960
0
0.0864
6
0.0836
Negative Control
12
0.0026*
vs.
18
0.0795
Mutant Stx-2
24
0.0329*
48
0.0418*
0
0.6545
6
0.7201
Mutant Stx-2
12
0.1396
vs.
18
0.0950
Stx-2
24
0.6650
48
0.0379*
0
0.6767
6
0.0564
Negative Control
12
0.0071*
vs.
18
0.5407
IL- 8 Inhibitor
24
0.0328*
48
0.0002*
0
0.0057*
6
0.1243
Negative Control
12
0.6162
vs.
18
0.1980
IL- 8 Inhibitor + Stx-2
24
0.4065
48
0.4844
0
0 .0 0 2 2 *
6
0.4521
IL- 8 Inhibitor
12
0.2681
vs.
18
0.1508
IL- 8 Inhibitor + Stx-2
24
0.1422
48
0.0001*
0
0.0177*
6
0.0410*
Stx-2
12
0.5593
vs.
18
0.1847
IL- 8 Inhibitor + Stx-2
24
0.9628
48
0.1207
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data show that necrosis is initiated in neutrophils exposed to both native and mutant Stx2, with comparable necrotic effects until 48 h when the mutant Stx-2-treated cells showed
elevated necrosis, possibly due to cell density differences between wells.

Neutrophils exposed to IL- 8 inhibitor showed significantly less necrosis at 12 h,
but significantly more necrosis at 24 and 48 h in comparison with the untreated control.
In addition, neutrophils exposed to a combination of native Stx-2 and IL- 8 inhibitor
demonstrated significantly more necrosis at 0 h when compared to untreated and IL- 8
inhibitor-treated samples, but also exhibited significantly less necrosis at 48 h when
compared to IL- 8 inhibitor-treated neutrophils. Finally, neutrophils exposed to native Stx2 and IL- 8 inhibitor were significantly more necrotic at 0 h and significantly less necrotic
at

6

h than cells exposed to native Stx-2 alone. These data indicate that IL- 8 inhibitor-

induced necrosis occurs after 24 h, and that this inhibitor also lowers native Stx-2induced necrosis overall, but only significantly at

6

h. It is believed that the significant

increases in neutrophil necrosis at 0 h in samples treated with native Stx-2 and IL- 8
inhibitor are not directly correlated with treatment, rather they are a result of cell damage
from the neutrophil isolation procedure, especially since the necrosis rates were low
overall (< 5.3%).

The effects of these treatments on neutrophil necrosis indicated that necrosis
rates were changed significantly; Native Stx-2-induced necrosis was highest between 6 12 h of exposure, mutant Stx-2-induced necrosis peaked at 48 h, and IL-8 -inhibitor-
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induced necrosis peaked at 24-48 h, and IL- 8 inhibitor with native Stx-2 necrosis rates
peaked at

5.4.2

12

h.

Apoptosis Rates

Significant differences in apoptosis rates (p < 0.05, 95% confidence interval) were
observed between samples. Apoptosis rates are shown in Figure 5.8 and a summary of the
statistical comparison is shown in Table 5.4. There was significantly more apoptosis in
cells exposed to native Stx-2 at 18 h than untreated cells. In addition, neutrophils exposed
to mutant Stx-2 showed a significant increase in apoptosis when compared to untreated
cells, however this was not observed until 48 h. It is believed that this significance may
not be practical since the level of apoptosis detected was extremely low (0 .0 2 % vs.
0.28%). Comparing native Stx-2 to mutant Stx-2, only a significant increase in native
Stx-2-induced apoptosis was observed at 18 h. No other statistical differences between
the two treatments were noted. Overall, these data show that apoptosis was observed for a
longer period of time in cells exposed to native Stx-2, but this does not equate to a delay
in apoptosis as the results were the same as the control prior to 18 h. Cells exposed to
mutant Stx-2 showed equivalent apoptosis rates to the control.

Neutrophils exposed to IL- 8 inhibitor showed an overall trend of higher apoptosis
than the untreated control at all time points, however significance was only achieved at 0
and 48 h. Cells exposed to IL- 8 inhibitor and native Stx-2 showed equivalent results to
untreated controls at 0, 6,12,24, and 48 h, but had significantly more apoptosis at 18 h.
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Neutrophil Apoptosis Rates Over Time
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Figure 5.8: Apoptosis rates for Blood Donor B. Data are presented as the average
percent apoptosis when compared to the positive assay control. Error bars represent the
standard deviation calculated between triplicates. Significant differences were observed
between treatments. The IL- 8 inhibition control, mutant Stx-2, and Stx-2 with IL- 8
inhibitor-treated samples showed peak apoptosis rates at 0 and 12 h, whereas native Stx2-treated neutrophils showed peak apoptosis rates between 12-18 h. The data support that
this 0 h apoptosis peak represents cell damage from the neutrophil isolation procedure,
and the 1 2 h apoptosis peak observed was representative of spontaneous neutrophil
apoptosis, unrelated to the treatment method. The peak observed at 18 h with Stx-2
treated neutrophils illustrated the apoptotic effect of the toxin.
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Table 5.4: Summary of Statistical Analysis for Blood Donor B: Apoptosis
* indicates a significant difference (p < 0.05)__________________________
Sample
Time Point (h)
Unpaired t-test P-value
0
0.9319
6
0.3041
Negative Control
12
0.3697
vs.
18
0.0207*
Stx-2
24
0.4065
48
0.0545
0
0.0973
6
0.3554
Negative Control
12
0.6882
vs.
18
0.5280
Mutant Stx-2
24
0.8750
48
0.0088*
0
0.2487
6
0.9865
Mutant Stx-2
12
0.3662
vs.
18
0.0183*
Stx-2
24
0.4307
48
0.0732
0
0.0223*
6
0.1859
Negative Control
12
0.1691
vs.
18
0.0556
IL- 8 Inhibitor
24
0.0937
48
0.0249*
0
0.2679
6
0.3417
Negative Control
12
0.1731
vs.
18
0.0017*
IL- 8 Inhibitor + Stx-2
24
0.9492
48
0.2939
0
0.0809
6
0.8134
IL- 8 Inhibitor
12
0.0029*
vs.
18
0.8963
IL- 8 Inhibitor + Stx-2
24
0.0972
48
0.0395*
0
0.4187
6
0.6642
Stx-2
12
0.3907
vs.
18
0.1213
IL- 8 Inhibitor + Stx-2
24
0.4305
48
0.0933
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In addition these cells also showed significantly less apoptosis at 12 and 48 h than cells
exposed to IL- 8 inhibitor alone, and the presence of an IL- 8 inhibitor had no effect on
Stx-2-induced apoptosis. This data show that the apoptotic effect of Stx-2 is exhibited
between 12 and 18 hours after exposure, despite the presence of IL-8 .

The effects of these treatments illustrated that neutrophil apoptosis rates were
significantly changed; native Stx-2-induced apoptosis peaked between 12-18 h, mutant
Stx-2-induced apoptosis peaked at 0 h and again at 12 h, IL- 8 inhibition control peaked at
0 and 12 h, and Stx-2 with IL- 8 inhibitor peaked at 0 and 12 h. Apoptosis rates were
highest overall at 0 h for all samples, however this peak represents that cell damage from
the neutrophil isolation procedure did occur. The apoptosis peak observed at 12 h was
related to spontaneous neutrophil apoptosis. The peak observed at 18 h with Stx-2 treated
neutrophils illustrated the apoptotic effect of the toxin.

5.5

Analysis of Neutrophil Caspase-8 and Caspase-9 Activation After Exposure
to Native Stx-2. Mutant Stx-2. and IL-8 Inhibitor

Caspase- 8

and Caspase-9 levels were measured using luminescence after

neutrophils isolated from Donor B were exposed in triplicate to native Stx-2, mutant Stx2, and IL- 8 inhibitor for 0, 6 , 12, 18, and 24 h. No blanking was performed on these
assays as there was a high background in the blanking wells resulting from luminescence
signal carryover in adjacent positive control wells. The mean and standard deviation of
measurements were calculated and t-tests performed on seven sample comparisons to
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assess the effects of native Stx-2, mutant Stx-2, and IL- 8 inhibitor on caspase- 8 and
caspase-9 activation.

5.5.1

Caspase - 8

Caspase- 8 activation was significantly different (p < 0.05, 95% confidence interval)
between five out of the seven comparisons. Caspase- 8 activation is summarized in Figure
5.9 and sample comparisons are summarized Table 5.5. No significant differences were
observed between native Stx-2-treated and untreated cells. A significant increase in
caspase- 8 activation was observed in mutant Stx-2-treated cells at 0 and 24 h compared to
the control. In addition, there was a significant increase in caspase- 8 activation at 0 h in
cells exposed to mutant Stx-2 when compared to native Stx-2.

The IL- 8 inhibitor treated cells showed lower caspase- 8 activation overall when
compared to the control; significance was achieved at 12 h and beyond. Neutrophils
exposed to IL- 8 inhibitor and Stx-2 showed significant decreases in caspase- 8 activation
at

12

and 18 h when compared to untreated cells, but did not show any significant

differences when compared to IL- 8 inhibitor-treated cells. Finally, neutrophils exposed to
IL- 8 inhibitor and native Stx-2 showed a sustained significant decrease in caspase- 8
activation after 12 h when compared to native Stx-2 alone.

Caspase- 8 activation was significantly different between these treatments; however
they all followed the same overall pattern with activation rates peaking at 6 h. This is
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Figure 5.9: Relative caspase- 8 levels for blood donor B. Relative caspase- 8 levels in
cells isolated from Blood Donor B. Error bars represent the standard deviation calculated
between triplicates. Caspase- 8 activation peaked in all samples at 6 h. It is believed that
this peak is related to spontaneous neutrophil apoptosis observed at 1 2 h, independent of
treatment method. Caspase- 8 activation was significantly different between treatments;
however they all followed the same overall pattern with activation rates peaking at 6 h.
This is likely related to the spontaneous neutrophil apoptosis peak detected at 12 h, as
caspase- 8 activation occurs prior to DNA framentation, which is the antigen primarily
detected in the ELISA. Note that no significant increase in caspase- 8 activation was
detected in the neutrophils treated with Stx-2.
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Table 5.5: Summary of Statistical Analysis for Blood Donor B: Relative Caspase-8
Levels
Sample
Negative Control
vs.
Stx-2
Negative Control
vs.
Mutant Stx-2

Mutant Stx-2
vs.
Stx-2

Negative Control
vs.
IL- 8 Inhibitor

Time Point (h)
0
6

0 .6 8 6 6

12
18
24

0.5118
0.3559
0.0824
0.0018*
0.8485
0.5553
0.0872
0.0014*
0.0032*
0.8961
0.9802
0.1809
0.1526
0.2962
0.1826
0.0245*
0.0299*
0.0317*
0.8268
0.1857
0.0014*
0.0474*
0.2861
0.7402
0.6563
0.0848
0.7921
0.0993
0.6952
0.2484
0.0353*
0.0104*
0.0420*

0
6

12
18
24
0
6

12
18
24
0
6

12
18
24
0

Negative Control
vs.
IL- 8 Inhibitor + Stx-2

IL- 8 Inhibitor
vs.
IL- 8 Inhibitor + Stx-2

Stx-2
vs.
Inhibitor + Stx-2

Unpaired t-test P-value
0.7106

6

12
18
24
0
6

12
18
24
0
6

12
IL- 8
18
24
* indicates a significant difference (p < 0.05)
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likely related to the spontaneous neutrophil apoptosis peaks detected at

12

h, as caspase- 8

activation occurs prior to DNA fragmentation, which is detected in the ELISA. In
addition, no significant increase in caspase- 8 activation was detected in the neutrophils
treated with Stx-2 which indicates that Stx-2 induced apoptosis does not occur through
the extrinsic apoptosis pathway.

5.5.2

Caspase-9

Caspase-9 activation was determined to be significantly different (p < 0.05, 95%
confidence interval) for five out of seven comparisons. Caspase-9 activation is
summarized in Figure 5.10 and sample comparisons are shown in Table 5.6.

No

difference in caspase-9 activation was detected for neutrophils exposed to native Stx-2
when compared to the untreated and mutant Stx-2-treated neutrophils. At 6 and 12 h there
was significantly less caspase-9 activation and at 18 h significantly more caspase-9
activation in neutrophils exposed to mutant Stx-2 when compared to the control.

Neutrophils treated with IL- 8 inhibitor demonstrated significantly less caspase-9
activation at 6 , 12, and 18h when compared to untreated cells as well as IL- 8 inhibitor
and Stx-2-treated cells. In addition, significantly less caspase-9 activation was seen at 12
h in cells treated with IL- 8 inhibitor and Stx-2 versus IL- 8 inhibitor only. Finally, there
was a significant sustained reduction of caspase-9 activation from 0 to 18 h in cells
exposed to IL- 8 inhibitor and Stx-2 as compared to Stx-2 only.
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Figure 5.10: Relative caspase-9 levels for blood donor B. Relative caspase-9 levels in
cells isolated from Blood Donor B. Error bars represent the standard deviation calculated
between triplicates. Caspase-9 activation was significantly different between these
treatments; samples treated with native and mutant Stx-2 showed overall higher caspase9 activation at 18 h, related to mitochondrial membrane permealibilazation (MMP).
Caspase-9 activation was reduced in all samples treated with IL- 8 inhibitor with
significance achieved at 6 ,12, and 18 h. This indicates that the intrinsic pathway is not
utilized in association with spontaneous neutrophil apoptosis.
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Table 5.6: Summary of Statistical Analysis for Blood Donor B: Relative Caspase-9
Levels
Sample

Time Point (h)
0

Negative Control
vs.
Stx-2

6
12

18
24
0

Negative Control
vs.
Mutant Stx-2

6
12

18
24
0

Mutant Stx-2
vs.
Stx-2

6
12

18
24
0

Negative Control
vs.
IL- 8 Inhibitor

6
12

18
24
0

Negative Control
vs.
IL- 8 Inhibitor + Stx-2

6
12

18
24
0

IL- 8 Inhibitor
vs.
IL- 8 Inhibitor + Stx-2

6
12

18
24
0

IL- 8

Stx-2
vs.
Inhibitor + Stx-2

6
12

18
24
* indicates a significant difference (p < 0.05)

Unpaired t-test P-value
0.9039
0.1096
0.0712
0.0544
0.2457
0.3497
0.0219*
0.0387*
0.0315*
0.2173
0.0562
0.2818
0.6754
0.7072
0.8474
0.2314
0.0087*
0 .0 0 0 2 *
0.0029*
0.5053
0.2241
0.0004*
<0 .0 0 0 1 *
0.0054*
0.6707
0.7526
0.1296
0.0006*
0.8720
0.4575
0.0248*
0.0059*
0.0034*
0.0042*
0.0890
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Caspase-9 activation was significantly different between these treatments; samples
treated with native and mutant Stx-2 showed overall higher caspase-9 activation at 18 h.
Significance was only achieved for mutant Stx-2, however the p-value for Stx-2 was
0.0544 which is very close to the significance threshold. It is believed that the increase in
caspase-9 activation is directly related to the effect of both mutant and native Stx-2 on the
neutrophils, resulting from mitochondrial membrane permealibilazation (MMP) which
can occur simultaneously with DNA fragmentation (78, 160). Caspase-9 activation was
reduced in all samples treated with IL- 8 inhibitor with significance achieved at 6 , 12, and
18 h. This indicates that the intrinsic pathway is not utilized in association with
spontaneous neutrophil apoptosis.

6.0

Discussion

During infection with E. coli 0157:H7, it has been observed that disease
pathogenesis is enhanced when neutrophils remain within the circulation and tissues to
provide maximum distribution of toxin (37, 208). It is thought that neutrophils may
provide a way for Stx-2 to be distributed throughout the body during infection (195).
Therefore, it is critical that neutrophil necrosis and apoptosis is delayed to increase the
number of neutrophils present. Previous studies on the impact of Stx-2-induced
neutrophil apoptosis have shown conflicting results. Liu et al. (118) observed a time- and
dose-dependent delay in spontaneous neutrophil apoptosis when exposed to Stx-2
whereas Flagler et al. (51) did not. Preliminary studies performed with supernatant from
E. coli 0157:H7 strain 90-2380 (Chapter 3) showed that a delay in apoptosis was
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observed in samples up to 12 h. In order to assess why these differences were observed, a
better understanding of the mechanisms of Stx-2 induced neutrophil apoptosis is needed.
Yin et al. (225) used mutants to understand Bcl-2 family dimerization between Bcl-2 and
Bax. It was thought the same technique could be utilized to understand Stx-2 and Bcl-2
family protein interactions, and confirm if they occur. The goal of these experiments was
to assess the effects that semi-purified native Stx-2 and Stx-2 containing a G225A
mutation had on the necrosis and apoptosis rates of neutrophils over a period of 48 h, and
to determine the role that IL- 8 plays in spontaneous and toxin-induced neutrophil
apoptosis. Caspase- 8 and caspase-9 levels were monitored over a period of 24 h to
determine which apoptotic pathways were being utilized, either extrinsic (caspase-8 dependent) or intrinsic (caspase-9-dependent). It was hypothesized that neutrophils
treated with mutant Stx-2 will show apoptosis rates that align with the baseline
(untreated) apoptosis rate, resulting from an inability to bind to the BH1 domain of the
Bcl-2 family pro-survival proteins, and that neutrophils treated with Stx-2 in combination
with an IL- 8 inhibitor will also show apoptosis rates that align with the baseline
(untreated) apoptosis rate indicating that IL- 8 was responsible for the delay in apoptosis
as opposed to Stx-2.

The data obtained in this study on semi-purified Stx-2-induced neutrophil
apoptosis were not consistent with the data obtained for neutrophils exposed to Stx-2containing supemate from E. coli 0157:H7 strain 90-2380 (Chapter 3). The supemate
study showed a delay in apoptosis up to and including 12 h. The present data showed no
significant differences in apoptosis at 0, 6 , 12, 24, and 48h, but showed a significantly
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higher rate of apoptosis after 18 h that was triggered through a caspase-9 dependent
mechanism. The two major differences between the present and previous studies were
sample concentration and purity. In the experiments performed in Chapter 3, the exact
amount of Stx-2 tested was unknown; however in this study, 5 ng/mL of Stx-2 was added
to each sample. It is possible that this concentration was insufficient to elicit the same
response to that observed previously. However, the most likely scenario is that the
supemate used in the previous study had residual LPS which is known to stimulate
cytokine production in neutrophils including IL- 8 and TNF-a (97). Production of these
cytokines could impact the timing of apoptosis as IL- 8 is known to delay neutrophil
apoptosis (96). Neutrophils exposed to LPS release IL- 8 in two phases; 20-30% of the
total IL- 8 production occurs in the first phase which begins approximately Vi hour after
exposure and continues uninhibited over several hours, and the remaining IL- 8
production occurs during the second phase (97) but it is more susceptible to the inhibitory
effects of other cytokines such as IL-10 (26). In other words, the protective effect of IL- 8
does not continue throughout the entire period that neutrophils are exposed to LPS
resulting in a point at which apoptosis occurs. During the supemate study (Chapter 3), the
delay in apoptosis observed with the Stx-2 exposed neutrophils ceased after 12 h thereby
supporting this theory. In the present experiment, the chances that LPS were present in
the semi-purified sample were low, therefore it is believed that these results give a better
indication of the true effect of Stx-2 on neutrophil apoptosis.

The effect of native Stx-2 exposure on neutrophil necrosis, apoptosis, and
caspase-8/-9 activation indicated that necrosis was significantly increased 6-12 h after
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exposure and that native Stx-2-induced apoptosis was observed after 18 h and was
associated with an increase in caspase-9 activation. It is possible that Stx-2-induced
necrosis can be triggered by mechanisms other than N-glycosidase activity.
Mitochondrial membrane permeabilization (MMP) results in programmed cell death
(PCD) as shown in Figure 5.12, and can trigger three outcomes; the activation of caspase9 which results in downstream apoptosis, the activation of apoptosis inducing factor
(AIF) and EndoG which result in direct DNA fragmentation and apoptosis-like cell death,
and the release of calcium and reactive oxygen species (ROS) which result in necrosis
like cell death (78). Calcium is known to be released as part of a stress response
originating from the ER (Figure 5.12), where Stx-2 is known to be located, or from MMP
as explained above (78, 160) which may occur if Stx-2 interacts with Bak on the
mitochondrial membrane. Previous research has stated that apoptosis is induced by Stx-1
though the ER stress response in human monocytic cells (110), and that DNA
condensation can occur in cells that overexpress Bax, despite the presence of a caspase
inhibitor (124, 222), which supports the use of alternative pathways that result in
apoptosis-like cell death such as those with AIF and EndoG. The data obtained in these
experiments support the theory that Stx-2 induced cytotoxicity is triggered by either by
ER stress and calcium release, a direct interaction between Stx-2 and Bcl-2 family
members at the mitochondrial membrane, or both, thereby resulting in apoptotic and
necrotic cellular responses through MMP and autophagy, a process that is associated with
autophagosomes and autolysosomes (199), respectively.
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Figure 5.11: The effects of mitochondrial membrane permeabilization (MMP) on
programmed cell death (PCD). Figure is adapted from M. Jaattela (78). MMP has many
downstream cellular effects that can lead to apoptosis-like PCD, true apoptosis, and
necrosis-like PCD. In these experiments, it is believed that apoptosis-inducing factor
(AIF) or EndoG may be triggered by Bak activation as a result of cytokine withdrawal or
binding to Stx-2 at the mitochondrial or ER surface (left box). In addition, the release of
calcium from the ER may also trigger necrosis-like PCD through autophagy (right box).
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The effect of mutant Stx-2 on neutrophil necrosis, apoptosis, and caspase-8/-9
activation indicated that necrosis was not remarkably different from native Stx-2, with
only a slight increase after 48 h; however there was a lack of mutant Stx-2-induced
apoptosis. In addition, no difference in caspase- 8 and caspase-9 activation was detected
between native and mutant Stx-2. This shows that the mutation did alter the cytotoxicity
of the toxin, and did not cause apoptosis of cells at 18 h as seen with native Stx-2. This
further supports that Stx-2 triggers ER stress followed by calcium release and/or directly
interacts with Bcl-2 family members such as Bak at the mitochondrial membrane leading
to downstream effects of MMP on cell death as explained by Jaattela (78) and Reed et al.
(160).

The effect of IL- 8 inhibitor on neutrophil necrosis, apoptosis, and caspase-8/-9
activation was remarkably different from native and mutant Stx-2. A steady increase in
necrosis was observed after

12

h and apoptosis rates were highest at

12

h, but caspase- 8

and caspase-9 levels were the lowest, even in the presence of Stx-2. This shows that the
IL- 8 inhibitor triggered programmed cell death through a caspase-independent apoptotic
pathway. It is suspected that this pathway involved Bak and destabilization of the
mitochondrial membrane which then caused the mitochondria to release apoptosisinducing factor (AIF) and EndoG. These molecules lead to DNA fragmentation,
chromatin condensation, and apoptosis-like programmed cell death, in a fashion similar
to the pathway shown on the right side of Figure 5.12 entitled “withdrawal of growth
factors/cytokines”. It is known that exposure to IL- 8 results in a delay of spontaneous
apoptosis, and without it TNF-a can rapidly increase neutrophil apoptosis 2 h after
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exposure (97, 143, 192). Even though apoptosis rates of neutrophils treated with IL- 8
inhibitor were consistently higher than the negative control at

6

h and beyond, the data

from these experiments do not support that the induction of apoptosis was due to TNF-a
because the low levels of caspase- 8 activation indicated that the extrinsic pathway
typically triggered by TNF-a was not used. These data do suggest that spontaneous
neutrophil apoptosis occurred at approximately 12 h in all samples despite the level of IL8

or Stx-2 present, however the negative control showed lower apoptosis rates indicating

that IL- 8 did have some protective effect against spontaneous neutrophil apoptosis,
although it was not significant at all time points.

The experiments performed in this study did not show a clear correlation between
a delay in apoptosis as a result of exposure to Stx-2; however they did demonstrate that
Stx-2 induced apoptosis was observed at 18 h and that cells exposed to mutant Stx-2 had
apoptosis rates similar to that of the untreated cells. Data from these experiments
supported that the mechanism of action of Stx-2 was either through the ER stress
response and/or interaction with Bcl-2 family members such as Bak at the mitochondrial
membrane therefore inducing MMP and its downstream effects. Additionally, mutant
Stx-2 was unable to interact with Bcl-2 family members such as Bak at the mitochondrial
membrane, preventing the downstream effects of MMP and cell death. However mutant
Stx-2 was still able to elicit the ER stress response, resulting in calcium release,
autophagy, and necrosis-like cell death. IL- 8 did not appear to play a major role in the
delay of spontaneous apoptosis or to Stx-2 induced apoptosis in these experiments, and
only showed a slight protective effect.
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CHAPTER 6

CONCLUSIONS AND FUTURE STUDIES

1.0

Conclusion and Future Studies

Escherichia coli 0157:H7 is the prototype organism of the STEC group, and has
caused numerous outbreaks in the United States associated with a wide variety of food
types since it first emerged in the early 1980’s (159). It is a dominant Shiga-toxin (Stx)
producing Escherichia coli (STEC) and although many toxic virulence factors are
produced by E. coli 0157:H7, the Stx toxins have been implicated as the most likely
inducers of Hemolytic uremic syndrome (HUS) and its symptoms (131). It is important
to understand the mechanisms by which these toxins elicit cytotoxic responses and how
they differ between host cell types. By doing so, novel therapies and/or vaccines can be
created to supplement current treatments, which are currently focused on maintaining
homeostasis (148). The experiments performed in these studies helped to elucidate the
mechanisms of Stx-2-induced programmed cell death.

Different cell types within the human body are known to contain different levels
of Bcl-2 family proteins, and are affected by cytokines and growth hormones in different
ways. Therefore, apoptotic responses may differ between these cell types. Numerous
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studies have been performed investigating the effects of Stx-1 and Stx-2-induced
apoptosis on many different cell types. A study by Fujii et al. (54) determined that Stx-2
induced apoptosis is mediated by C/EBP homologous protein (CHOP) in human brain
microvascular endothelial cells. Another study performed by Park et al. concluded that
CHOP enhances NFk-B signals by repression of peroxisome proliferator-activated
receptor y in intestinal epithelial cells (147). NFk-B controls the up-regulation of IL- 8
and inhibitor of apoptosis proteins (IAPs) and can inhibit apoptosis by preventing
caspase-9/-3 activation (184). A third study concluded that shiga-like toxins induced
apoptosis of Hep-2 cells by cleavage of Poly (ADP-Ribose) (PARP) and activation of
caspases (35). All of these studies support that shiga-like toxins use different apoptotic
pathways in the tested cells. This shows it is necessary to investigate the effects of Stx-2induced programmed cell death on each cell type typically associated with disease in
order to ensure the correct mechanisms are identified.

Human intestinal epithelial cells and neutrophils are two cell types that have been
associated with the pathogenesis of HUS, and were used in the experiments performed in
this research. Human intestinal epithelial cells allow toxins produced in the colon to
translocate into the blood stream using either a microtubule-dependent or -independent
method (75, 113). Neutrophils are the first line of defense in the human host immune
system and constitutively undergo apoptosis in the circulation, and have an estimated
half-life of

6

to 18 h (3, 67, 173, 213). Increased counts of both neutrophils and

macrophages in circulation have been associated with an increased severity of renal
failure during HUS (156), suggesting that the normal rate of apoptosis may be altered

194

during infection with Stx-2. Previous studies performed by Suzuki et al. (190) have
indicated that Stx-2 but not Stx-1 interacts with a pentameric sequence, NWGRI within
the BH1 domain (a highly conserved region) on the pro-survival protein, Bcl-2 (residues
143 to 147), and this induces target cell death from caspase-3 activation. This same
sequence is found in other members of the Bcl-2 protein family as well as in Stx-2
(residues 222-228) (190). Therefore, it is possible that Stx-2 is acting in a similar manner
to the Bcl-2 protein family by forming heterodimers with these proteins and influencing
the outcome of the cell’s fate.

The goal of this research was to elucidate how Stx-2 interacts with the Bcl-2
protein family and to determine what role it plays in host cell apoptosis, especially in
human neutrophils. In these studies, protein interactions between Stx-2 and select Bcl-2
family proteins (Bcl-2,

B c 1-X l ,

Mcl-1, Bcl-w, and Bax) were examined using Far

Western Blot and Co-Immunoprecipitation in a human intestinal epithelial cell model
(Caco-2). Necrosis and apoptosis rates of human neutrophils as well as the corresponding
pathways used (e.g. caspase- 8 and/or caspase-9) were also determined following
exposure to Stx-2 and mutant Stx-2 (G225A) to determine the extent that the pentameric
sequences plays in regulating apoptosis. The protein interaction studies concluded that
protein binding between Stx-2 and Bcl-2, B c 1-X l , or Bax was not demonstrated in Caco-2
cells. One potential interaction was observed, but the identity of this protein was
unknown. Identifying this interaction could be a challenge; however if the interaction was
demonstrated in repeat experiments, the binding protein could be identified. First, this
protein should be isolated from a PVDF membrane or gel, and the amino acid sequence
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determined using Edman degradation or mass spectrometry. Once the protein sequence
has been determined, it can be compared to a database of known protein sequences using
the basic local alignment search tool (BLAST) to determine its identity. The protein
interactions between Stx-2 and this protein can then be determined using the same
methods used in these experiments, and the presence of this protein can also be identified
in other cell types, such as neutrophils. In order to confirm protein interactions,
alternative techniques should be used such as yeast or mammalian two-hybrid systems or
ultracentrifugation of protein complexes labeled with fluorescent probes. Gaining this
knowledge will further elucidate the pathway by which Stx-2 programmed cell death
occurs.

The neutrophil apoptosis studies concluded that Stx-2-induced apoptosis is
delayed for 12 h after exposure, but only in the presence of crude supernatant fluid. It is
believed that this observation is due to LPS-induced IL- 8 upregulation, which is known
to delay neutrophil apoptosis (96). This delay was not observed in neutrophils treated
with semi-purified Stx-2 as there was no reduction in spontaneous neutrophil apoptosis
observed within the first 12 h. Instead, a distinct peak of Stx-2 induced apoptosis was
observed at 18 h in addition to spontaneous neutrophil apoptosis peak observed at

12

h.

Data supported that the mechanism of action of Stx-2 was either through the ER stress
response and/or interaction with Bcl-2 family members such as Bak at the mitochondrial
membrane therefore inducing MMP and its downstream effects. IL- 8 did not appear to
play a major role in the delay of spontaneous apoptosis or to Stx-2 induced apoptosis in
these experiments, and only showed a slight protective effect. The neutrophil necrosis
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studies concluded that Stx-2-induced necrosis was significantly increased 6-12 h after
exposure, and that this was triggered by a mechanism other than N-glycosidase activity.
It is believed that Stx-2 is able to elicit a stress response within the ER that results in
calcium release, autophagy, and necrosis-like cell death. Further experiments should be
performed to confirm that the proposed mechanisms are involved in Stx-2-induced
programmed cell death. To determine if Stx-2 does indeed induce an ER stress response,
intracellular calcium, calpain, and ROS levels in neutrophils exposed to Stx-2 in a dosedependent manner should be examined. The transcription and protein levels of AIF and
EndoG should also be examined to determine if these proteins are the cause of caspaseindependent apoptosis. Cells exposed to Stx-2 in a dose-dependent manner should be
observed using electron microscopy for the formation of autophagosomes and
autolysosomes. The presence of all of the above plus confirmation of the identity of the
unknown protein interaction described previously would confirm that Stx-2-induced
apoptosis and necrosis is occurring as a result of an ER stress response.

The number of variables involved in toxin-mediated cellular programmed cell
death provides a challenge when trying to elucidate the molecular mechanisms involved.
The research performed in these experiments was conducted over a time frame of nine
years, and hypotheses were initially developed in 2005. Three toxin batches were
produced during this time and toxin potency was confirmed through Vero cell
cytotoxicity testing to ensure no batch variation was present. Much progress has been
made over the last decade to understand the complexities of both cellular apoptosis and
Stx-2 mechanisms of action including the identification of a number of new proteins and
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signaling pathways that are involved in determining the fate of a cell (78, 160). The
research performed in these experiments was limited to a small number of proteins that
were predominantly known to be involved in the process of apoptosis at the time the
study was designed. However, from this research two molecular mechanisms for Stx-2
induced apoptosis and necrosis have been proposed. Providing increased knowledge of
the mechanisms of Stx-2-induced programmed cell death will help future discoveries and
open up new avenues for treatments and/or vaccines for E. coli 0157:H7 infection.
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APPENDIX A:

MICROORGANISMS, MEDIA, AND REAGENTS

1.0

Microorganisms

The strains of E. coli 0157:H7 used in these studies, the toxins they produced,
and the origins of each are shown below.

E. coli 0157:H7 strains used
Strain

Toxin Produced

Origin

90-2380

Stx-2

National Laboratory for Enteric Pathogens Canada

95-2157

Stx-1

National Laboratory for Enteric Pathogens Canada

43895

Stx-1, Stx-2

American Type Culture Collection

43888

None

American Type Culture Collection

2.0

Microbiological Media

2.1

Lnria Bertani (LB) Agar

10 g Bacto-Tryptone (Difco 0123-01-1)
5 g Bacto-yeast extract (Difco 0127-05-3)
lOgNaCl
15 g Bacto-agar (Difco 0140-01)
Distilled H2 O to 1 L
Add ingredients to an Erlenmeyer flask. Bring the volume up to 1L with distilled
H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for 20
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minutes at 121°C, 15psi, and cool to 55 °C , and pour into sterile Petri dishes (20
mL/plate).

2.2

Luria Bertani (LB) Broth

lOg Bacto Tryptone
5g Yeast Extract
lOgNaCl
1 L distilled H2 O
Add ingredients to an Erlenmeyer flask. Bring the volume up to 1L with distilled
H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for 20
minutes at 121°C, 15psi, and store at room temperature.

2.3

LB Agar with 50iig/mL Ampicillin

2.5 g Bacto-Tryptone (Difco 0123-01-1)
1.25 g Bacto-yeast extract (Difco 0127-05-3)
2.5 g NaCl
3.75 g Bacto-agar (Difco 0140-01)
Distilled H2 O to 250mL
Add ingredients to an Erlenmeyer flask. Bring the volume up to 250mL with
distilled H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for
20 minutes at 121°C, 15psi and cool to 55 °C , add Ampicillin (2.5mL of a 5mg/mL stock
solution per 250mL media) and pour into sterile Petri dishes (approx. 20 ml/plate).

2.4

LB Agar with 1% Glucose. 25iig/mL Chloramphenicol. 50iig/mL Ampicillin

5 g Bacto-Tryptone (Difco 0123-01-1)
2.5 g Bacto-yeast extract (Difco 0127-05-3)
5 g NaCl
5 g Glucose
7.5 g Bacto-agar (Difco 0140-01)
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Distilled H2 O to 500mL
Add ingredients to an Erlenmeyer flask. Bring the volume up to 500mL with
distilled H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for
20 minutes at 121°C, 15psi, and cool to 55 °C , add antibiotics (2.5mL of 5mg/mL
Chloramphenicol and 5mL of 5mg/mL Ampicillin per 500mL media) and pour into
sterile Petri dishes (20 mL/plate).

2.5

LB Agar with 25ug/mL Kanamvcin

2.5 g Bacto-Tryptone (Difco 0123-01-1)
1.25 g Bacto-yeast extract (Difco 0127-05-3)
2.5 g NaCl
3.75 g Bacto-agar (Difco 0140-01)
Distilled H2 O to 250mL
Add ingredients to an Erlenmeyer flask. Bring the volume up to 250mL with
distilled H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for
20 minutes at 121°C, 15psi, and cool to 55 °C , add Kanamycin (1.25mL of 5mg/mL
stock solution per 250mL media) and pour into sterile Petri dishes (20 mL/plate).

2.6

Trypticase Sov Broth with 15% Glycerol

30g Trypticase Soy Broth Powder
7.5mL Glycerol
500mL distilled H2 O
Dissolve TSB powder in the distilled water and remove 7.5mL of broth. Add
7.5mL glycerol and mix well. Autoclave on the liquid cycle for 20 minutes at 121°C,
15psi, and store at room temperature.
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2.7

SOC Medium

20g Bacto Tryptone
5g Bacto Yeast Extract
2ml of 5M NaCl.
2.5ml oflM K C l.
1 0 ml of 1 M MgCl2
10ml of 1M MgS0 4
2 0 ml of 1 M glucose
ddH20 to 1L
Add ingredients to 900mL of distilled H2 0 . Bring the volume up to 1L with
distilled H20 and stir until all ingredients are dissolved. Autoclave on the liquid cycle for
20 minutes at 121°C, 15psi.

3.0

Antibiotic Stock Solutions
Stock solutions of ampicillin, chloramphenicol, kanamycin, and tetracycline were

prepared as needed per the recipes below. In all cases, antibiotics were mixed until
dissolved, sterile filtered with 0.2pm filters (Pall), and added to media in the desired
concentration.

3.1

Ampicillin (Amnl: Stock of 5 mg/mL in sterile ddwater (sddH2Q).

0.5 g Ampicillin (Sigma A-9518)
Sterile ddH20 to 100 ml
3.2

Chloramphenicol (Chi): Stock of 5 mg/mL in 95% ethanol (EtOHl.

0.05 g Chloramphenicol
95% EtOH to 10 ml
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3.3

Kanamvcin (Kan): Stock of 5 mg/ml in sterile ddwater (sddH2Q).

0.05 g Kanamycin
Sterile ddH2 0 to 10 mL
3.4

Tetracycline (Tet): Stock of 5 mg/ml in 95% ethanol (EtOHt.

0.05 g Tetracycline-HCl
95% EtOH to 10 ml

4.0

Biochemical Reagents

4.1

Phosphate Buffered Saline (PBS), pH 7.4

1.44g Sodium phosphate, dibasic (Na2 HP0 4 )
8 g Sodium chloride (NaCl)
0.2g Potassium Chloride (KC1)
0.24g Potassium Phosphate, monobasic (KH2 PO4 )
1L distilled H20
Add ingredients to flask, bring up the volume to 1L with distilled water, and stir
until dissolved. Adjust pH to 7.4 using HC1. Autoclave on the liquid cycle for 20 minutes
at 121°C, 15psi, and store at room temperature.

4.2

0.5M Ethylene Diamine Tetraacetic Acid (EDTA). pH 8.0

46.5 g NaEDTA (Sigma)
200 mL distilled H20
Adjust to pH 8.0 with approximately 5 g of NaOH pellets (Sigma). Autoclave on
the liquid cycle for 20 minutes at 121°C, 15psi, and store at room temperature.
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4.3

50x Tris-Acetate-EDTA Buffer (TAEL p H 8.5

242g Tris Base
lOOmL 0.5M EDTA, pH 8.0
57.1mL Glacial Acetic Acid
distilled H2 O
Add ingredients to flask, bring up the volume to 1L with distilled water, and stir
until dissolved. Adjust pH to 8.5 with Glacial Acetic Acid. Store at room temperature.

4.4

DNA Extraction Lvsis Buffer

250pL 10% SDS
50|iL lONNaOH
9.7mLdH20
Add ingredients to a conical tube and mix well. If the SDS does not dissolve,
place tube into a warm water bath for 5 minutes. Vortex to mix. Store at room
temperature for no longer than 2 months.

4.5

Loading Dve

7mL 0.25% Bromophenol Blue
7mL 0.25% Cylene Cyanol
6 mL Glycerol
Add ingredients to a conical tube and mix well. Store at room temperature.

4.6

50x Native Gel Running Buffer (1M Tris. 1M Glvcine. 0.1M EDTA!. p H 8.8

121.14g Tris
75.07g Glycine
32.73g EDTA
Distilled H20
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Add ingredients to flask, bring up the volume to 1L with distilled water and stir
until dissolved. Adjust pH to 8 . 8 with HC1. Store at room temperature or 2-8°C. To use,
dilute stock 50-fold with deionized water to obtain a lx solution for each native
electrophoresis run. Mix thoroughly before use.

4.7

5X Sample Loading Buffer

2.423g Tris
1.501g Glycine
0.372g EDTA
25mL Glycerol
lmL Bromophenol blue
Distilled H2 O
Add ingredients to a flask containing 50mL distilled H2 O, bring up the volume to
lOOmL with distilled water and stir until dissolved. Use 2.5mL per lOmL sample
processed.

4.8

1M PMSF

0.1742g PMSF
lmL methanol
Dissolve PMSF in methanol. Vortex to mix. Store at -20°C.

4.9

Acrvlamide/Bisacrvlamide (30%T. 2.67 %C1

87.6g acrylamide
2.4g N ’N’-bis-methylene-acrylamide
Bring up volume to 300mL with deionized water. Filter using Whatman #1 paper
and store at 4°C in the dark.
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4.10

10% (w/v) Sodium Dodecvl Sulfate (SDS)

lOg SDS
Distilled H2 O
Dissolve lOg SDS in 90mL water with gentle stirring and bring volume up to
lOOmL with deionized water.

4.11

Resolving Gel Buffer (1.5M Tris-HCl). p H 8.8

27.23g Tris base
80mL deionized water
Adjust to pH

8 .8

with 5N HC1. Bring total volume to 150mL with deionized water

and store at 4°C.

4.12

Stacking Gel Buffer (0.5M Tris-HCll. p 6.8

g Tris base
60mL deionized water
6

Adjust to pH 6 . 8 with 5N HC1. Bring total volume to lOOmL with deionized water
and store at 4°C.

4.13

Sample Buffer (SDS Reducing Buffer)

3.55mL deionized water
1.25mL 0.5M Tris-HCl, pH 6 . 8
2.5mL glycerol
2.0mL 10% (w/v) SDS
0.2mL 0.5% (w/v) bromophenol blue
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Add ingredients to a conical tube and mix well. Store at room temperature. Prior
to use, add 50pl p-mercaptoethanol to 950pL sample buffer. Dilute the sample at least 1:2
with sample buffer and heat at 95°C for 4 minutes.

4.14

lOx Electrode SDS-PAGE (Running) Buffer. Tris-Glvcine p H 8.3

30.3g Tris base
144.0g Glycine
lO.Og SDS
Distilled H2 O
Dissolve ingredients in 700mL deionized water and bring the total volume up to
1L. Do not adjust pH with acid or base. Store at 4°C. If precipitation occurs, warm to
room temperature before use. Prior to use, dilute 50mL lOx stock with 450mL deionized
water for each electrophoresis run. Mix thoroughly.

4.15

10% Ammonium Persulfate (APS) (made fresh daily)

lOOmg ammonium persulfate
lmL deionized water
Dissolve lOOmg ammonium persulfate in lmL of deionized water and vortex to
mix well.

4.16

6% Stacking /12% Resolving Acrvlamide Gel

Resolving Gel (lOmL):
4 mL Acrylamide/Bisacrylamide (30%T, 2.67%C)
2.5mL Resolving gel buffer
3.5mL distilled H2 O
5pL TEMED
50pL APS
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Stacking Gel (5mL):
lmL Acrylamide/Bisacrylamide (30%T, 2.67%C)
1.25 Stacking gel buffer
2.75mL distilled H2 O
5pL TEMED
25|4.L APS
Add resolving ingredients to a conical tube in the order listed. Mix gently and
allow to de-gas for at least five minutes. Carefully pipette resolving gel solution into gel
casting stand until 3A full. Gently add a layer of water and allow to solidify. Pour off
water and prepare stacking gel in the same manner. Insert comb into the top of the gel
casting stand and allow to solidify.

4.17

Coomassie Blue Staining Buffer

lg Coomassie Blue R250
lOOmL Glacial Acetic Acid
400mL Methanol
500mL Distilled H2 O
Add acetic acid to distilled water followed by methanol and Coomassie blue. Mix
well and filter with Whatman #1 filter paper to remove large particles. Store at room
temperature.

4.18

Coomassie Blue Destain Buffer

200mL Methanol
lOOmL Glacial Acetic Acid
700mL Distilled H2 O
Add lOOmL glacial acetic acid to 700mL of dEhO followed by 200mL methanol
and mix well. Store at room temperature.
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4.19

lOx Western Blot Transfer Buffer (Tris Glycine). pH 8.3

30.3g Tris base
144.0g Glycine
Distilled H2 O
Dissolve ingredients in 700mL deionized water and bring the total volume up to
1L. Do not adjust pH with acid or base. Store at 4°C. If precipitation occurs, warm to
room temperature before use. Prior to use, dilute 1:10 with deionized water for each
electroblot transfer. Mix thoroughly.

4.20

Blocking Buffer (5% Dehydrated Skim Milk)

5g dehydrated skim milk powder
lOOmL lx Phosphate Buffered Saline (PBS)
Add 5g of dehydrated skim milk powder into lOOmL PBS. Vortex until dissolved.
For extended storage, store at -20°C.

4.21

1Ox Tris Buffered Saline (TBS!

24.20g Tris Base
292.4g NaCl
Distilled H2 O
Add ingredients to 500mL distilled water, adjust the pH to 7.5 with HC1 and bring
the volume up to 1L. Dilute 1:10 with distilled water prior to use. Store at 2-8°C.

4.22

0.05% Tween Tris Buffered Saline (TTBS). p H 7.5

1L lx TBS
0.5mL Tween 20
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Add Tween 20 to 1L lx TBS and mix well. Store at room temperature.

5.0

Cell Culture Media and Reagents

5.1

Trvpsin-EDTA Solution

0.5g Trypsin
0.2g EDTA
1L HBSS modified
Add ingredients and mix until dissolved. Sterile filter with 0.2pm filters (Pall) and
transfer aliquots into 15mL conical tubes. Store at -20°C.

5.2

Trypan Blue

0.04g Trypan Blue
lOOmL lx Phosphate Buffered Saline (PBS)
Add ingredients and mix until dissolved. Sterile filter with 0.2pm filters (Pall) and
store at room temperature.

5.3

HBSS Modified (no Ca++ or Mg++)

2 bottles pre-measured, powdered HBSS modified (no Ca++ or Mg++) (Atlanta
Biologicals, Atlanta GA)
0.70g sodium bicarbonate
2L distilled H20
Add ingredients and mix well. Adjust pH to 7.2 with HC1. Sterile filter into
autoclaved bottles using 0.2pm filter units (Nalgene Nunc, Rochester, NY). Incubate
media overnight at 37°C for sterility check. Store at 2-8°C.
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5.4

RPMI-1640 with 10% FBS

10.44g RPMI-1640 powder
Distilled H2 O up to 1L
2 .0 g sodium bicarbonate
lOmL non-essential amino acids, lOOx
50mL Fetal Bovine Serum (FBS)
Add ingredients and mix well. Adjust pH to 7.2 with HC1 if required. Sterile filter
into autoclaved bottles using 0.2pm filter units (Nalgene). Incubate media overnight at
37°C for sterility check. Add 200mL FBS and return to incubator for an additional
overnight sterility check. Store at 2-8°C.

5.5

DMEM Modified (5% FBS. Hepes. Bicarbonate. High Glucose, and nonessential amino acids)

2 bottles pre-measured, powdered DMEM modified (DMEM-4.5, high glucose
with L-glutamine, 25mM HEPES buffer, without sodium pyruvate) (Atlanta
Biologicals)
7.40g sodium bicarbonate
20mL non-essential amino acids, lOOx
1.8L distilled H2 O
lOOmL fetal bovine serum (FBS)
Add ingredients (except FBS) and mix well. Adjust pH to 7.2 with HC1. Sterile
filter into autoclaved bottles using 0.2pm filter units (Nalgene). Incubate media overnight '
at 37°C for sterility check. Add 200mL FBS and return to incubator for an additional
overnight sterility check. Store at 2-8°C.

5.6

Caco-2 Media

18.8g Eagles Minimal Essential Medium (Atlanta Biologicals)
29.6g Leibovitz-15 Medium (Atlanta Biologicals)
16.88g HEPES
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1.168g L-glutamine
3g Sodium bicarbonate
40mL non-essential amino acids, lOOx
3.6L distilled H20
400mL Fetal Bovine Serum (FBS)
Add ingredients (except FBS) and mix well. Sterile filter into autoclaved bottles
using 0.2pm filter units (Nalgene). Incubate media overnight at 37°C for sterility check.
Add 400mL FBS and return to incubator for an additional overnight sterility check. Store
at 2-8°C.
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APPENDIX B

MAINTENANCE OF EUKARYOTIC CELL CULTURES

1.0

Vero Cell Growth and Crvopreservation

African green monkey kidney (vero) cells (designated CCL-81) were obtained
from the American Type Culture Collection (ATCC) and cellular morphology was
confirmed by microscopic analysis. Aliquots of vero cells (lmL containing lx 106
cells/vial) were cryopreserved in DMEM modified with 5% FBS (Appendix A, 5.5) and
5% dimethylsulfoxide (DMSO), and stored in liquid nitrogen. Working cell lines were
maintained in DMEM modified medium for five passages per stock vial, and grown at
37°C in an open system containing 5% CO2 .

2.0

Caco-2 Cell Growth and Crvopreservation

Caco-2 cells (designated HTB-37) were obtained from the ATCC and cellular
morphology was confirmed by microscopic analysis. Aliquots of cells were
cryopreserved in Caco-2 media (Appendix A, 5.6) and 5% dimethylsulfoxide (DMSO),
and stored in liquid nitrogen. Working cell lines were maintained in Caco-2 media for
five passages (passage #42-46) per stock vial and grown at 37°C in a closed system.
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